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CHAPTER I 
 
INTRODUCTION 
 
Programmed cell death (PCD) is an important process by which developing organisms 
remove excess cells, form complex structures, and through which adult organisms maintain 
homeostasis and remove harmful or abnormal cells (1). Deficiencies in this process can lead to 
abnormalities at the cellular to whole-organism level or organism death. Two key types of PCD 
include Apoptosis and Necroptosis (programmed necrosis). Apoptosis is characterized 
morphologically by shrinkage of the cell membrane and organelles and formation of apoptotic 
blebs which are swiftly taken up by phagocytic cells (2, 3). Conversely, necroptosis is 
characterized by swelling and bursting of the cell membrane and organelles and loss of plasma 
membrane integrity (4, 5). While much is known regarding the signaling pathways involved in 
apoptosis execution, necroptosis is an emerging area of programmed cell death. Developing a 
better understanding of these pathways holds implications for understanding and treating 
diseases such as cancer, where targeting aberrant cell death is an essential objective. 
The B cell lymphoma-2 (BCL-2) family is well known for their role in the regulation of 
apoptosis (6). However, many recent studies demonstrate that several of these proteins have 
alternative functions in survival, metabolism, and mitochondrial dynamics (7–10). In my studies 
I have characterized an alternative function of Bid (BH3-interacting domain death agonist), a 
proapoptotic, BH3 domain-only containing protein within the BCL-2 family in the inhibition of 
the necroptotic (programmed necrosis) pathway. This discovery was made through study of mice 
and cells deficient for Bid, as well as Bax and Bak to remove the apoptotic arm of Bid’s function 
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in the hematopoietic system, and allow for characterization of Bax/Bak independent functions of 
Bid. These studies reveal that overwhelming necrosis of the bone marrow negatively impacts the 
hematopoietic system leading to bone marrow failure and premature death in these animals. 
Additionally, through development of cell lines from our mice attuned to undergo either 
apoptosis or necroptosis following stimulation, we were able to mechanistically begin to 
understand how Bid functions to inhibit necroptotic death. These studies revealed that Bid’s 
presence promotes the cleavage of Rip1 through modulation of the activity of the proteases 
Caspase-8 and Granzyme B.  
 
Programmed Cell Death 
 
While there are many types of programmed cell death, there are two key types which will 
be the focus of my studies, apoptosis and necroptosis (programmed necrosis). Apoptosis is 
important in the crafting of complex structures of anatomy such as digits (1). Similarly, 
necroptosis is key in development as deficiency for receptor-interacting kinase 3 (Rip3) rescues 
the embryonic lethality of Caspase-8 deficiency in mice (11). While the outcome of both 
apoptosis and necroptosis is cell death, the morphological characteristics, signaling pathways, 
execution, and consequences of execution differ significantly between these two paths to death. 
Additionally, while apoptosis and necroptosis can be stimulated downstream of death receptors 
such as Tumor necrosis factor receptor 1 and 2 (TNFR1 and 2), and a number of the proteins 
involved in each are similar, the downstream mediators of apoptotic or necroptotic signaling 
differ (12). Apoptotic execution is dependent upon this upstream pathway to signal activation of 
cysteine-dependent aspartate-specific proteases (Caspases), whereas necrosis is dependent upon 
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activation of the RIP kinases 1 and 3, as well as mixed lineage kinase domain-like (MLKL) (5, 
13). Lastly, the consequences of apoptotic versus necroptotic death are drastically different and 
as a result can have distinct effects on the surrounding cells in the organism. Because apoptotic 
cells form small blebs that bud off from the main cell body, and then are immediately taken up 
by phagocytes, there is typically no immune response. Conversely, necroptotic death leads to 
loss of membrane integrity and/or bursting of the cell causing leakage of damage-associated 
molecular patterns (DAMPs) in the extracellular space (14). This in turn promotes inflammation 
and an innate immune response (15).  
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Figure 1.1 Morphological characteristics of apoptosis versus necrosis 
Death by apoptosis versus necrosis is morphologically distinct and requires distinctly different 
proteins. Apoptosis is characterized by an immunologically silent death in which the cells shrink 
and bud off into small buds which are rapidly phagocytosed. Conversely, necrosis is 
characterized by the swelling of the cell, leading to the loss of plasma membrane integrity. While 
apoptosis requires Caspases for its execution, necrosis is independent of Caspases and instead 
requires the activity of Rip kinase 1 and 3.   
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Programmed cell death in human disease 
 Aberrant cell death has devastating effects on an organism, demonstrating the importance 
of programmed cell death in maintaining homeostasis. A number of human diseases are 
characterized by lack of, or too much programmed cell death (apoptosis and/or necroptosis). One 
of the best known instances in human disease where lack of programmed cell death is recognized 
as being paramount is in the development of cancer (16). Evasion of programmed cell death is a 
contributing factor to the development of many neoplasms. Other settings where lack of or 
altered programmed cell death promotes disease is in the development of autoimmunity, where 
immune cells that are reactive to “self” are not properly eliminated. Diseases that manifest as a 
result of this include Diabetes mellitus, Lupus erythematosus, and Rheumatoid arthritis (17–20). 
Another setting in which lack of programmed cell death promotes a disease state is in the 
clearance of viral infection. In some viral life cycles, death of cells infected with virus blocks the 
completion of the viral propagation cycle blocking further infection. As such, prevention of both 
apoptotic and necroptotic death are demonstrated to be important in the viral defense against the 
host (21, 22). An example of this is in infection with the vaccinia virus in mice, which contains 
the viral protein B13R. B13R inhibits apoptosis, which in turn promotes RIP3-mediated necrosis, 
aiding in the clearance of infection (23, 24). Similarly, in infection with the Influenza A virus in 
vitro both apoptotic and necroptotic death are important in blocking further infection (25). 
Conversely, infection with the T1L strain of Reovirus appears to require apoptosis during its life 
cycle to promote viral growth and aid in infection and pathogenesis in vivo (26, 27). However, 
more recent studies demonstrate that another Reovirus strain, T3D, induces necroptosis at a 
different stage in the viral life cycle which also promotes virulence, suggesting that programmed 
cell death is often, but not always key in viral clearance (28). These examples reiterate the 
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importance of programmed cell death execution in maintenance of tissue homeostasis, proper 
immune regulation, and in viral clearance.  
 There are also several settings in which too much cell death promotes a number of human 
diseases. Programmed cell death following ischemia/ reperfusion injury can lead to apoptotic 
and/or necroptotic death of tissue. Studies with human tissue and mouse models of myocardial 
infarction demonstrate a role for both apoptosis and necroptosis in damage and remodeling of 
cardiac tissue (29, 30). Similarly, following stroke, both apoptotic and necroptotic death are 
implicated in the death of neurons (31–33). Importantly, while studies on both mouse and human 
tissues following ischemic/reperfusion to study apoptosis activation have been utilized, only 
mouse models have been utilized in the study of necroptosis following ischemia/reperfusion 
injury, suggesting our understanding of this may be incomplete (34). In neurodegenerative 
disease, death of neurons or other neural cell types leads to progressive loss cognitive and motor 
capabilities and eventually death (35, 36). Both apoptosis and necroptosis are implicated in these 
events. In Alzheimer’s disease Caspase activation has been implicated in the death of neurons 
along with the formation of plaques of Amyloid-β and neurofibrillar tangles of  the protein tau 
(37). Additionally, more recent preliminary studies in vitro and in vivo suggest a role for 
necroptosis in neuronal death in a mouse model of Alzheimer’s Disease (38, 39). In Parkinson’s 
Disease, in vitro studies demonstrate that overexpression of α- synuclein, the major component 
of Lewy Bodies found in Parkinson’s Disease, promoted death in dopamine neurons (40). 
Similarly, in Huntington’s Disease neurons die as a result of accumulation of mutant Huntingtin 
protein. Preliminary studies in mice in vivo and in vitro, as well as in human in vitro studies 
demonstrate that both apoptotic and necroptotic death lead to loss of neurons (41, 42).  Lastly, 
recently multiple sclerosis (MS) was shown to be associated with necroptosis of 
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oligodendrocytes, the myelin-producing cells of the nervous system. Through study of mouse 
models of MS as well as human samples with MS lesions, the authors demonstrate that 
necroptosis execution may play a role in this process through use of the necroptosis inhibitor, 
7N-1. Additionally through proteomic studies, the authors find that a number proteins found to 
aggregate in both Alzheimer’s and Parkinson’s disease are also upregulated in human MS patient 
samples (43). This same group also recently discovered that necroptosis mediated by Rip1, Rip3, 
and MLKL plays a role in axonal degeneration, contributing to the pathogenesis of amyotropic 
lateral sclerosis (ALS) (44). While apoptotic death has been implicated in the pathogenesis of 
many diseases for many years, more recent studies implicate necroptotic death as well. As such, 
 a better understanding of necroptotic signaling and its role in human disease in vivo present a 
new avenue of therapeutic targets to pursue in the treatment of human disease (45). 
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Table 1.1 Human diseases associated with abnormal programmed cell death  
Disease/ 
Pathology 
Death 
Dysregulation Type of PCD Result of Dysregulation Reference 
Cancer Loss  Apoptosis 
Overgrowth of cells due to 
apoptosis resistance (16) 
Diabetes Mellitus Loss Apoptosis 
Apoptosis of β-Cells in 
the pancreas as a result of 
autoimmunity due to 
failure of removal of cells 
recognizing "self" (17) 
Lupus 
Erythematosus Loss  Apoptosis 
Fas Resistance of "self" 
recognizing lymphoid 
cells to PCD (18, 19) 
Rheumatoid 
Arthritis  Loss Apoptosis 
Resistance of 
macrophages to apoptosis (20) 
Clearance of viral 
infection Loss  Apoptosis/ Necroptosis 
Continued increase of 
viral infection  (21–25) 
Myocardial 
Infarction Too much  Apoptosis/ Necroptosis 
Death of cardiac tissue 
after ischemia/reperfusion 
injury (29, 30) 
Stroke Too much Apoptosis/ Necroptosis 
Death of neural tissue 
after ischemia/reperfusion 
injury (31, 33, 34, 46) 
Alzheimer's 
Disease Too much  Apoptosis/ Necroptosis 
Death of neurons due to 
accumulation of Amyloid-
β plaques and 
neurofibrillar tangles of 
the tau protein (37–39) 
Huntington's 
Disease Too much  Apoptosis/ Necroptosis 
Accumulation of 
Huntingtin protein in 
neurons causing PCD (41, 42) 
Parkinson's 
Disease Too much  Apoptosis 
Death of dopamine 
neurons due to 
accumulation of α-
synuclein, the principle 
component of Lewy 
Bodies (40) 
Multiple Sclerosis Too much  Necroptosis 
Necroptotic cell death of 
oligodendrocytes leading 
to loss of myelination (43) 
Amyotropic 
Lateral Sclerosis Too much  Necroptosis 
Degeneration of axonal 
portion of neurons due to 
necroptotic death (44) 
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Apoptosis 
 Apoptosis is a programmed cell death process that is highly conserved among multi-
cellular organisms, and is extremely important in the crafting of complex structures within 
different tissues and organs during development (1). Apoptosis also maintains homeostasis and 
balance of cell numbers within tissues. Lastly, apoptosis regulates the removal of damaged, 
defective (e.g. transformed), or excess cells (e.g. hematopoietic cells generated during an 
immune response which are no longer required).  
Apoptotic signaling is carried out through two distinct pathways; the extrinsic and 
intrinsic apoptotic pathways (47, 48). Activation of the extrinsic pathway occurs when death 
receptors such as TNFR (tumor necrosis factor receptor), TNF-related apoptosis inducing ligand 
(TRAIL) Receptor, and FAS (Apoptosis antigen 1 (APO-1), tumor necrosis factor superfamily 
member 6 (TNFSF6)) are activated through the binding of their cognate ligands, TNFα, TRAIL, 
and Fas ligand, respectively (49, 50). Upon ligand binding, these receptors trimerize, bringing 
together their death domain-containing cytoplasmic tails, and with adapter proteins form the 
Death-inducing signaling complex (DISC) (51). Adapter proteins such as Fas-associated death 
domain protein (FADD) and TNF-related associated death domain protein (TRADD) contain 
death domains (DD), and allow for association with the cytoplasmic regions of the trimerized 
death receptors (52, 53). The DISC serves to transduce the death signal into the cell, and 
promotes the direct activation of initiator cysteine-dependent aspartate-specific proteases 
(Caspases) -8 and -10 through engagement of Death effector domains (DED) present in these 
proteins (54–56).  
In extrinsic apoptosis activation, initiator Caspases-8 and -10 promote the direct 
activation of executioner Caspases, which include Caspase-3 and Caspase-7 (48). These 
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proteases initiate a Caspase cascade that promotes the breakdown of cellular contents. The 
intrinsic pathway of apoptosis functions as an amplification loop of apoptosis activation, through 
an increase in Caspase activation. The intrinsic pathway is activated as a result of an intracellular 
death stimulus, which may result from irreparable DNA damage, or as a result of activation 
through the extrinsic apoptotic pathway, through cleavage of the BCL-2 family member Bid by 
Caspase-8. This cleavage activates Bid, causes its translocation to the mitochondrion where it 
promotes activation of the Bax and Bak, proapoptotic BCL-2 family members. Bax and Bak 
form pores within the OMM causing MOMP and allowing the release of several factors from the 
intermembrane space (IMS), including high-temperature-requirement-protein A2 
(HTR2A/OMI), and Second mitochondrial-derived activator of Caspases/ direct inhibitor of 
apoptosis-binding protein with low pI (SMAC/Diablo), Cytochrome C, Apoptosis-Inducing 
Factor (AIF), and Endonuclease G (57). SMAC/Diablo and HTR2A/OMI block the activity of 
X-linked inhibitor of apoptosis (XIAP), an E3 ligase which promotes the degradation of 
Caspases, through directly binding to them (58–61). Cytochrome C release promotes apoptosis 
activation through formation of a complex with Apoptotic protease activating factor-1 (APAF-1), 
known as the apoptosome, which recruits and activates Caspase-9 (62, 63). Caspase-9 activates 
Caspase-3 and Caspase-7, promoting the Caspase cascade, which leads to the digestion of 
cellular contents to promote enzymatic activation and to cause protein cleavage (64). DNA 
fragmentation additionally occurs through activation of Caspase activated DNase (CAD) (65). 
Following MOMP and Caspase activation, mitochondrial membrane potential is lost, rendering 
cells unable to make adenosine triphosphate (ATP), the necessary energy required for survival. 
Cells additionally expose phosphatidylserine on the outer plasma membrane, a phospholipid 
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primarily present on the inner leaflet of the plasma membrane, which serves as an “eat me” 
signal for phagocytic cells to engulf an apoptotic cell (66).   
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Figure 1.2 Extrinsic versus intrinsic apoptosis and reliance on each pathway in Type I and 
Type II cells 
There are two pathways to apoptotic cell death, extrinsic and intrinsic apoptosis. Extrinsic 
apoptosis is activated downstream of death receptor signaling. Activation of Caspase-8 promotes 
the cleavage and activation of Caspase-3, activating the apoptotic program. Cells reliant on 
extrinsic apoptosis activation to execute cell death are known as Type I cells. Intrinsic apoptosis 
is activated through the cleavage of Bid by Caspase-8. As a BH3-Only activator, Bid translocates 
to the mitochondrion where it activates Bax and Bak, promoting their activation and 
oligomerization. Pore formation leads to the release of several factors, including Cytochrome C. 
Cytochrome C associates with APAF-1 and Pro-Caspase-9 to promote activation of Caspase-9.  
Caspase-9 activates Caspase-3 activation the apoptotic program, executing apoptosis. Cell reliant 
on intrinsic apoptosis to execute cell death are termed Type II cells.  
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Type I and Type II cells  
Early studies of death receptors revealed the intrinsic and extrinsic apoptotic pathways, 
and determined that different cell types rely more on one pathway versus the other following 
death receptor activation to execute apoptosis. The reliance of a cell on extrinsic versus intrinsic 
apoptosis to die classifies cells as being either Type I or Type II, respectively (67). The key 
difference between these types of death is direct activation of downstream caspases through 
Caspase-8 (extrinsic) versus a mitochondrial amplification loop that promotes increased 
activation of executioner caspases and Caspase-8 through Caspase-9 activation. Through 
examination of the type of Caspase activation downstream of Fas receptor activation and of 
kinetics of Caspase activation in relation to mitochondrial permeabilization and apoptosis 
execution it was determined that 1) Caspase-8 activation differed when it occurred within the 
DISC versus after mitochondrial permeabilization and 2) Caspase-8 activation primarily occurs 
in the DISC in Type I cells, whereas it primarily occurs downstream of the mitochondrion in 
Type II cells (48). Later studies demonstrate that minimal activation of Caspase-8 in Type II 
cells was transmitted to the mitochondrion through cleavage and translocation of the BCL-2 
family member, Bid. The reliance of Type II cells on mitochondrial amplification of the 
apoptotic signal versus the independence of Type I cells makes apoptosis execution inhibitable at 
this level of signaling. Anti-apoptotic BCL-2 and BCL-XL, members of the BCL-2 family, 
promote this inhibition highlighting the importance of these proteins in apoptosis regulation.  
 
Caspases 
Caspases are cysteine proteases that cleave peptide bonds specifically after aspartic acid 
residues, serving to either activate or inactivate proteins (68). For example, Caspase-1, the first 
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member of this family of cysteine proteases discovered, was originally demonstrated to cleave 
Pro interleukin-1β (proIL-1β) (the immature form of IL-1β), generating the mature cytokine that 
promotes an inflammatory response (69, 70). Since this discovery there have been a total of 10 
caspases identified in the Mus Musculus species (Caspase 1-3, 6-9, and Caspase-11, 12, and 14) 
and 12 caspases identified in humans (Caspase 1-10, and Caspase-12 and -14). These proteins 
have various roles in inflammatory and apoptotic signaling pathways, as well as keratinocyte 
differentiation and hematopoiesis (71, 72). There are three subclasses of caspases, which are 
delineated based upon the structure and function of the caspase in each pathway. The first 
subclass includes Caspases that are important for the activation of inflammatory cytokines such 
as IL-1β and IL-18 (73–75) . These caspases function to promote the cleavage of substrates that 
incite inflammation, namely intracellular cytokines. Caspase-1, Caspase-4 (human only), 
Caspase-5 (human only), Caspase-11 (mouse only), and Caspase-12 are members of this group 
of caspases, which primarily function as initiators of inflammatory responses. The second 
subclass of caspases is classified as apoptotic effectors and function to promote the execution of 
the apoptotic program through cleavage of crucial substrates for apoptotic execution. Caspases 
that are members of this subclass include Caspase-3, Caspase-6, and Caspase-7. These caspases 
become activated by initiator caspases, which make up the third subclass of caspases. Initiator 
caspases include Caspase-8, -9, and -10, which serve as initiators of the caspase cascade in the 
extrinsic and intrinsic apoptotic pathways. These caspases become activated through 
extracellular and intracellular signals which promote apoptotic signaling and allow for the 
execution of the apoptotic program.  
Apoptotic caspases begin as inactive zymogens and become activated through a 
systematic dimerization and/or cleavage process, which can be autocatalytic or be mediated by 
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other caspases (71). The general structure of caspases includes a prodomain, which may contain 
either a Death-effector domain (DED) or a caspase activation and recruitment domain (CARD)), 
along with a large subunit, connected through a linker region to the small subunit (76). Initiator 
caspases involved in apoptosis exist in the cytosol as inactive monomers and become activated 
through interaction with the DISC (Caspase-8, -10) or through association with the proteins 
APAF-1 and cytochrome C (Caspase-9). This activation was described as the “induced 
proximity” model in which caspases dimerize without cleavage (77). However, activation of 
Caspase-8 and Caspase-10 requires cleavage (78). Caspase interaction within the DISC occurs 
through binding of Caspase-8 zymogens to FADD through DEDs. This docking of Caspase-8 
serves as an activation platform whereby Caspase-8 can form dimers with either another 
Caspase-8 molecule or with a cellular FLICE-like inhibitory protein (cFlip) molecule, a protein 
similar to Caspase-8, which lacks catalytic cleavage activity. cFlip exists in two main isoforms 
(cFlipS and cFlipL) which have differential effects on Caspase-8 activity. Binding of cFlipS 
blocks Caspase-8 apoptotic activity, blocking apoptotic activation. Conversely, binding of cFlipL 
allows Caspase-8 activation, but alters its activity (79). This Caspase-8: cFlipL heterodimer 
displays differential substrate specificity than Caspase-8 homodimers, a point that will be 
important in later discussions of Caspase-8’s role in necroptotic signaling (Chapter III) (80). 
Binding of another Caspase-8 molecule allows for homodimerization of these molecules, and is 
the first step in activation. Next, an initial autocatalytic cleavage occurs in the linker region. In 
Caspase-8 during apoptosis this cleavage occurs at Asparagine 374 or 384. This is followed by 
cleavage between the prodomain and large subunit at Asparagine 210, 216, or 223 (56, 77, 81). 
Following cleavage, the molecule is fully activated and can then cleave other substrates such as 
Bid or Rip1. Activation of Caspase-9 does not require an autocatalytic cleavage event, but does 
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require association with the apoptosome, a heptameric molecule that forms through association 
of APAF-1 and cytochrome C. There is controversy within the field regarding whether activation 
of Caspase-9 occurs as a dimer or monomer, however it has been clearly established that this 
activation occurs through a single interaction of CARDs present in APAF-1 and Caspase-9 (82, 
83). More recently the CARD has been purported to play a key role in activation through three 
distinct interactions, with CARD domains from two APAF-1 molecules interacting with a single 
Caspase-9 CARD (84). Lastly, executioner caspases exist in the cytosol as inactive dimers, held 
in check due to steric hindrance from the interdomain linker (85). While there are three identified 
executioner caspases (Caspase-3, -6, and -7) many studies on this class of caspases have focused 
on activation mechanism of Caspases-7. Studies of Caspase-3 suggest a similar method of 
activation to Caspase-7 through highly conserved residues (85). Caspase-6 is implicated to have 
a role in not only apoptosis, but also in alternative functions such as degeneration of axons (86). 
Studies of Caspase-7 indicate that cleavage of the interdomain linker allows for a conformational 
change and stabilization of the active site loop, and full activation (87, 88). Cleavage of this 
domain by initiator caspases allows for full activation, activation of the caspase cascade, and 
execution of apoptosis.  
While the execution of apoptosis by caspases is an important process in the maintenance 
of tissue homeostasis, this process, like all biological processes requires regulation through 
inhibition. There are three types of inhibitors of caspases: viral inhibitors, cellular-derived 
inhibitors, and chemical inhibitors. The one known viral inhibitor in mammals is a protein 
known as CrmA and is derived from the cowpox virus (89, 90). In infected organisms it inhibits 
the activity of Caspase-1 and Caspase-8. Additionally, there is a single confirmed cellular-
derived inhibitor in mammals known as X-linked apoptosis inhibiting protein (XIAP) (91). XIAP 
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contains three baculoviral IAP repeat (BIR) domains, which aid in interaction with Caspases. 
XIAP blocks the catalytic activity of Caspase-3 and Caspase-7 through interaction with the 
linker region between BIR1 and BIR2 in XIAP with the active site in these caspases (92). XIAP 
also blocks the activity of Caspase-9 through interaction of BIR3 with the amino terminal after 
processing (93). While another set of proteins, the inhibitors of apoptosis (IAPs) known as 
cellular IAP 1 and 2 (cIAPs), were initially purported to have a role in apoptosis inhibition 
through direct inhibition of catalytic caspase activity, later studies determined that interaction 
with caspases did not modulate caspase activity (94). Chemical inhibitors of Caspases are 
synthesized molecules that specifically bind to the active site in Caspases, that may also contain 
modifications allowing for irreversible or reversible binding. These inhibitors are generated to 
either inhibit all caspases (pan-caspase inhibitors) or specific to certain caspases (e.g. Z-DEVD-
FMK which inhibits Caspase-3). 
Caspases also have alternative roles in cell survival and proliferation, as well as inhibition 
of other programmed cell death pathways. For example, Caspase-8 in addition to promoting 
apoptotic death is also important for survival, as Caspase-8 deficiency leads to embryonic 
lethality in mice (95). Additionally, further studies implicate a role for Caspase-8 in the 
inhibition of programmed necrosis (also referred to as necroptosis) through cleavage of the 
Receptor-interacting protein (RIP) kinases 1 and 3 (96, 97). Our studies (discussed in Chapters II 
and III) with mice and cells deficient for BCL-2 family members Bax, Bak, and Bid suggest a 
role for Bid in the mediation of Caspase-8 activity. Caspase-8 promotes the cleavage of Bid to 
promote intrinsic apoptosis execution. The studies detailed later will explore an alternative 
interaction between Caspase-8 and Bid in the setting of necroptotic death and how this affects 
the stability of Rip1.  
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Figure 1.3 Structure of Caspases 
A) Caspases contain three main domains: The prodomain which may contain death effector 
domains (DED) or death domains (DD), the large subunit, and the small subunit. Between the 
prodomain and the large subunit is the prodomain linker region. The linkage region between the 
large and small subunit is the interdomain linker region. Asparagine within these regions serve as 
sites of cleavage. B) Initiator caspases exist as monomers in healthy cells. Upon receipt of an 
apoptotic stimulus, these caspases are recruited to activation platforms through their Death 
effector or Caspase activation and recruitment domains (DED or CARD). At these sites Caspases 
undergo induced dimerization through proximity, promoting autocatalytic activity. An 
autocatalytic cleavage leads to the formation of the mature initiator caspase. C) Effector caspases 
exist as dimers within healthy cells and are maintained in an inactive state by the intact 
interdomain linkage. Activated initiator caspases cleave this region promoting activation of 
effector caspases. Adapted from (76). 
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The BCL-2 Family and Apoptosis Regulation 
 Early studies of the development of nematode Caenorhabditis elegans demonstrated that 
a specific number of cells were always eliminated during development of the organism (98). 
Mutagenesis screens led to the determination that programmed cell death is very important in the 
proper development of these animals. Utilizing these screens, egg-laying defective mutants 
(EGL) were identified and characterized, which led to the identification of EGL-1, an ortholog of 
BH3-only members of the BCL-2 family (99). Further mutagenesis screens resulted in the 
identification of cell death abnormal (CED) mutants. Initially CED-3 (corresponding to a 
caspase) and CED-4 (corresponding to APAF-1) mutants were identified due to a lack of death 
of specific cells identified to undergo programmed cell death in wild type animals (100). Further 
studies led to the discovery CED-9 gain-of-function mutants (ortholog of BCL-2), which were 
able to rescue the defects in EGL-1 mutants, and also could dominantly block cell death in cells 
which typically died in wild type animals (101).   
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Figure 1.4 Conservation between Mammalian BCL-2 Family and regulators of cell death in 
C. elegans  
Programmed cell death in C. elegans like mammalian organisms is regulated by a family of 
proteins.  The BH3-Only protein EGL-1 activates apoptotic death through interaction with CED-
9, similar to interaction of BH3-only proteins with antiapoptotic proteins such as BCL-2. 
Mammalian and C. elegans signaling diverge in the transduction of the apoptotic death in that 
the CED-9 homolog (BCL-2) is able to directly bind CED-4 (homolog of Apaf-1) to inhibit 
apoptosis. In the absence of this interaction, CED-4 can bind CED-3 promoting its activation and 
execution of apoptosis. Thus C. elegans do not require MOMP to promote apoptosis. This is in 
contrast to mammalian signaling in which BH3-only proteins can additionally activate execution 
of apoptosis through Bax and Bak, which allows for MOMP and promotes Caspase activation. 
Adapted from (102). 
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Around the same time the founding member of the BCL-2 family of proteins, which are 
orthologs to several proteins identified in C. elegans (as described above), was identified. B cell 
lymphoma-2 (BCL-2), which was first identified when the breakpoint of the chromosomal 
translocation between chromosomes 14 and 18 t(14:18), was cloned. This translocation was 
found to result in the fusion of the BCL-2 gene to the immunoglobulin locus in human follicular 
B cell lymphomas and B cell leukemias (103, 104). Further investigation revealed the exact 
location of the break, that it caused BCL-2 overexpression, and that it was similar in most 
patients that developed follicular lymphoma, suggesting it was a result of defective class-
switching in B cells (105). Soon after it was discovered that c-MYC cooperates with BCL-2 to 
protect hematopoietic progenitors from cytokine withdrawal-induced cell death through 
introduction of a human BCL-2 transgene (overexpressiong BCL-2) into bone marrow from Eμ-
Myc mice (106). The lab of Stanley Korsmeyer developed a transgenic mouse with an artificial 
chromosome containing the t(14:18) mutation. These studies caused overexpression of BCL-2 
and confirmed that it promotes increased survival in B cells (107). The increased survival led to 
accumulation of mutations within cells in the follicles of the spleen that over time had the 
capability to transform to lymphoma (107, 108). These studies established BCL-2 as a part of a 
novel class of proteins. The overexpression identified BCL-2 as a new type oncogene at the time, 
one playing a role in cell death (109) (as evasion of cell death is a defining feature of cancer 
found with the discoveries of both BCL-2 and TP53 (110)). 
 Members of the BCL-2 family function as regulators of intrinsic apoptosis, regulating 
execution of mitochondrial outer membrane permeabilization (MOMP), the “point of no return” 
in apoptosis execution.  These proteins share conserved domains of homology known as the 
BCL-2 Homology (BH) domains, of which there are four. These domains are made up of  
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helices which are key structures in BCL-2 family members, and also promote their function 
through interaction with each other and membranes. All four BH domains are present in the 
founding member BCL-2, and each member contains homology to at least one BH domain. BH 
domains allow the BCL-2 family to interact with each other and subsequently for exertion of 
their functions. Proteins within the BCL-2 family are subdivided into three subgroups based 
upon the presence of these domains and their function. These include the multi-domain 
antiapoptotic proteins, the multi-domain proapoptotic effector proteins, and the BH3-only 
sensitizer and direct activator proteins. Like most biological pathways, the BCL-2 family is 
regulated through several post-translational modifications (phosphorylation, cleavage, 
ubiquitylation, and fatty acid addition), and through subcellular localization (6). 
The BH3-only subgroup of the BCL-2 family contains members with homology to only the 
BH3 domain (e.g. Bid, Bim, Bad, Noxa, and Puma). Several of these proteins also contain a 
transmembrane domain which allows for membrane interaction. BH3-only proteins serve as the 
first layer of regulation in intrinsic apoptotic activation, sensing apoptotic stimuli through a 
variety of cellular stresses and transducing the cellular response through post-translational 
modification. These proteins are further divided into two groups whose function is mutually 
exclusive and is to either sensitize proapoptotic multi-domain members (through quenching of 
antiapoptotic multi-domain members) to activate apoptosis, or to promote the activation of 
apoptosis directly through activation of the multi-domain proapoptotic members (111). The BH3 
domain within these proteins is key in the interaction with other members of the BCL-2 family to 
carry out functions in the promotion of apoptosis (112). While the levels of each of these 
proteins is important in determining the outcome of apoptotic activation in a cell, other factors, 
such as the stimulus and method of activation, are important in their activation and the final 
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outcome. For instance, Bid is activated through cleavage by Caspase-8 following death receptor 
activation which promotes translocation to the mitochondrion and Cytochrome C release (113, 
114). PUMA and Noxa are directly transcriptionally upregulated by p53 following DNA damage 
(115–117). Conversely, Bad is phosphorylated which promotes binding to other non-BCL-2 
family proteins, and blocks its proapoptotic activity (118, 119). Following their activation, the 
BH3-only proteins promote multi-domain proapoptotic protein activation and inhibit 
antiapoptotic proteins. These proteins serve distinct roles in sensing different death stimuli and 
transmitting the signal downstream to promote apoptosis.  
The multi-domain proapoptotic proteins, which include Bax, Bak, and Bok, contain BH 
domains 1-3, as well as a transmembrane domain. These proteins interact with the OMM and 
upon activation disrupt the OMM through pore formation. As such, these proteins serve as the 
guards of OMM integrity in the face of BH3-only protein activation and anti-apoptotic protein 
inhibition. Loss of Bax and Bak inhibits cytochrome C release, inhibiting intrinsic apoptosis 
(120, 121). Previous studies demonstrate that Bax and Bak are activated through direct and 
indirect methods leading to conformational changes which allow for OMM localization as well 
as homo- and heteroligomerization to form pores in the mitochondrion (122–124). While Bax is 
localized to the cytosol, and translocates to the mitochondrion upon activation by Bid (125), Bak 
is constitutively localized to the OMM. This oligomerization event forms a pore in the OMM and 
allows for the release of cytochrome C, and apoptosis activation. The outcome of interaction of 
members of this subgroup with BH3-only and multi-domain antiapoptotic proteins at the OMM, 
determines if apoptosis proceeds (activation) or is halted (inhibition).  
Members of the multi-domain antiapoptotic group (e.g. MCL-1, BCL-XL) contain all 
homology domains present in BCL-2 as well. These proteins block apoptosis by inhibiting the 
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activation of multi-domain and BH3-only proapoptotic proteins. Inhibition occurs through 
sequestration, which provides a second opposing layer of regulation in apoptosis activation. This 
event is described as “mutual sequestration” and results in two effects: first antiapoptotic 
proteins binding to BH3-only proteins prevents BH3-only proteins from activating Bax and Bak; 
second binding of BH3-only proteins to antiapoptotic proteins blocks antiapoptotic proteins from 
hindering the activation of Bax and Bak. This in turn leaves other BH3-only proteins free to bind 
and activate Bax and Bak. As a result, the relative stoichiometry and interaction of antiapoptotic 
proteins to multi-domain and BH3-only proapoptotic molecules plays some role in the outcome 
of apoptotic signaling (126). Another factor that plays a role in this outcome is the subcellular 
localization of these proteins. While antiapoptotic proteins are primarily found in the OMM they 
may also be present in the inner mitochondrial membrane (IMM), cytosol, or at the endoplasmic 
reticulum (127, 128). Depending upon their location these proteins can exhibit differential 
functions involved in apoptosis or alternative roles within the cell.  
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Figure 1.5 Members of the BCL-2 family have distinct functions in the regulation of 
apoptosis  
The BCL-2 Family is made up of proteins sharing domains of homology known as BCL-2 
homology domains (BH domains) found within the founding member BCL-2. There are four BH 
domains, and the presence or absence of these domains as well as function categorize these 
proteins into subgroups. There are three subgroups within this family; the multi-domain 
antiapoptotic proteins, the multi-domain proapoptotic proteins, and the BH3-Only proteins. The 
multi-domain antiapoptotic proteins serve as inhibitors of apoptosis and function at the 
mitochondrion to inhibit the actions of multi-domain proapoptotic and BH3-Only proteins. 
Multi-domain antiapoptotic proteins contain all BH domains as well as a transmembrane domain 
aiding in association with membranes. The multi-domain proapoptotic proteins function to 
execute apoptosis through formation of pores in the OMM. These proteins contain BH domains 
1-3 and also contain a transmembrane domain aiding in their association with membranes. BH3-
Only proteins serve as sensitizers and activators of apoptosis through displacement of multi-
domain proapoptotic proteins from multi-domain antiapoptotic proteins (removing inhibition) 
and through direct activation of multi-domain proapoptotic proteins, respectively. Adapted from 
(6). 
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BCL-2 family members interact with each other through α helical BH domains. Previous 
studies demonstrate that the BH1, BH2, and BH3 domains present in antiapoptotic proteins form 
a hydrophobic groove that is capable of binding the BH3 α helix present in proapoptotic proteins 
(6). However, while members of each subgroup contain the same BH domains, members display 
different specificity in their binding to each other. This in turn affects apoptotic activation 
downstream of different stimuli and/or in different cell types. These differences in specificity are 
particularly important in the activation of Bax and Bak by BH3-only proteins which led to the 
classification of these proteins as sensitizers and activators of apoptosis (111, 129). Activator 
BH3-only proteins (e.g. Bid, Bim, and Puma) are able to directly promote the activation of Bax 
and Bak (122, 130–133).  Conversely sensitizer BH3-only proteins Bad and Noxa are unable to 
promote the direct activation of Bax and Bak (111, 134). These proteins instead inhibit 
antiapoptotic proteins through direct interaction, which in turn lowers the threshold of BH3-only 
protein needed for activation of Bax and Bak. Additionally, BH3-only proteins demonstrate 
specificity in binding to other BCL-2 family members based upon the structure of their BH3 
domain. For instance, while Bad is capable of binding BCL-2 and BCL-XL, Noxa is only able to 
bind MCL-1 (130, 134).   
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Figure 1.6 Apoptotic regulation by BH3-only sensitizers and activators 
BH3-Only sensitizers and activators function in a mutually exclusive manner to regulate intrinsic 
apoptosis. A) BH3-only proteins are classified based on their ability to interact with different 
classes of BCL-2 family members. Activator BH3-only proteins can interact with proapoptotic 
Bax and Bak to promote apoptosis. Sensitizer BH3-only proteins interact exclusively with the 
antiapoptotic proteins, and can aid in apoptosis activation through release of Bax and Bak from 
antiapoptotic protein inhibition. Interaction between antiapoptotic proteins and Bax/Bak results 
in “mutual sequestration”, a phenomenon in which the binding of these proteins to each other 
inhibits binding to other BCL-2 family proteins. This results in an apoptotic threshold that must 
be overcome to activate apoptosis. As such, this threshold is quite sensitive to the stoichiometry 
of BCL-2 family members at the mitochondrion. B) Activator BH3-only proteins are capable of 
interaction Bax and Bak. Sensitizer BH3-only proteins are limited to binding certain 
antiapoptotic proteins. While Bad is capable of binding both BCL-2 and BCL-XL, Noxa is only 
capable of binding MCL-1. Adapted from (135). 
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In addition to their canonical functions in MOMP in apoptosis, mounting evidence 
demonstrates that members of the BCL-2 family also have alternative functions in many 
important cellular functions (136). For example, there are many examples of BCL-2 family 
members playing roles in mitochondrial fusion/fission, metabolism, and respiration. These 
include Bax and Bak, which are implicated in the fusion of mitochondria in homeostatic settings 
through formation of a complex with mitofusin-2 (MFN2) (137, 138), and Bax which aids in 
fission along with dynamin-related protein 1 (DRP1) in the setting of cell death (139). Bax and 
Bak also localize to the endoplasmic reticulum (ER) where they can promote apoptosis following 
calcium depletion through activation of Caspase-12 (140). An alternative isoform of MCL-1 
present in the IMS is also implicated in the maintenance of IMM cristae structure, regulation of 
membrane potential, mitochondrial fusion, and ATP production (141). Additionally BCL-XL aids 
in the efficiency of respiration through the interaction with mitochondrial F1F0 ATP synthase 
aiding in the stabilization of mitochondrial membrane potential (142–144). The BCL-2 family 
additionally has many prosurvival roles at the cellular level. For example, BAD promotes 
survival prior to apoptotic activation through formation of a mitochondrial complex with 
glucokinase (hexokinase IV) and other factors that aid in glycolysis (145–147). Additionally, 
NOXA promotes survival through promotion of glucose metabolism through the pentose 
phosphate pathway (148). Additionally, Bax, BCL-2, and BCL-XL are implicated in calcium 
homeostasis through localization to the ER and release of calcium to the mitochondria 
independent of their apoptotic functions (136). BCL-2 family antiapoptotic members BCL-2, 
MCL-1, and BCL-XL also inhibit autophagy through interaction with the BH3-only protein 
Beclin. Lastly, previous studies, and studies completed in the Zinkel lab demonstrate a role for 
Bid in the DNA damage response (DDR). These studies demonstrate that Bid is phosphorylated 
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by Ataxia Telangiectasia Mutated (ATM) and ATM and Rad-3 related (ATR) and is a part of the 
ATR-directed DNA damage sensing complex, which also contains ATR-interacting protein 
(ATRIP)  (8, 9, 149, 150). Bid is also implicated in the regulation of mitochondrial ROS 
downstream of ATM, which is important in the maintenance of hematopoietic stem cell 
quiescence. This role is mediated through cooperation with mitochondrial carrier homolog 2 
(MTCH2) which resides at the mitochondrion (151). This alternative function of Bid is also 
mediated through phosphorylation (152). Bid was also implicated in the inflammatory and innate 
immune response following nucleotide-binding and oligomerization domain (NOD) receptor 
signaling (153).  
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Table 1.2 Alternative function for the BCL-2 Family 
Member Alternative Function Reference 
Bax Mitochondrial fusion/ fission, calcium homeostasis at the ER  (136–139) 
Bak Mitochondrial fusion  (138) 
MCL-1 Maintenance of mitochondrial cristae structure and fusion, ATP production  (141) 
BCL-XL Maintains efficiency of respiration, calcium homeostasis at the ER 
(136, 142–
144)  
Bad Aids in glucose metabolism promoting survival (145–147)  
Noxa Promotes glucose metabolism through the pentose phosphate pathway  (148) 
BCL-2 Calcium homeostasis at the ER  (136) 
Bid Aids in the DNA damage response, inflammatory, and innate immune signaling 
 (8, 9, 149, 
150, 153, 154) 
 
 
BH3-only protein Bid  
The BH3-only protein Bid (BH3-interacting domain death agonist) was discovered in 1996 
as a protein that was key in the mitochondrial activation of apoptosis through interaction with 
Bax (155). These studies revealed that competition between the interaction of the BH3 domain of 
Bid and the BH1 domain of Bax or BCL-2 determines the outcome following stimulation. 
Formation of Bid-Bax heterodimers allows for apoptosis execution, while Bid-BCL-2 
heterodimers inhibits this process. Further study revealed that Bid is cleaved by the cysteine-
protease Caspase-8 at aspartic acid 59 to promote apoptosis, translocates to the mitochondria, 
activates Bax, and promotes Cytochrome C release (113, 114, 133, 156). Cleavage of Bid by 
Caspase-8 was further determined to be important in the activation of apoptosis at the organismal 
level through examination of mice after tail-vein injection of Fas ligand to promote activation of 
the Fas receptor and to promote apoptotic death of the liver. These studies found that mice 
deficient for Bid were protected from fulminant liver apoptosis as compared to wildtype animals 
(157), demonstrating the key role of Bid in apoptosis activation.  
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The solution structure of human and mouse Bid was determined in the same year and 
provided some insight into how Bid mediates apoptosis activation (158, 159). These studies 
revealed that contrary to other BH3-only proteins, Bid is very structured, and maintains that 
structure even after cleavage by Caspase-8 (160). Further structural studies demonstrate that 
Bid’s structure is more similar to the multi-domain anti- and pro-apoptotic proteins (Bax in 
particular), fitting with its strong ability to promote apoptosis (161). The NMR structure of Bid 
reveals that is composed of 8 α helices, with two hydrophobic helices making up a core 
surrounded by 6 amphipathic helices and an unstructured loop. The Caspase-8 cleavage site of 
Bid is contained in the unstructured loop of Bid. The resulting cleavage allows for the 
dissociation of α helices 1 and 2 from α helix 3, exposing the BH3 domain. OMM interaction is 
facilitated by a protein known as (MTCH2) which is present in the OMM. MTCH2 facilitates the 
targeting of cleaved Bid to the mitochondrion, and promotes unfolding of Bid which is critical 
for its insertion into the OMM (162, 163). 
While Bid is best-known for it role in activation of apoptosis following cleavage by 
Caspase-8, several studies implicate its cleavage by other proteases. For example, Bid can be 
cleaved by activated Caspase-3 and is believed to be a part of a positive feedback loop that 
promotes propagation of the apoptotic signal (164). Additionally Calpains were demonstrated to 
promote cleavage of Bid in vivo in the setting of ischemia/reperfusion injury and in vitro 
following Cisplatin treatment (165, 166). Cathepsins, proteases found in lysosomes and activated 
by low pH can also promote cleavage of Bid and promote apoptosis following damage of the 
lysosome (167–169). Lastly Granzyme B, a protease present in cytotoxic T cells and other 
immune cell types, is demonstrated to promote rapid apoptosis through the release of cytolytic 
granules into cells. Bid was determined to be the factor mediating this rapid response through 
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cleavage by Granzyme B (170, 171).  My studies presented in Appendix B also implicate an 
alternative interaction of Granzyme B and Bid that is important in the inhibition of necroptotic 
signaling.  
Bid has multiple alternative functions promoting survival and modulating the innate immune 
response. These alternative functions are mediated through another post-translational 
modification of Bid, phosphorylation. Phosphorylation of mouse Bid at serine 61 (S61) and 
serine 64 (S64) by Casein Kinase I II (CK1 and CK2) blocks cleavage by Caspase-8 and blocks 
apoptotic activation (172). Bid is phosphorylated at S61, S64 and S78 by Ataxia Telangiectasia 
Mutated (ATM) and ATM and Rad-3 related (ATR) kinases in response to DNA Damage (7, 9, 
150, 173) aiding in efficient activation of the DNA damage response. Additionally, 
phosphorylation of human Bid at S64, S65, and S76 as well as the aforementioned sites in mouse 
Bid is important in activating innate immunity and the inflammatory response downstream of 
NOD signaling (10). Phosphorylation in the unstructured loop aids in the binding of NOD1 and 
NOD2. These findings demonstrate an important role in phosphorylation in alternative functions 
for Bid.  
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Figure 1.7 NMR Solution Structure of Mouse Bid 
The NMR solution structure of Bid revealed that it was composed of 8 α helices and an 
unstructured loop between helix 2 and 3 (Protein data bank entry:1DDB) (158, 159). Upon death 
receptor activation Bid is cleaved at Aspartic Acid 59 by Caspase-8 and translocates the 
mitochondrial membrane where it promotes the activation of Bax and Bak and apoptosis. 
Phosphorylation of Bid promotes alternative functions (e.g. Phosphorylation by ATM/ATR and 
participation in the DNA damage response).  In our studies of Bid’s role in necroptosis we 
hypothesize that Caspase-8’s specificity for Bid is altered in necroptosis inhibition.  
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Necroptosis  
 The study of necroptosis (also known as programmed necrosis) is an emerging area of the 
programmed cell death field, which was only recognized in the last 16 years. Previously, 
necrosis was purported to be an unprogrammed, default cell death executed in settings where an 
overwhelming cell death stimulus occurred (e.g. freeze-thaw cycles, ischemia/reperfusion injury, 
or oxidative stress) (174). As a result, necrosis was largely disregarded in the study of 
programmed cell death within the field. However, the recognition that stimulation with TNFα 
could promote both an apoptotic and necrotic death in different cell types implicated that cell 
death programs might be an intrinsic, programmed process (12). Studies of TNF signaling 
continued, with the proteins involved in the upstream signaling processes of TNFR and FasR 
rapidly being elucidated, but the main outcomes recognized being apoptosis and NF-κB 
mobilizing cytokine signaling (53). However, in 2000 studies with mouse and human T cells 
revealed that Receptor-interacting protein 1 (Rip1) was required for the execution of necroptotic 
death if Caspase activation was inhibited, providing evidence that necrosis was likely a 
programmed process, and that the Rip kinases were involved in the signaling of this pathway 
(175). Previous studies implicated necrosis as an outcome of TNF signaling as well as a role for 
Rip1 in apoptosis, but the finding from Jurg Tschopp’s group was the first to implicate the 
involvement of a signaling protein in this process (176, 177). The term necroptosis was coined 
with development of Necrostatin-1 (Nec-1) which was first determined to block necrosis in 
ischemic brain injury through an unbiased screen of small molecules  (46). Later studies 
identified Rip1 as a target of Nec-1 through inhibition of the kinase activation of Rip1 (178). 
Since that time our understanding of this signaling process has steadily increased through study 
of necroptotic signaling downstream of death receptors (e.g. TNFR1, TNFR2, FAS), and pattern 
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recognition receptor (PRR) signaling. However, many key questions still exist such as; What 
other upstream signaling pathways can feed into the downstream necroptotic pathway? What are 
the distinct complexes (and members within them) that lead to necroptotic activation?  And 
importantly, my data will address: What causes a cell to signal toward an apoptotic versus 
necroptotic death? 
 
Necroptosis Regulation  
 Signaling through death receptors utilizes the same proteins upstream of either an 
apoptotic or necroptotic outcome. As such, necroptotic signaling downstream of death receptors 
begins in the same manner as described above with the activation of death receptors through 
trimerization and conformational change of the cytoplasmic domains. The cytoplasmic domains 
then associate with adapter proteins forming the DISC or Complex I (51). Three possible 
outcomes exist through modulation of stability of key proteins, post-translational modifications, 
and Caspase activation; Apoptosis activation, necroptosis activation, and activation of NF-κB 
and mitogen-activated protein kinase (MAPK)/ Jun amino kinase (JNK) signaling. The activation 
of Caspases-8/-10 leads to apoptosis activation through cleavage of executioner Caspases and 
apoptotic substrates such as BH3-only Bid. Additionally, Caspase-8 promotes the cleavage of 
several other proteins, including Rip1, which in turn blocks NF-κB, MAPK-JNK, and 
necroptosis activation. Within Complex I, Caspase-8 promotes the cleavage of cylindromatosis 
(CYLD) a deubiquitylating enzyme that removes ubiquitylation from Rip1 (179–183). 
Necroptosis proceeds in cases where Rip1 and Rip3 are activated through phosphorylation. 
However, the Rip kinases can also be inactivated through cleavage and degradation (leading to 
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an apoptosis outcome if Caspases are activated) or ubiquitylated (Rip1 only, promoting NF-κB 
and MAPK-JNK signaling activation).  
Ubiquitylation of these proteins is carried out by cIAP1 and cIAP2, E3 ubiquitin ligases 
which are recruited to Complex I and stabilized by TNFR-associated factor 2 (TRAF2) which 
allows for the formation of linear ubiquitin chain assembly complex (LUBAC) (184, 185). 
Formation of LUBAC is facilitated by SHANK-associated RH domain-interacting protein 
(SHARPIN), Heme-oxidized iron regulatory protein 2 ubiquitin ligase-1 (HOIL-1), and HOIL-1 
interacting protein (HOIP) (186, 187).  This ubiquitylation of Rip1 through Lysine 63 on 
ubiquitin (K63-linkage) allows it to serve as a docking site for the proteins Transforming growth 
factor-β activated kinase 1 (TAK1) and TAK1-binding protein 2 and 3 (TAB2 and TAB3) 
promoting TAK1 activation (188, 189). NF-κB signaling is promoted through the recruitment of 
the IKK complex (Inhibitor of NF-κB kinase γ/ NF-κB essential modulator (NEMO), Iκα kinase 
(IKKα), Iκβ kinase (IKKβ) to complex I. Phosphorylation of IKKβ by TAK1 activates the IKK 
complex, and in turn allows it to phosphorylate IκBα (190). Phosphorylation of IκBα promotes 
its ubiquitylation and degradation, releasing NF-κB. MAPK-JNK signaling proceeds through the 
phosphorylation of MAPKs by TAK1 which stimulates the activation of JNK signaling (190) 
A20, a protein with both deubiquitylation and E3 ligase domains, has a controversial role in this 
process. While initial studies implicated A20 in the inhibition of NF-κB through removal of 
K63-linked ubiquitin and replacing it with K48-linked (degradative) ubiquitin, more recent 
studies implicate a role for A20 in the stabilization of the LUBAC assembly, blocking its 
removal by deubiquitylating enzymes and cell death (191, 192).  
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Figure 1.8 Outcomes of death receptor signaling 
Activation of death receptor signaling can have two main outcomes, signaling to promotes death, 
survival, or stress signaling pathway activation. Death signaling can result in apoptotic or 
necroptotic signaling, depending upon the activation of Caspase-8/10. Additionally, survival 
signaling through NF-κB occurs with the addition of linear ubiquitin by LUBAC, which serves 
as a scaffold for binding of NEMO. Similarly stress signaling through MAPK-JNK is facilitated 
by phosphorylation of the MKK6 by TAK1, which is activated through ubiquitylation, that 
promotes phosphorylation of JNK and activation of JNK signaling. Adapted from (190).  
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Signaling downstream of death receptors proceeds with the formation of Complex II 
containing Rip1, Rip3, FADD, and/or TRADD, and Caspase-8, which are capable of binding to 
each other through DEDs and DDs (193). This complex can promote both apoptosis and 
necroptosis. As discussed above, apoptosis occurs in the presence of Caspase-8/10 activation, in 
this instance, this complex is proapoptotic and is termed Complex IIA. Necroptosis proceeds in 
cases where Rip1 is deubiquitylated effectively allowing its translocation to the cytosol and 
recruitment to this complex. Necroptosis also proceeds in cases where Caspases cannot be 
activated to promote Rip kinase cleavage. Within this complex Rip1 and Rip3 become activated 
through either an autophosphorylation event or cross phosphorylation of the kinases on each 
other and is known as Complex IIB (24, 194). In human Rip, phosphorylation occurs on Serine 
161 and 166 in Rip1, and Serine 199 in Rip3 (195, 196). In mouse Rip this event occurs on Rip1 
at Serine 161 and in Rip3 at Serine 204. Necroptosis inactivation by Caspase-8 occurs through 
the cleavage of both Rip1 and Rip3 within this complex, inhibiting their phosphorylation (96, 
197). Importantly, formation of active Caspase-8/c-FlipL heterodimers (as opposed to active 
Caspase-8 homodimers) also promotes the cleavage of Rip1, but has decreased specificity for 
cleavage of Bid, which will become an important point in our later studies of necroptotic 
signaling (80, 198). Following phosphorylation of Rip3, mixed-lineage kinase domain like 
(MLKL) is recruited to and phosphorylated by Rip3 at Threonine 357/ Serine 358 in human 
MLKL and at Serine 345 in mouse MLKL (199–201). This phosphorylation event releases a 
“latch” on a four helix bundle within MLKL that allows for its oligomerization and translocation 
to membranes containing phosphatidylinositol phosphates and cardiolipin (e.g. plasma and 
intracellular membranes). MLKL oligomers are capable of binding to these lipids, disrupting 
membrane integrity and promoting execution of necroptosis (199, 202–204). This leads to loss of 
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membrane integrity in the plasma and organelle membranes, often causing bursting of cells, and 
release of alarmins, molecules found within the cell released after execution of programmed cell 
death (14). 
In the context of the studies presented here we hoped to answer a key unknown in the 
field of programmed cell death: How is the decision made to undergo either an apoptotic or 
necroptotic cell death downstream of death receptor signaling? Several proteins (including 
Caspase-8 and cFlipL) are purported to be key in this decision, however incomplete studies of 
distinct complex formation cloud the understanding of the mechanistic regulation of this 
decision. Our studies suggest that Bid cooperates with Caspase-8 and cFlipL as well as Rip1 to 
determine the path to death. Additionally, several groups believe that Rip3, but not Rip1 is 
required for necroptosis activation and execution. Our studies, as well as studies from other 
groups including Junying Yuan and Michelle Kelliher suggest that Rip1 is also important in 
necroptosis activation (43, 44, 205). Overall, our studies will provide insight into understanding 
this key unknown, with the hope that this may provide not only better understanding of 
necroptotic signaling, but also targeting of this pathway in human disease.  
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Figure 1.9 Downstream death receptor signaling toward apoptosis or necroptosis 
Death receptor signaling can lead to two potential outcomes of death; apoptosis or necroptosis. 
Apoptosis proceeds in cases where Caspase-8/10 becomes activated and can cleave BID, 
Caspase-3, Rip1 and other substrates. Cleavage of Rip1 inhibits promotion of necroptosis. 
Necroptosis proceeds in cases where ubiquitylation of Rip1 is effectively removed or when 
Caspase-8/10 is unable to be activated. In these settings Rip1 forms Complex IIB with Rip3, 
Caspase-8, and FADD and is able to be activated through phosphorylation. Phosphorylation of 
Rip3 occurs as well, allowing it to activate MLKL and execute necroptosis. 
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Necroptosis Execution 
Additionally, a protein known as phosphoglycerate mutase family member 5 (PGAM5), a 
phosphatase that localizes to the mitochondrion, has also been implicated in necroptosis 
execution through the activation of DRP1 (206). However, the involvement of PGAM5 in 
necroptosis is controversial, as more recent studies suggest that PGAM5 functions instead to 
inhibit necroptosis. One in vivo study of PGAM -/- mice demonstrates increased necroptosis and 
inflammation, manifest by increased infarct size after ischemia/reperfusion injury. This study 
suggests that PGAM5 is important in promoting mitophagy, a process that removes defective 
mitochondria and prevents necroptosis. PGAM5 mediates this process through binding with 
Phosphatase and Tensin (PTEN)- induced putative kinase 1 (PINK1) to promote mitophagy. In 
the absence of PGAM5 mitophagy does not occur, leading to accumulation of defective 
mitochondria, increased ROS production, and increased necroptosis (207). Another study 
implicates decreased size and survival in PGAM5 deficient mice. In vitro studies of cells from 
these animals demonstrate increased necroptosis but decreased IL-1β production, mediated 
through decreased NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) 
inflammasome activation which is necessary for the production of mature IL-1β (208). These 
studies suggest that PGAM5 functions to instead inhibit necroptosis through regulation of 
mitochondrial turnover, however further studies are necessary to fully understand the role of this 
mitochondrial protein in necroptosis in relation to normal cell homeostasis.  
Production of reactive oxygen species (ROS) is also implicated in necroptosis execution, 
although it is not required in some instances (194, 209). The first instance of this was reported 
downstream of TNFR signaling, which demonstrated that downstream ROS production could be 
inhibited by antioxidants and causes ultrastructural damage to mitochondria (210). ROS is 
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believed to be generated from two main structures, the mitochondrial respiratory chain and 
plasma membranes. Respiratory bursts as a result of increased glycolysis, glutaminolysis, and 
glycogenolysis are believed to promote the production of ammonia and ROS as well as leading 
to mitochondrial uncoupling which is toxic to the cell (211, 212). The enzyme NADPH oxidase 
1 (NOX1) is believed to promote ROS production from plasma membranes following 
stimulation of TNFR through recruitment by Rip1 (213). Additionally, increased production of 
ceramide through the hydrolysis of sphingomyelin by sphingomyelinases (SMAses) is believed 
to promote ROS production as well as lipid peroxidation (214, 215). Lipid peroxidation 
promotes breakdown of lipid structure through removal of electrons forming radicals (216). The 
production of reactive nitrogen species (RNS) is also implicated to play a role in necroptosis 
execution (217, 218). Studies of RNS suggests that they promote oxidation and peroxidation of 
proteins and lipids, destroying these structures and promoting death (219). While there is still 
much to be learned about the involvement of ROS and RNS in the execution of necroptosis, the 
evidence available thus far suggests they can be important in programmed cell death.  
 
Necroptosis activation following other stimuli  
 Much of the early studies regarding necroptosis describe our understanding following 
death receptor signaling following TNFR or FasR activation. However, more recently 
necroptosis stimulation downstream of pattern-recognition receptors (PRR) family members, 
which are associated with innate immunity, has been demonstrated (220). For example, the Toll-
like receptors (TLRs) can promote necroptotic death. Stimulation of necroptosis is often 
mediated through the RHIM domain, and interaction between Rip1 and Rip3 or Rip3 with a 
RHIM-containing adapter protein. TLR signaling, which is activated in response to binding of 
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pathogen-associated molecular patterns (PAMPs) (e.g. lipopolysaccharide (LPS) or 
Polyinosine:polycytidylic acid (Poly I:C)), signals through Toll/Interleukin-1 receptor domain-
containing adapter inducing interferon β (TRIF), myeloid differentiation on gene 88 (Myd88), or 
Toll-interleukin-1 domain containing adapter protein (TIRAP)(190). TRIF binds to Rip3 through 
the RHIM and promotes necroptotic execution through MLKL activation (221, 222). These 
studies implicate this signaling in response to activation of TLR2, TLR3, TLR4, TLR5, and 
TLR9. Additionally, DNA-dependent activator of interferon (IFN) regulatory factors (DAI) can 
directly sense foreign DNA within the cytoplasm, and bind to Rip3 to stimulate necroptosis, as 
well as NF-κB and interferon type 1 signaling responses mediated through interferon regulatory 
factor (IRFs) (223–225). Additionally, activation of Interferon signaling through Interferon α/β 
Receptor (IFNAR) by IFNα or IFNβ stimulates Janus Kinase 1 (JAK1) which promotes the 
formation of the Interferon-stimulated gene factor 3 (ISGF3) complex containing Signal 
transducer and activator of transcription 1 and 2 (STAT1, STAT2) and IRF9. This complex 
promotes transcription-dependent necroptosis activation through activation of Rip1 and Rip3 
(226). Necroptotic signaling through other receptors provides an explanation for the activation of 
necroptotic death from diverse stimuli, and also aids in understanding how crosstalk between 
receptor signaling determines the final outcome of the signal.  
 
 
 
 
 44 
 
 
Figure 1.10 Alternative stimuli for necroptosis 
In addition to being stimulated through death receptor signaling, necroptosis can also be 
stimulated through Toll-like receptors (TLRs) and Interferon α/β Receptor 1(IFNAR). A) 
Stimulation through TLRs can occur through several adapter proteins including MyD88, TIRAP, 
and TRIF. TRIF is capable of binding Rip1 and Rip3 through the RHIM domain to promote their 
activation and necroptosis signaling. B) Signaling through IFNAR promotes the activation of 
JAK1. JAK1 signaling leads to formation of the Interferon-stimulated gene factor 3 complex 
containing STAT1, STAT2, and IRF9. This complex activates transcription and promotes the 
activation of Rip1 and Rip3, leading to necroptosis. C) Lastly, binding of DNA-dependent 
activator of IFN regulatory factors (DAI) can directly bind viral DNA, and in turn complex with 
Rip3 through its RHIM domain to promote its activation and necroptosis execution. Adapted 
from (15). 
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Inhibitors of necroptosis 
 Since the discovery that necrosis is a programmed process mediated by the activation of 
Rip kinase 1 and 3, and MLKL, many inhibitors that block necroptosis at specific levels of 
signaling have been identified. The first inhibitor of necroptosis was discovered before the 
identification of necrosis as a programmed process. The laboratory of Junying Yuan initially 
identified Necrostatin-1 (Nec-1) as an inhibitor of ischemic/reperfusion injury in the brain and 
cardiac tissue (32, 227). Later, Nec-1 was identified as a direct inhibitor of the kinase activity of 
Rip1 (178). While Nec-1 held much promise for therapeutic potential of pathological necrosis in 
disease, it was later demonstrated that Nec-1 has off target effects on another kinase and poor 
stability in vivo (228). Later Yuan’s group identified a more specific Rip1 inhibitor with 
implications for blocking death in neurologic disease. 7N-1 blocked the death of myelin-
producing cells known as oligodendrocytes which are lost in multiple sclerosis, implicating a 
role for necroptosis in oligodendrocyte death (43). 7N-1 also inhibits phosphorylation of Rip1 
blocking necroptosis and can function to inhibit both human and mouse Rip1. Additionally, 
GlaxoSmithKline (GSK) developed specific inhibitors of Rip1 and Rip3. The GSK’963 Rip1 
inhibitor demonstrates promise in specificity and stability, inhibiting necroptosis in vitro in 
mouse and human cells following pharmacologic necroptotic stimuli as well as viral and 
bacterial infection, and in vivo in a TNF- induced septic shock model (229–231). GSK Rip3 
inhibitors showed initial promise in necroptotic inhibition following TLR and TNF signaling, but 
later proved to be toxic due to the induction of apoptosis at higher concentrations (221, 232). 
Necrosulfonamide (NSA) was identified as an inhibitor of Rip3-mediated necroptosis through a 
chemical screen of compounds that could block necroptosis following a known chemical 
stimulus. The authors reporting this story determined that this inhibition occurs downstream of 
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Rip1 and Rip3 at the mitochondrion, and thus identified MLKL as a target of NSA in the 
inhibition of necroptosis. This compound binds directly to MLKL blocking the downstream 
execution of necroptosis through a specific cysteine residue in that is not conserved between 
mice and humans in MLKL (233). As such, this compound is only effective on human MLKL. In 
addition to pharmacologic inhibitors of the Rip kinases, viruses have evolved proteins which are 
also capable of inhibition of necroptosis. One such instance is in the infection with murine 
cytomegalovirus. Certain strains of this virus encode a protein known as m45/ viral inhibitor of 
Rip activation (vIRA) containing a RHIM domain that blocks the activation of necroptosis 
through interaction with Rip1 or Rip3, inhibiting their ability to bind together and become 
activated (234, 235). Additionally, Herpes Simplex virus type I and II (HSV-I and HSV-II) have 
evolved proteins which are a part of the R1 large subunit of ribonucleotide reductase (ICP6 and 
ICP10, respectively) that are capable of blocking both Caspase-8 mediated apoptosis and Rip 
kinase mediated necroptosis (231). ICP6 and ICP10 mediate this function through binding to 
Caspase-8’s death domain as well as the RHIM domain within the Rip kinases in murine cells, to 
promote necessary interactions for apoptosis and necroptosis activation. However, this role is 
controversial in human cells as in vitro studies suggest this protein inhibits necroptosis (236). 
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Table 1.3 Inhibitors of necroptosis 
Name Source Target Specificity Reference 
Necrostatin-1 
Chemically produced small-
molecule 
Activating 
phosphorylation site in 
Rip1 
Human and 
Mouse Rip1 (46, 178, 227)  
7N-1 (Nec-1s) 
Chemically produced small-
molecule 
Activating 
phosphorylation site in 
Rip1 
Human and 
Mouse Rip1 (43)  
GSK '963 
Chemically produced small-
molecule 
Blocks kinase activity 
of Rip1 
Human and 
Mouse Rip1 (229–231)  
GSK '843 and 
'872 
Chemically produced small-
molecule 
Blocks kinase activity 
of Rip3 
Human and 
Mouse Rip3  (237) 
Necrosulfonamide 
Chemically produced small-
molecule 
Blocks activation of 
MLKL 
Human 
MLKL only (233)  
vIRA 
Protein found in Murine 
Cytomegalovirus 
Rip1 and Rip3 RHIM 
domain 
Mouse Rip1 
and Rip3  (234, 235) 
ICP6/ICP10 Herpes Simplex Virus-I, -II 
Rip1 and Rip3 RHIM 
domain 
Mouse Rip1 
and Rip3  (231, 236) 
 
 
 Rip Kinases  
 The Rip kinases are a family of proteins demonstrated to interact with receptors to 
transduce signals in response to external stimuli promoting cellular cytokine signaling, death and 
survival pathways, and keratinocyte differentiation (238). There are seven Rip kinases (Rip1-
Rip7) identified, with four having demonstrated definitive roles in cell signaling identified thus 
far (239). While all members of this family contain a conserved kinase domain, each protein has 
unique domains, which have been demonstrated to or likely play an important role in the 
function of each member. The intermediate domain present in Rip1, Rip2, Rip4, and Rip5, 
allows for interaction with TRAFs 1,2, and 3 which are important for transduction of death 
receptor signals inside the cell (240, 241). The Rip homotypic interaction motif (RHIM) allows  
interaction between Rip1 and Rip3, the only members containing this motif, along with other 
proteins such as TRIF (221, 238). The death domain is present only in Rip1, and is key in its 
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interaction with other death domain containing proteins such as FADD and TRADD, transducers 
downstream of death receptor signaling. Rip2 contains a CARD which allows for interaction 
with Caspase-1 to promote inflammatory and survival signaling (242, 243). Rip4- Rip7 contain 
Ankyrin domains which are demonstrated to be important for protein-protein interactions (244).  
Rip6 and Rip7 (also known as Leucine-rich repeat kinase 1 and 2 (LRRK1 and 2)) contain 
leucine-rich repeats, which are also key in protein-protein interactions (245). While the domains 
present in the members of the Rip kinase family are diverse, the known functions of these 
proteins cluster in similar facets of cell biology.  
 Rip kinase 1 was originally identified as a protein that interacted with the intracellular 
domain of the Fas receptor and TNFR1 (246). Later, Rip1 was also implicated in NF-κB 
signaling downstream of TNFR activation and study of this protein focused exclusively on this 
function (247). This was due to the finding that loss of Rip1 led to early postnatal death due to 
lack of NF-κB and MAPK mediated survival signaling, overwhelming inflammation of the 
dermis, and cell death in the intestine (247). Similarly, acute global deletion of Rip1 in adult 
mice leads to rapid cell death due to increased apoptosis in the intestinal and hematopoietic cell 
lineages (248). While these data to suggest that Rip1 is required for activation of this signaling 
pathway is plentiful, some controversy regarding this exists after in vitro studies with Rip1-/- 
mouse embryonic fibroblasts (MEFs) were found to maintain the ability to activate NF-κB 
signaling (249). Several years later, with the finding that Rip1 was required for necrosis 
activation downstream of TNF signaling and that it could be inhibited, the term programmed 
necrosis was coined and studies continued to understand how Rip1 modulated necrotic signaling 
(175). Rip1 was also demonstrated to functionally complement the embryonic lethality of loss of 
FADD in mouse embryos, suggesting that necroptosis and/or survival signaling is important in 
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development as well (250). As discussed above, previous structural studies revealed that Rip1 
contains a death domain, which was key in its interaction with other adapter proteins involved in 
death receptor signaling, and that this death domain alone could stimulate apoptosis (246, 247). 
Additionally studies revealed this domain is additionally important in survival signaling through 
activation of MAPK kinase kinase 1 and 2 (MEKK1 and MEKK2) to stimulate NF-κB signaling, 
as well as Focal adhesion kinase (FAK), which suppresses Rip1 activation of apoptosis (251–
253). While the kinase domain of Rip1 is important in mediating its necroptotic function, it is not 
necessary for embryonic development as mice with a Rip1 knock-in of a mutation to render the 
kinase domain inactive (henceforth referred to as kinase dead) survive into adulthood (254). 
However, as expected these animals and cells demonstrate deficiencies in the activation of 
necroptosis in response to known necrotic stimuli, demonstrating the importance of Rip1 kinase 
activation in the activation of necroptosis. While Rip1 has recently been implicated in only being 
important in survival and apoptotic signaling (255), (with Rip3 being touted as the key activator 
of necroptosis) our and others studies with mice and hematopoietic cells suggest that modulation 
of the stability of Rip1 is also very important in necroptotic activation. As mentioned previously, 
in addition to its pronecrotic activity Rip1 is also implicated in the activation of apoptosis. This 
was first discovered with the finding that Caspase-8 mediated cleavage of Rip1 promoted death 
in vitro (97). Later, it was found that removal of ubiquitylation on Rip1 was an important step in 
this process, as this blocked NF-κB survival signaling (256). Further studies seeking to 
understand Rip1 activation of apoptosis identified that formation of the ripoptosome in the 
absence cIAPs regulated the outcome of TNF signaling, depending upon the presence of c-Flip 
isoforms (198, 257). This process is inhibited by cFlipL but promoted by cFlips through 
modulation of Caspase-8 activity. Additionally, Rip1 is implicated in the activation of 
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inflammasomes downstream of TLR signaling in a FADD and Caspase-8 dependent manner 
(258). Lastly, Rip1 is also implicated in the production of TNFα following caspase inhibition 
through activation of Jun amino-terminal kinase (JNK) signaling. This production is believed to 
promote autocrine TNF signaling in certain contexts that promotes necroptotic death in response 
to certain stimuli (259). 
Rip kinase 2 was discovered in 1998 by several groups and identified to be important in 
NF-κB, MAP kinase signaling, and alteration of apoptosis (243, 260, 261). Further study 
demonstrates that the kinase activity of Rip2 is important in maintaining its stability as well as 
MAPK signaling, but not NF-κB signaling (262, 263). NF-κB and MAPK signaling through 
Rip2 is mediated through interaction with NOD1 and NOD2, which mediate the mucosal innate 
immune response (264). Rip2 is recruited to NODs following their activation and 
oligomerization and is ubiquitylated (265, 266). This ubiquitylation serves as a docking site for 
adapter proteins important in activation of NF-κB and MAPK signaling, similar to activation of 
these pathways following Rip1 ubiquitylation downstream of death receptor signaling (267). 
Additionally, the BH3-only BCL-2 family member Bid is implicated to associate with Rip2 in 
the setting of NOD signaling, playing an important role in activating the innate immune response 
in intestinal mucosa (10). Accordingly, earlier studies implicated that loss-of-function mutations 
in NOD2 increases susceptibility to the inflammatory bowel disease (IBD), Crohn’s Disease 
(268–270). Additionally gain-of-function NOD2 mutations lead to sarcoidosis and Blau 
Syndrome, inflammatory diseases affecting numerous areas of the body (271, 272).  
Rip kinase 3 was identified though the screening of a human fetal brain cDNA library for 
proteins with homology to Rip1 and Rip2 (273). These initial studies implicated Rip3 
overexpression in apoptosis activation, through binding to Rip1 and partial blockage of its NF-
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κB signaling capability. This role of Rip3 persisted within the field until it was discovered that 
Rip3 forms a complex with Rip1 through RHIM domain interaction, and this in turn promotes 
necroptosis through its phosphorylation (24, 96, 194, 274). Mice deficient for Rip3 survive into 
adulthood, and demonstrate lack of necroptotic death in response to necrotic stimuli. 
Additionally, loss of Rip3 rescues the embryonic lethality of Caspase-8 deficiency, suggesting a 
role for necroptosis in embryonic development (11). These findings solidified the role of Rip3 in 
necroptotic signaling.  
The role of Rip3 kinase activity in embryonic development was determined through the 
development and characterization of kinase dead knock-in mice. These animals die at E11.5 due 
to apoptosis of the vasculature in the yolk sac (275). However, crossing these animals to 
Caspase-8 deficient mice rescued viability, demonstrating that both apoptosis and necroptosis 
activation are important in embryonic development. Rip3 is also important in necroptotic 
execution through activation of MLKL, and correspondingly Rip3 deficiency has important 
implications in settings where necroptotic death is necessary. For example, studies with models 
of viral infection demonstrate that necroptotic death becomes an important pathway to viral 
clearance in the setting of apoptosis inhibition by viruses. The Vaccinia virus (VV) has evolved a 
number of proteins geared toward the inhibition of apoptosis through Caspase inhibition (276).  
However, necroptosis execution through Rip3 activation is a key factor in clearance of this virus 
in mice (24, 277). Conversely, murine cytomegalovirus (MCMV) evolved to produce proteins 
that inhibit both apoptosis and necroptosis through inhibition of Bax and Bak and through 
inhibition of Rip1 association with Rip3, respectively (278, 279). These findings demonstrated 
that necroptosis is also key in mediating host defense, and has implications for treatment of viral 
infection.  
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In addition to its role in necroptosis, Rip3 is also implicated in apoptosis activation. 
Several in vitro studies implicate that Rip3 promotes apoptosis activation following TNFR 
stimulation through activation of Caspase-8 in contexts where cIAP1 and 2 are depleted, when 
TAK1 is inhibited, or in MLKL deficiency (280, 281). In the setting of viral infection (Influenza 
A) Rip3 is demonstrated to activate not only necroptosis through MLKL but also apoptosis in a 
Rip1 independent, but FADD dependent manner (25). Additionally, Rip3 is implicated in the 
activation of the NLRP3 inflammasome through activation of Caspase-1 (281). This process is 
inhibited by Caspase-8, and can occur with or without Rip3 kinase activity (258, 282).  
Rip4 was originally identified through a yeast two hybrid screen of a human keratinocyte 
cell line to identify proteins interacting with Protein kinase C (PKC)-δ (Delta) isoform, and was 
originally named Delta protein interacting kinase (DIK) (283). A year later, a mouse ortholog 
was identified through its interaction with PKC-β isoform, and was named protein kinase C- 
associated kinase (PKK) (284). Further investigation revealed that these proteins contained a 
kinase and intermediate domain similar to previously identified Rip kinases as well as ankyrin 
repeat domains. As such, these proteins were renamed as human (DIK) and mouse (PKK) Rip4 
(285, 286). Overexpression studies of Rip4 in vitro revealed increases in NF-κB and JNK 
signaling. Signaling through NF-κB can occur independent of or require phosphorylation by 
MEKK2 and 3 depending on the stimulus (287). Examination of NF-κB signaling revealed that 
the IKKα and IKKβ subunits of the IKK complex were required for this signaling. Additionally, 
Rip4 was found to bind to several members of the TRAF family, and that dominant negative 
versions of TRAF1, TRAF3, and TRAF6 (lacking the ability to bind to elements necessary for 
this signaling pathway) blocked NF-κB signaling. Lastly, cleavage of Rip4 by Caspases inhibits 
NF-κB activation (286). Deletion of Rip4 in mice leads to lethality at birth, due to lack of 
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differentiation of epithelial cells into keratinocytes leading to fusion of the airway (285). This 
phenotype is quite similar to the phenotype seen in IKKα knockout animals, suggesting that both 
proteins may be part of a similar signaling pathway that is important in keratinocyte 
differentiation (288).  
Sugen kinase 288 has high sequence homology and structure to Rip4 as well as ankyrin 
repeats, which lead to classification of this protein as a member of the Rip kinase family, and 
naming as Rip5 (238). Thus far, a function for Rip5 has not been discovered, but its 
overexpression leads to programmed cell death that causes DNA fragmentation (289).  
Similar to Rip5, the function of Rip6 and Rip7 are not known, however, these proteins 
are referred to as such due to their structural homology to Rip kinases (238). These proteins 
contain unique domains not present in other members of this family such as leucine-rich repeats 
(LRR) (both), C-terminal of ras of complex proteins (ROC) domain (COR) (Rip6), and WD40 
repeats (Rip7). The most prominent feature is the LRR repeat, and as such these proteins are also 
known as Leucine-rich repeat kinase 1 (LRRK1) (Rip6) and LRRK2 (Rip7). In seeking to 
understand their function, it was discovered that mutations in Rip7 as opposed to Rip6 are more 
neuronally toxic in vitro (290). Correspondingly, mutations in Rip7 are demonstrated to play a 
role in the pathogenesis of autosomal dominant and sporadic mutations in Parkinson’s Disease 
(291). 
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Figure 1.11 Structure of the Rip Kinases 
The Rip kinases are a family of proteins implicated in cell signaling. Of the 7 members, 4 have 
defined roles (Rip1-4), and the remaining are purported to be involved in cell death (Rip5) and in 
the pathology of Parkinson’s Disease (Rip6 and Rip7). Adapted from (239). 
ID= Intermediate Domain, KD= Kinase Domain, RHIM= Rip homotypic interaction motif 
ANK= Ankyrin Repeats, DD= Death Domain, CARD= Caspase activation and recruitment 
domain, LRR= Leucine Rich Repeats   
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Inflammatory and innate immune activation following necroptosis 
Execution of necroptosis leads to the release of a number of DAMPs which can be 
categorized as pathogen-associated molecular patterns (PAMPs) and cell death-associated 
molecules (CDAMs) (also known as alarmins). Release and detection of these molecules 
promotes the activation of inflammatory and innate immune responses, with these molecules 
serving as adjuvants functioning with cytokines to promote signaling (292). This belief is as a 
result of the danger model, a model of how the immune system distinguishes between the 
presence of a molecule as being harmful or innocuous, as opposed to simply recognizing “self” 
versus “non-self” (293). DAMPs serve as the triggers which suggest the presence of 
danger/damage hence their characterization as such in this context.  
One of the most prominent CDAMs includes a protein that associates with the chromatin 
known as high mobility group box 1 (HMGB1). This protein is released into the extracellular 
space from the nucleus following necroptotic death, promoting inflammation (294). Another set 
of CDAMs includes Heat shock proteins (HSPs), which are demonstrated to be released 
specifically from necrotic, but not apoptotic cells (295). Release of HSPs gp96, 90, and 70 
promotes cytokine release from macrophages and activation of antigen presenting cells (APCs). 
Additionally, the release of uric acid into the sodium-rich extracellular space is believed to cause 
the formation of monosodium urate (MSU) crystals, which stimulates dendritic cell maturation 
(296). Another CDAM is the release of ATP, which is capable of signaling through P2 receptors 
leading to innate and adaptive immune signaling (297). 
DNA can serve as either a CDAM or a PAMP depending upon its source. Double-
stranded genomic DNA (dsDNA) from the dead cell itself can be sensed by the adapter DAI, 
which in turn can promote inflammatory and death signaling as well as the maturation of APCs 
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(298). DNA from a viral or bacterial source serves as a PAMP, and signals through the TLRs 
through the adapter Myeloid differentiation primary response gene 88 (MYD88) which again can 
promote cytokine release, death, and innate immune signaling (299). Similarly, the detection of 
foreign RNA from a viral or bacterial source stimulates signaling through TLRs through the 
adapter MYD88 to promote a similar outcome (300). IL1-α is a DAMP released from necroptotic 
cells that is capable of inducing inflammation through activation of macrophages and promotion 
of cytokine secretion (14). While many DAMPs have been identified thus far, it is believed that 
many more have yet to be defined. 
 
Other types of programmed cell death  
  While my studies primarily focus on the crossroads of programmed cell death pathways 
in apoptosis and necroptosis, there are several identified programmed cell death pathways within 
the literature. For example, ferroptosis is a programmed cell death requiring iron uptake that is 
executed by ROS, and morphologically characterized by shrinkage of the mitochondria, loss of 
cristae, and ATP depletion (301). It was originally identified in tumor cells as a different type of 
cell death downstream of Ras targeted treatments in Ras-mutated cell lines (erastin) (302, 303). 
This death is morphologically distinct from apoptosis and necroptosis, and additionally does not 
require any of the proteases implicated in cell death (Caspases, Cathepsins, or Calpains), nor 
autophagic, or lysosomal function (301). This ROS-mediated death is executed through lipid 
peroxidation and believed to be promoted through the NOX enzyme family, which produces 
superoxides. This death can be inhibited by a compound the discovering authors identified called 
ferrostatin-1, through iron chelation, or blocking iron uptake. 
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 Another type of programmed cell death is termed pyroptosis and is associated with 
Caspase-1 and Caspase-7 activation, and was originally identified as a specific type of death in 
macrophages after infection with Salmonella Typhimurium (304). Continued study revealed that 
this death occurred downstream of infection with several types of bacteria including Bacillus 
Anthracis and Listeria Monocytogenes (305, 306). This death displays morphological features of 
both apoptosis and necroptosis, including DNA fragmentation and loss of plasma membrane 
integrity (307). Activation of inflammasomes downstream of NLR signaling through either 
Apoptosis-associated speck-like (ASC) or Absent in melanoma 2 (AIM2) adapter proteins 
promotes the activation of Caspase-1 (308, 309). Caspase-1 activation also occurs through the 
formation of the pyroptosome made up of ASC dimers (310). This activation leads to the 
production of IL-1β and IL-18, which promotes inflammatory signaling. In certain but not all 
instances, this promotes the activation of Caspase-7 which in turn promotes programmed cell 
death (311).  
Autosis is a programmed cell death process caused by overactive autophagy, which is 
promoted in vitro through overexpression of Beclin-1 (a protein associated with autophagy) and 
in vivo in a model of hypoxia-ischemia in the rat cerebrum (312). This cell death is characterized 
by severe vacuolization, accumulation of autophagosome/ autolysosomes, nuclear shrinkage with 
perinuclear ballooning, and plasma membrane rupture that leads to extrusion of cellular contents. 
Autosis is inhibited by the cardiac glycoside digoxin, which blocks the function of the 
Na+K+ATPase pump present at the plasma membrane. Autosis is unaffected by ROS, inhibition 
of the Rip kinases, and deletion of Bax and Bak, suggesting it is executed through a signaling 
pathway independent of apoptosis and necroptosis (313). While these types of cell death are new 
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with well-defined morphologies and requirements, other types of cell death are still under 
consideration in terms of their consideration as a true programmed cell death process.  
Autophagic cell death is defined as a rare cell death directly caused by autophagy due to 
massive cytoplasmic vacuolization due to accumulation of autophagosomes (314). The 
controversy surrounding classifying this process as an actual programmed cell death arises in 
data suggesting that autophagy is actually a mode of clearance for cells that are already targeted 
to die by a programmed cell death process. For example, in a model of mouse development, 
embryoid bodies lacking genes important in autophagy were unable to clear dead cells, and 
embryos similarly shows defects in the clearance of dead cells within tissue (315).  Additionally, 
while this death is inhibited by suppression of autophagy, studies reveal difficulty in determining 
what qualifies as a true inhibition (e.g. inhibition of plasma membrane disruption in the presence 
of DNA fragmentation), making it difficult to understand what role autophagy plays in the cell’s 
demise (316). Lastly, this death so far has only been observed in vitro (but not in vivo) in 
mammalian systems or in other non-mammalian systems, leaving in question the actual 
applicability of this process in humans. 
 Another programmed cell death known as Netosis is characterized by caspase-inhibition, 
activation of NOX enzymes, and release of neutrophil extracellular traps (NETs). This 
programmed cell death is characteristic of eosinophils and neutrophils, but the release of NETs is 
a process that can occur in the absence of cell death. NETs are comprised of chromatin, histones, 
and antimicrobial granules and are released from viable cells in response to physiological stimuli 
such as IL-8 and LPS as part of host defense (317, 318). However, NET release and cell death 
occurs in response to treatment with Phorbol-12-myristate-13-acetate (a non-physiological 
stimulus) (319, 320). This death is characterized by ROS production, although it is not required 
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in this process. Correspondingly, this death is inhibited with NOX family of enzymes inhibitors 
(317, 321). Another process of netosis is the formation of NETs and involves a process known as 
histone-citrunillation, in which positively charged arginine side chains are made into polar 
uncharged molecules (322). The controversy in classifying this process as a programmed cell is 
that not all cells dying with these features release NETs, and not all cells releasing NETs die. 
While there are several types of programmed cell death programs and several emerging 
programmed cell death programs, much study is still needed to fully understand a number of 
these new processes and to understand their applicability to human health.     
  
Hematopoiesis in the Mouse 
 
Mouse hematopoietic development  
 Hematopoiesis is an important biological process that ensures the production of new 
blood cells and maintenance of the hematopoietic system. Multi-cellular organisms rely on 
hematopoiesis for the oxygenation of tissues, defense against outside pathogens, and maintaining 
hemostasis at external sites of injury. Hematopoietic cells are characterized into a hierarchy 
based upon their ability to self-renew and differentiate into more mature cell types (potency). 
Hematopoietic stem cells (HSCs) sit at the top of this hierarchy with the ability to both self-
renew (ability to divide repeatedly to produce another stem cell) and to develop multiple cell 
types (multipotent) (323). Next in the hematopoietic hierarchy after HSCs are progenitor cells 
which can self-renew, but primarily differentiate into fewer cell types. Lastly, terminally 
differentiated cells are capable of proliferation (limited divisions only producing another 
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terminally differentiated cell), but do not self-renew or differentiate. In our studies of mice with 
overwhelming necrosis of the bone marrow we explore how this context affects stem and 
progenitor populations, and also how this affects hematopoietic homeostasis.  
Hematopoiesis begins early during embryogenesis, and is characterized by two 
hematopoietic bursts. The first burst, the primitive wave, produces temporary cells which are not 
found in the adult organism (324–326). This wave begins in the yolk sac within mesodermal cell 
masses also known as “blood islands” at E7.5 (327). These blood islands produce the first red 
blood cells (RBCs) known as primitive RBCs, which function to oxygenate the rapidly growing 
embryo (328). These cells are characterized by increased size (as compared to adult RBCs), the 
presence of nuclei, and the presence of fetal hemoglobin (329–331). The first macrophage 
progenitors are also formed, followed by an early erythroid-myeloid progenitor (332, 333). Cells 
from the macrophage progenitor population eventually migrate to the brain to become microglia 
(specialized macrophages present in the brain) and to the epidermis where they become 
Langerhans cells (specialized macrophages present in the skin) (334, 335).   
The blood islands within the yolk sac fuse forming vasculature of this structure and allow 
the primitive RBCs to circulate. Because the cells forming the primitive RBCs and the 
vasculature (endothelium) appear at approximately the same time and from the same spatial area, 
it is hypothesized that they derive from one cell type, known as the hemangioblast (336). This 
phenomenon was first described in the 1800s, and was later examined in vitro in mouse 
embryonic stem cells and human pluripotent cells (337, 338). While this process has not been 
observed in vivo, there are multiple studies in the literature supporting this phenomenon. 
The second burst of hematopoiesis is known as the definitive wave, during which cells 
that will be present in the adult are formed. Studies with several species of organisms (including 
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chick, quail, and frogs) demonstrates that these cells are derived exclusively from the embryo, 
and not the yolk sac (325, 326, 339). In vitro studies were performed to examine the intricacies 
of which portion of the developing embryo had multipotent hematopoietic potential, as well as 
reconstitution capability. Culture of cells from the para-aortic splanchnopleura (PAS) (region 
surrounding the dorsal aorta) demonstrates that these cells have multipotent and lymphoid 
capability (340, 341). Additionally, cells from the aorta-gonad mesonephrous (AGM), which 
derives from the PAS, also demonstrate multipotency through the presence of colony forming 
unit-spleen (CFU-S) cells which are capable of forming multipotent hematopoietic cells within 
the spleens of irradiated mice (342). From here, these cells move to the fetal liver, the next site of 
hematopoiesis.  
Next, hematopoietic cells seed into the fetal liver, the site of hematopoiesis within the 
fetus until just after birth (343, 344). The fetal liver is capable of producing not only blood, but 
also macrophages and other myeloid cells (345). Development of mature RBCs occurs in 
erythroblastic islands (EBIs) (346). These terminally differentiated myeloid cells are produced in 
a hierarchical fashion with CMPs giving rise to these cells, similar to adult hematopoiesis (345). 
Cells are believed to seed from the AGM directly to the fetal liver as well as the bone marrow, 
however is it also suggested that cells may seed from the fetal liver and then to the bone marrow 
(341, 347, 348). Cells from the AGM also migrate to the thymus and spleen (328). 
In the adult organism, all hematopoietic cells arise from HSCs which are primarily 
present in the bone marrow. These cells differentiate and mature within the bone marrow, or 
within peripheral hematopoietic organs (thymus, spleen, and lymph nodes) (349–351). 
Hematopoietic cells differentiate and commit to a specific lineage and proliferate in response to 
cues from cytokines. In response to exposure to certain cues, HSCs can self-renew or 
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differentiate into the multipotent progenitor (MPP), which can further differentiate into the 
common myeloid progenitor (CMP) or the common lymphoid progenitor (CLP). The CMP 
differentiates into the megakaryocyte-erythrocyte progenitor (MEP) or the granulocyte-
macrophage progenitor (GMP). MEPs produce RBCs and megakaryocytes, the producers of 
platelets. The GMP produces granulocytes and macrophages. These cells are important in a 
number of roles including tissue oxygenation, hemostasis, and the innate immune response.  The 
CLP produces B and T cells, as well as natural killer (NK) cells, which are important in 
launching the adaptive immune response, and the maintenance of immunity (351).  
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Figure 1.12 The Hematopoietic Hierarchy  
The hematopoietic hierarchy demonstrates the classification of hematopoietic cells by their 
capability to self-renew, as well as their ability to differentiate into different cell types. At the top 
of the hierarchy is the HSC which is capable of differentiating into all cell types as well as self-
renew. Underneath the HSC are the progenitors, which can be subdivided into the common 
myeloid progenitor (CMP) and the common lymphoid progenitor (CLP) which give rise to 
myeloid and lymphoid cells, respectively. The CMP gives rise to all cells of the myeloid lineage 
including the platelets and RBCs through the Megakaryocyte erythrocyte progenitor (MEP), as 
well as basophils, eosinophils, and neutrophils through the Granulocyte macrophage progenitor 
(GMP). The CLP gives rise to lymphoid cells including B and T cells, as well as natural killer 
cells. In our studies, the myeloid arm of hematopoiesis is affected with decreases in myeloid 
progenitor populations. Adapted from (352). 
 
 
 
 64 
Hematopoietic stem cells  
 Hematopoietic stem cells (HSCs) are essential to the maintenance of the hematopoietic 
system and were first discovered as cells that were able to form colonies from the spleen of 
irradiated animals (353). Hematopoietic cells derived from the yolk sac do not contribute to the 
adult hematopoietic system, however there is data to suggest that fetal HSCs from other sources 
do contribute to adult HSC populations. The discovery that adult HSCs do not derive from yolk 
sac hematopoiesis was made during studies to examine the origin of the HSC. These studies 
demonstrated that cells from the AGM had long-term reconstitution ability suggesting that this 
population of cells contained stem cells (354). Additionally, utilization of fate-mapping studies 
to examine expression of proteins expressed exclusively in early HSCs determined that the 
definitive wave during which these cells were produced was relatively short. These studies 
demonstrated that vascular endothelium Cadherin (VE-Cad) and Runt-related transcription factor 
1 (Runx1) turned on from E8.5-E9.5, consistent with a burst of cell production characterizing the 
definitive wave (355, 356). These immature HSCs were later demonstrated to be present in a 
VE-Cad+ CD41+ population of cells. Later designation of the pre-HSC (the next step in HSC 
maturation) was identified to be distinguishable through examination of CD45 positivity. Pre-
HSCs were characterized as being Type I (VE-Cad+ CD41+ CD45-) and then maturing into Type 
II (VE-Cad+ CD41+ CD45+)  through acquisition of CD 45 positivity (357). A similar study later 
identified that the acquisition of CD45 positivity as well as markers for the major 
histocompatibility complex class I (MHC class 1) was also important in the maturation of HSCs 
(358). This process is hypothesized to occur in the fetal liver, and to contribute to the 
development of the adult hematopoietic system (359). While it is understood that HSCs are 
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present in the fetal liver and beyond in hematopoietic development, it is not clear from where 
and when HSCs present in the adult bone marrow originate.  
 Previous studies imply that in the adult organism, many HSCs remain primarily in a 
quiescent (G0) state, with many HSCs entering into the cell cycle only in response to insults or 
cytokine cues (352). These studies utilized BrdU or tritiated Thymidine to understand how HSCs 
proliferate in how HSCs proliferate (360, 361).  However, use of these labels present a number 
of limitations including loss of label overtime due to slow cycling and BrdU labeling that is not 
specific to HSCs (362). More recently, several studies demonstrate that at some point within a 
matter of months, all HSCs divide but do so quite slowly (363–365). These studies utilized mice 
ubiquitously expressing fusion proteins of Histone 2B and GFP following doxycycline treatment 
to fate-map HSCs over time. Examination of these mice over time after doxycycline pulse 
revealed that HSCs are maintained in this state through localization to microenvironments within 
the bone marrow known as niches (365). These niches are important in the maintenance and self-
renewal of HSCs through HSC interaction with stromal cells and exposure to cytokines which 
maintain their quiescent/ slow proliferating state (352). In response to hematopoietic injury or 
insult, an increased number of HSCs cycle and self-renew as well as differentiate to replace lost 
cells. HSC proliferation maintains hematopoiesis through the generation of progenitors which 
rapidly proliferate and differentiate to replace lost terminally differentiated cells. Several studies 
suggest that amongst the HSC population, there are further distinguishing factors including 
reconstitution ability and proliferation state (entrance into cell cycle), which further distinguish 
functionality of this population (364, 365). As such, HSCs are characterized into units of 
function that are heterogeneous, and are capable of short-term reconstitution and while other 
HSCs capable of maintaining hematopoiesis long-term. One of the key methods in which this is 
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tested is through hematopoietic cell or HSC transplantation and serial transplantation (366). 
However, there are some discrepancies regarding how these assays are completed, the potential 
heterogeneity of hematopoietic populations, as well as what this type of assay truly tests (367). 
As such, transplant studies utilized in the measurement of true HSC activity are questioned in 
terms of their ability to understand how HSCs behave under homeostatic conditions. Several 
recent studies are attempting to understand how HSCs function under homeostatic conditions, 
and to understand how HSC function over time versus single snapshot measurements of 
quiescence (368).  These studies suggest that despite the identification of a relatively pure HSC 
population utilizing CD and SLAM markers, there is still heterogeneity within this population.  
 
Identification of hematopoietic cells by flow cytometry using immunophenotyping 
Different types of hematopoietic cells are identified through expression of surface 
markers known as clusters of differentiation (CD). These markers identify the immunophenotype 
of hematopoietic (and many other types) of cells (369). Utilizing flow cytometry, and antibodies 
conjugated to fluorescent probes, hematopoietic populations are readily identified using 
established CD markers for various cell types. While terminally differentiated cells express 1-2 
of these markers (indicating terminal differentiation), less terminally differentiated cells are 
typically identified by expression (or lack there of) of three or more markers (370). Pioneering  
studies from the lab of Irving Weissman elucidated the markers to identify HSC and progenitor 
populations, revolutionizing the study of these populations in mice with implications for 
treatment of human disease (371). In the studies presented here, cells of the myeloid lineage, 
including progenitors, as well as HSCs will be the focus of our findings.  
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Identification of HSCs and myeloid progenitors  
 Hematopoietic stem and progenitor cells (HSPCs) are identified through their phenotypic 
expression (or lack there of) of CD markers on their surface. As discussed above, HSCs and 
progenitors are the least mature cells of the hematopoietic system, and as a result are negative for 
markers of terminally differentiated cells including: (B cells (B220/CD45R), T cells (CD3), 
Erythroid cells (Ter119), and granulocytic cells (Ly6G), and a marker for less terminally 
differentiated lymphocytes (C127/IL-7Rα). Cells negative for these markers are termed “lineage 
negative” (Lin-). Identification of an HSPC enriched population is achieved through examination 
of Lin- cells and examination of positivity for c-Kit, a cytokine tyrosine receptor, and stem cell 
antigen 1 (Sca-1), also designated as the LSK population (372–374). The myeloid progenitor-
enriched population (defined as such since CLPs are depleted through use of IL-7Rα as a marker 
for differentiated cells) is only positive for c-Kit and is designated as Lin- Sca-1- c-Kit+. This 
myeloid population can be further examined to identify the CMP, GMP, and MEP populations 
through examination of CD34 and FcγIIR/CD16/CD32. These populations are identified as 
follows: CMP: CD34+ FcγIIR- , GMP: CD34+ FcγIIR+ , and MEP: CD34- FcγIIR- (375). The 
HSC-enriched population is identified by positivity for both markers and is designated as Lin- 
Sca-1+ c-Kit+. The HSC-enriched population can be further purified through the examination of 
the status of CD135/Fetal liver kinase 2 (flk2)/ FMS-like tyrosine kinase3 (flt3) (376). Cells 
negative or low for this marker are termed Long term-HSC (LT-HSC), where as cells that are 
intermediately positive are classified as short-term HSCs (ST-HSC), and cells that are highly 
positive are MPPs. The LT-HSC population can be further purified through examination of the 
status of two signaling lymphocyte activation molecule (SLAM) markers, CD48 and CD150. 
Cells that are negative for CD48, but positive for CD150 represent the most pure HSC 
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population identified in mice and are known as the SLAM-HSC population (377). In my studies, 
examination of the myeloid progenitor enriched and SLAM-HSC populations revealed defects in 
hematopoietic homeostasis as a result of overwhelming necrosis in the bone marrow of 
VavBaxBakBid TKO mice (see Chapter II).  
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Table 1.4 Table of Clusters of Differentiation and other markers to identify hematopoietic cells 
 
 
Cell Type Marker(s) Function/ Description 
SLAM-HSCs 
Lin- Sca-1+ (Ly6A/E) c-Kit+ (CD117) 
Flt3Low (CD135/Flk2) CD150+ Repopulation of the hematopoietic system 
Long Term-HSC Lin- Sca-1+ c-Kit+ Flt3Low 
Long-term repopulation of the hematopoietic 
system 
Short Term-HSC Lin- Sca-1+ c-Kit+ Flt3Int 
Short-term repopulation of the hematopoietic 
system 
Multipotent 
Progenitor Lin- Sca-1+ c-Kit+ Flt3Hi 
Progenitor capable of differentiating into 
terminally-restricted progenitors 
CLP Lin- c-Kit+ CD34+ IL-7R+ 
Lymphoid restricted progenitor capable of 
differentiating into mature lymphoid cells 
B cells  CD45R+ (B220) 
Part of adaptive immune response, production of 
antibodies  
T cells CD3+ 
Part of adaptive immune response, targeting cells 
for death and activation of other immune cells 
CMP Lin- c-Kit+ CD34+ FcγIIR- (CD16/32) 
Myeloid restricted progenitor capable of 
differentiating into mature myeloid cells 
GMP Lin- c-Kit+ CD34+ FcγIIR+ 
Progenitor capable of differentiation into 
monocytes, granulocytes, and macrophages 
MEP Lin- c-Kit+ CD34- FcγIIR+ 
Progenitor capable of differentiation into 
megakaryocytes and reticulocytes 
Monocytes  CD11b+ (MAC)  Gr-1+ (Ly6G/C) 
Precursor for macrophages capable of 
phagocytosing antigens 
Macrophages  CD11b+ 
Innate immune cells that monitor tissues for 
antigen and phagocytose antigens to present to 
other immune cells 
Neutrophils  Gr-1+ 
Innate immune cells capable of phagocytosing 
antigen or releasing granules capable of killing 
cells and bacteria 
Pro-Erythrocyte CD71+ Ter119- 
RBC precursor capable of differentiating into a 
mature RBC 
Basophilic 
Erythroblast (Ery 
A) Ter119Hi CD71+ FSCInt-Hi 
RBC precursor developing after the Pro-
erythrocyte  
Polychromatic 
Erythroblast (Ery 
B) Ter119Hi CD71+ FSCLo 
RBC precursor developing after the Basophilic 
erythroblast 
Orthochromatic 
Erythroblast (Ery 
C) Ter119Hi CD71- FSCLo 
RBC precursor developing after the 
polychromatic erythroblast 
Erythroid cells Ter119+ 
General marker for precursors/progenitors of 
RBCs  
Megakaryocytes CD41+ 
General marker for megakaryocytes producers of 
platelets 
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Figure 1.13 Flow schematic for Identification of hematopoietic stem cells 
Immunophenotyping by flow cytometry allows for the characterization of the bone marrow to 
look for expression (or absence of expression) of surface markers which allows for the 
determination of what types of cells are present in the bone marrow. The forward scatter (FSC) 
and side scatter (SSC) of the cells allows for examination of their size and complexity, 
respectively. A gate is placed on the smaller, less complex cells which are typically less 
differentiated. The next gate is place on cells that are negative for markers expressed on 
terminally differentiated cells (e.g. Granulocytes, lymphocytes, megakaryocytes, etc.). From this 
population cells that are positive for both c-Kit and Sca-1 are gated. This subset is the stem cell-
enriched population. From the stem cell-enriched gate cells that are negative for CD135/Flt3 are 
gated on. This population is known as the long-term HSC (LT-HSC). Lastly, from the LT-HSC 
gate the CD48- CD150+ subset of cells are gated on. This population is known as the signaling 
lymphocyte activation molecule (SLAM-HSC) and currently the purest mouse HSC population 
identified in the literature. Adapted from (364, 378). 
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Cytokine signaling in hematopoietic cells  
 Cytokines are small proteins secreted by various hematopoietic cells as well as other cell 
types that direct hematopoietic cells to proliferate, survive, differentiate, die, mature, and activate 
(379).  These functions are exerted through two types of action to promote a response, through 
lineage restriction and through action on multiple lineages at once. However, while a single 
cytokine is often enough to stimulate action, certain cell types require stimulation with multiple 
cytokines to promote a response (e.g. HSCs) (380). Additionally, cytokines may be present in 
both secreted and membrane-bound forms, aiding in their ability to act on specific cell types 
(381). While initial studies revealed cytokines are important for normal maintenance and 
regulation of hematopoiesis, other cytokines have been identified in the promotion of 
inflammation, inhibition of inflammation, and immune responses. Studies discussed within this 
dissertation will focus on inflammatory cytokines.  
 Cytokines were first identified as factors that could stimulate colony production in vitro 
(382). The first cytokine discovered, erythropoietin (EPO) a stimulator of RBC production, was 
found in a patient with aplastic anemia and later demonstrated to promote RBC production 
directly once it was purified (383). Key studies also demonstrated that both granulocyte-
macrophage colony stimulating factor (GM-CSF) and Granulocyte- Colony-stimulating factor 
(G-CSF) were  important in maintaining viability of neutrophils and eosinophils (384). 
Systematic studies of cell cycle and signaling also revealed that colony-stimulating cytokines 
also promote proliferation (385). Several studies also demonstrated how increased cytokine 
stimulation promoted further increases in proliferation, differentiation, or further cytokine 
release, or that artificial or genetic loss of the cytokine led to dramatic decreases in action clearly 
demonstrated their importance in hematopoiesis. For example, studies with G-CSF, which 
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promotes the production of neutrophils, demonstrated that injecting mice with G-CSF promoted 
overwhelming production of neutrophils, and this was exacerbated with removal of the spleen, a 
key site for extramedullary myelopoiesis in settings of hematopoietic stress (386). Additionally, 
the ability of a cytokine to promote multiple actions became more clear with the discovery of 
cytokine receptors and understanding of the signaling following cytokine stimulation (387). 
These studies also delved into demonstration of the ability of cytokines to promote 
differentiation and maturation of hematopoietic cells. For GM-CSF, this was demonstrated 
through expression of the receptor for GM-CSF and subsequent stimulation with GM-CSF led to 
differentiation down the myeloid lineage, demonstrating the importance of cytokines in 
promoting differentiation (387). Cytokines, though small proteins are important in regulating 
hematopoietic cells to maintain homeostasis and respond to insults.  
Inflammatory cytokines promote inflammation and in turn stimulate the activation of 
innate and adaptive immune responses. The action of these cytokines are important in initiating 
the front line of host defense in a setting of infection. Four of the most important inflammatory 
cytokines include TNFα, IL-6, IL-1β, and the interferon (α and γ). Our studies focus on the role 
of inflammatory signaling in hematopoietic cell death and bone marrow failure. These studies 
suggest the inflammatory cytokine, TNFα, plays a role in this process. TNFα was originally 
identified as a protein with the ability to induce necrosis of tumor cells from both mice and 
humans (388, 389). It is expressed by a wide variety of cells including macrophages, T cells, 
fibroblasts, and natural killer cells (NK cells) (390). TNFα functions to promote inflammation 
through activation of NF-κB signaling in target cells which stimulates the production of many 
other cytokines including GM-CSF and M-CSF (391). TNFα is known to cause systemic 
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inflammation and its overproduction is implicated in a number of inflammatory diseases 
including those discussed in this manuscript, MDS and inflammatory bowel diseases (392, 393).  
IL-6 was first discovered in the supernatant of T cells, and was later shown to be 
important in T cell activation (394). It was additionally implicated in the activation of antibody 
production in B cells, following stimulation with bacteria. In addition to lymphocytes, IL-6 acts 
on many other cell types and is also crucial in the activation of myelopoiesis during infection 
stimulating the acute innate immune response (395). IL-1β is a potent inducer of fever in 
organisms which led to its discovery in 1977 (396). It is primarily produced by monocytes, 
macrophages, NK cells, and B cells (397). IL-1β is highly inflammatory and is not secreted in 
the absence of stimulation in normal conditions. Detection of an antigen by TLRs stimulates IL-
1β production and promotes an inflammatory response. Interferons were first identified as agents 
that could block the growth of the influenza virus in chick embryos (398). There are two types of 
interferons, Type I (α) and Type II (γ). IFNα is expressed by lymphocytes and promotes the 
expression of IL-1β following bacterial infection through gene expression (399). IFNα is also 
implicated in anti-inflammatory responses, and as such its action is context-dependent (400). 
IFNγ production is the quintessential macrophage activation factor and is produced by NK cells, 
lymphocytes, and antigen presenting cells (macrophages/dendritic cells) (APCs) (401). It attracts 
leukocytes to the site of infection, and directs the proliferation, maturation, and differentiation of 
several cell types (402). Inflammatory cytokines are important factors in the clearance of 
infection, but can also be pathogenic if they promote too much inflammatory signaling.  
More recently, the involvement of inflammatory cytokines in HSPC development and 
populations has become a topic of great interest. Recent studies suggest that inflammatory 
cytokine signaling is required for the proper development of HSPC populations in mice and 
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zebrafish (403). Discovery of an inflammatory cytokine profile in this population prompted 
investigation of transcriptional activation of this cytokine expression. Speck and colleagues 
found that knockdown of IRF2, a negative modulator of interferon transcriptional activation lead 
to increases in the expression of interferon targets, and increases in HSPC production in 
development (403). Additional studies implicate inflammatory cytokines in increases in 
proliferation states, and suggest that TNFα aids in HSC development, and suggests that cytokine-
producing myeloid cells are required for proper HSC development (404). While these studies 
have been performed in zebrafish, their insight provide potential therapeutic value for human 
disease (405). 
 
Table 1.5 Abbreviated list of cytokines important in hematopoietic regulation and inflammation 
Name 
Year 
Discovered Function Reference 
EPO 1977 Promotes production of RBCs (383, 406)  
GM-
CSF 1984 
Stimulates the production of granulocytes and maturation of 
macrophages  (407, 408) 
G-CSF 1985 Stimulates production of and survival of neutrophils  (409, 410)  
M-CSF 1979 Stimulates the production of macrophages  (411, 412) 
IL-3 1986 
Required for survival of myeloid cells, potentiates growth, involved 
in inflammatory signaling  (406, 413) 
SCF 1990 Ligand for c-Kit, promotes proliferation  (406, 414) 
TNFα 1985 
Promotes cell death, survival and stress signaling, stimulates the 
production of other cytokines  (388, 389, 391)  
IL-6 1990 
Promotes activation of lymphocytes and stimulate production of 
other cytokines regulating inflammatory response (394, 395, 415, 416)  
IFNγ 1957 Key activator of macrophages  (401, 402, 417) 
IFNα/β 1957 
Stimulates production of other inflammatory cytokines/ anti-
inflammatory in some contexts (399, 418)  
IL-1β 1977 Potent activator of inflammation (396, 397)  
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Hematopoietic homeostasis 
Following the completion of hematopoietic development, birth, and maturation of the 
organism, the hematopoietic system must still be maintained to function normally and respond to 
insults over the lifetime of the organism. As such, hematopoiesis is intricately controlled by 
proliferation and programmed cell death, and is extremely responsive to insults (e.g. blood loss, 
infection). In response to any perturbations, more terminally differentiated cells are removed, 
and as a result the HSCs and progenitors proliferate and differentiate to replace lost cells. As 
such, HSCs and progenitor populations are the most important cells in the maintenance of 
hematopoiesis. Often, issues with hematopoiesis arise from defects within these populations, 
leading to a failure to maintain terminally differentiated populations (371).  
Additionally, the hematopoietic system must constantly address maintenance of the 
hematopoietic system to keep the number of cells within each population of the hierarchy 
constant. This is due to the constant turnover of terminally differentiated cells such as platelets 
(7-10 days), neutrophils (6-8 hours), RBCs (120 days), and T cells (70-90 days) (419–422). 
Again proliferation of hematopoietic stem and progenitor populations, as well as programmed 
cell death to remove excess, damaged, and autoreactive cells is very important to maintain 
hematopoiesis in a healthy state.  
Early studies of understanding the role of HSPCs in hematopoietic homeostasis focused 
on methods to intervene in the ablative properties of irradiation. Irradiation greatly affects the 
bone marrow, leading to death of cells shortly after exposure, and death of the organism in high 
doses (423). Later studies determined that delivery of adult bone marrow could rescue this 
lethality through reconstitution of the hematopoietic system with the injected cells (424). This 
finding suggested that certain cells within the bone marrow had the capability to carry out 
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hematopoiesis long-term, and as such, studies with limiting dilution assays of bone marrow were 
carried out to understand how many cells were needed to reconstitute the hematopoietic system 
(425). Additionally, in studying these transplanted mice, it was noted that they developed 
nodules on the spleen soon after transplantation. These nodules contained clones of transplanted 
cells, suggested they derived from transplanted cells. Colony-forming assays were utilized to test 
the capability of these cells to proliferate and produce mature blood cells which at the time were 
called colony-forming units of the spleen (CFU-S) (366). Additionally, the finding that cells 
within these colonies had the capability to produce nodules in secondarily irradiated hosts 
suggested that daughter cells derived from these assays were capable of again developing clones 
(426). This finding introduced the concept of “self-renewal”, which is a defining feature of HSCs 
(427). Continued study of these cells suggested that they are typically quiescent in the setting of 
the bone marrow, which made them resistant to cytotoxic treatments (e.g. irradiation) that target 
dividing cells (428). Lastly, while initial CFU-S assays demonstrated that myeloid cells typically 
arose from nodules, it was also determined that these cells had lymphoid potential, 
demonstrating that some cells within these nodules had the capability to generate all mature cell 
types (429). Together, these studies implicated the existence of HSCs, capable of generating all 
mature hematopoietic cell types and of long-term repopulating capability. Progenitors were later 
identified through in vitro assays which revealed that these populations were distinct from the 
CFU-S, and served as the intermediate step between HSCs and mature cells types (430, 431).  
HSC proliferation is an important aspect of maintenance of hematopoietic homeostasis in 
the setting of injury or insult, however how HSCs become activated in order to maintain 
homeostasis was initially not well understood. Typically, HSCs are thought to be in a quiescent 
state, however in the setting of transplantation (an insult), when host cells are lost and 
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transplanted cells are injected to reconstitute the hematopoietic system, it was found that self-
renewal and proliferation of the injected HSCs was necessary for reconstitution to occur (432). 
Alternatively, it was hypothesized that a process known as “Clonal succession” occurred in 
which new HSCs are activated when active HSCs became exhausted. This was examined 
through the retroviral-mediated transfer of genes into hematopoietic cells as a marker, and then 
examining the fate of these cells over time (433). More recently, with the development of better 
labeling strategies which includes the use of conditional expression of fusion proteins (see 
hematopoietic stem cells), the LT-HSC, the most immature cell within the hematopoietic system, 
is thought to have 20% of its population slowly proliferating on a daily basis (365). These cells 
undergo what is termed a “Perfect self-renewal” in which the number of divisions resulting in 
self-renewal and differentiation are equal, and the number of cells required to maintain this 
population is minimal (434). Cells differentiating from the LT-HSC become ST-HSCs, which 
undergo “Near self-renewal”, as the number of differentiating divisions is slightly greater than 
self-renewing divisions. These cells feed downstream into MPP and committed lymphoid and 
myeloid populations. 
 Correspondingly, as a balance to proliferation, programmed cell death is also required in 
the maintenance of the HSC population and in turn its homeostasis. Studies with hematopoietic 
cells and mice overexpressing BCL-2 first implicated this through demonstration that blocking 
apoptosis increases HSC number and their repopulating capability (435). Additionally BCL-2 
overexpression decreased the sensitivity of the hematopoietic system to irradiation (436). Further 
studies demonstrate that more HSCs are produced than are needed at any given time likely to 
support death or egress of HSCs from the bone marrow (437). Studies showing that HSC number 
is tightly controlled, that studies with BCL-2 overexpression increases this number, and that 
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apoptotic cells are present within an isolated fraction of these cells, demonstrate that apoptosis is 
an important factor in the control of this population (364, 435).  
Maintenance of the progenitor populations is additionally key in hematopoietic 
homeostasis. MPPs, the next most mature population after ST-HSCs, maintain downstream 
production of committed progenitors through maintaining the ability to self-renew and 
proliferate (434). In contrast to MPPs, lineage committed progenitors (CMPs and CLPs) 
constantly proliferate and differentiate in order to produce terminally differentiated cells (438). 
This “transit” population has far greater divisions producing differentiated cells than divisions 
promoting self-renewal (434). As a result of this increased differentiation, many cells are 
required to maintain this population, and as such the input into its development is much larger 
and faster than it is for HSCs. Production of CMPs and CLPs varies quite substantially, with 
CMP production outweighing CLP production by several fold, likely as a result of the fact that   
lymphoid cell turnover much slower than myeloid cells. While, cell death is not characteristic of 
this population, aberrant cell death within committed progenitor populations can lead to bone 
marrow failure disorders, which particularly affect myeloid populations (discussed in greater 
detail in Hematopoietic Disease) (439, 440). 
 
Stress and emergency hematopoiesis  
Settings of stress hematopoiesis are activated in response to moderate insults such as 
local tissue infection or inflammation and promote activation of similar response pathways as 
seen in emergency hematopoiesis, but to a lesser extent (441, 442). For example, in the setting of 
local infection innate immune cells present in tissues before insult perform their antimicrobial 
tasks and additionally secrete cytokines and chemokines. This in turn promotes increases in 
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innate immune cell production locally through cytokine release and HSPC differentiation and 
recruits more immune cells (including lymphocytes) (443). Once the infection or inflammatory 
insult is cleared, excess cells are removed through programmed cell death. Additionally in the 
setting of repeated RBC loss, HSC proliferation and self-renewal increases within the bone 
marrow and spleen as well as the number of erythroid progenitors (Ter119+) (444).  
Emergency hematopoiesis is characterized by insults that affect systemic hematopoiesis. 
In the setting of systemic infection with bacterial or viral pathogens, this threat is sensed by not 
only terminally differentiated cells, but also progenitors and HSCs (445–448). Initial studies of 
this process suggest that the constant egress of HSPCs from the bone marrow to peripheral 
tissues aids in surveillance for infections and in the production of innate immune cells in host 
defense (449). These infections are primarily sensed through TLRs and promote cytokine 
release. Mature cells release Granulocyte-Colony Stimulating Factor (G-CSF), Interleukin-3 (IL-
3), IL-6, and Flt3 stimulating increased production of granulocytes, macrophages, and other 
myeloid cells (450–452). Rapid depletion of neutrophils induces a response known as 
“Emergency Granulopoiesis” in which neutrophils are generated de novo by G-CSF leading to 
release of mature and immature neutrophils (453). This process is believed to be essential for 
survival of systemic infection as defects in this process quite often lead to decreases in survival 
(454).  
HSCs sense infections through TLRs and as a result can secrete similar cytokines 
secreted by mature cells including IL-6, however this process is thought to be negligible in the 
overall response (455). Release of inflammatory cytokines such as IFNα and IFNγ during 
infection also affect HSCs (445). IFNα stimulates increased HSPC production through increased 
Signal transducer and activator of transcription 1 (STAT1) signaling (418). However the amount 
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of this cytokine is important in its activity as too little limits repopulation capability, while too 
much is detrimental and causes HSC exhaustion (364, 456). IFNγ affects HSPC function through 
stimulation of HSC activity and the accumulation of a c-Kit Hi progenitor population (457, 458). 
Artificial settings in which these cells types are ablated such as with irradiation or treatment with 
chemotherapeutics likely produce similar response as discussed above, but additional studies are 
needed to understand these settings which are termed “reactive granulopoiesis” (443).  
 While programmed cell death is important in the maintenance of homeostatic 
hematopoiesis, it can also be important or detrimental to the activation of emergency 
hematopoiesis (459). Execution of pyroptotic and necroptotic death promotes the release of 
cytokines directly and indirectly through release of DAMPs and through their secretion from 
inflammatory innate immune cells, respectively. For example IL-1β, which promotes pyroptotic 
death, promotes production of IL-6 and G-CSF, key cytokines in emergency granulopoiesis 
(460). Similarly release of IL-1α from necroptotic or pyroptototic cells can promote release of 
these same cytokines to promote emergency granulopoiesis (299, 461). Pyroptosis and 
necroptosis also block emergency hematopoiesis through indirect blockade of HSC activation. 
This is mediated through IFNα, which inhibits HSC proliferation and differentiation in settings 
of chronic exposure (418). Additionally, increased IFNα signaling is also purported to increase 
Rip3-mediated necroptosis, and Caspase-11 mediated pyroptosis through TLR and 
inflammasome activation in mature populations (226, 462). Additionally, is it also hypothesized 
that pyroptosis and necroptosis may directly impact emergency hematopoiesis through the death 
of HSCs. This is mediated through TNFR-dependent Rip3-dependent necroptosis as well as 
Caspase-1 and Caspase-11 dependent pyroptosis (248, 463).  
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Hematopoietic Disease 
Perturbations in the hematopoietic system typically promote a response that causes 
proliferation and differentiation of the HSPCs and death of terminally differentiated cells. 
However, in settings in which these cells do not respond properly, or are unable to respond 
hematologic disease arises. In the aging hematopoietic system, disease can arise as a result of 
increased DNA damage, development of a myeloid bias in hematopoiesis, or changes in 
epigenetic regulation leading to changes in gene expression. While mounting evidence suggests 
that these defects in HSCs occur with increased age, there is some controversy regarding whether 
these effects are specific to aged HSCs or are characteristics of HSCs which are not functioning 
properly (464). Further functional and genomic studies of aged and young HSCs are needed to 
clarify this point.  
 In the aging hematopoietic system HSCs begin to accumulate DNA damage due to 
increased ROS and telomere shortening (465–467). This accumulation of damage is likely due to 
poor DNA repair mechanisms present in aging HSCs (468, 469). In support of this, a 
comprehensive study in mice suggests that the number of times HSCs divide is directly related to 
this increased DNA damage, suggesting entry into the cell cycle increases the potential for DNA 
damage (470). This damage often affects HSC capability to self-renew and in turn reconstitution 
ability. Studies examining transplant of HSCs from younger and older individuals suggests that 
HSCs from older individuals have less reconstitution ability that is associated with decreased 
survival of recipients (471).  
DNA damage can additionally affect the potential of HSCs, biasing HSCs toward a 
myeloid potential (438, 472, 473). This bias is demonstrated to occur not due to changes in HSC 
activity, but instead as a result of a clonal expansion of a HSC with an inherent myeloid 
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potential, and a decrease in HSCs with lymphoid potential. This in turn leads to a decrease in 
immune competence with age (472). Another study demonstrated that with age HSCs had 
increased expression of genes associated with myeloid potential, but decreases in genes 
associated with gene potential (474). These data taken together along with the fact that myeloid 
cells are produced more often than lymphoid cells in normal hematopoietic homeostasis, likely 
leads to the increased occurrence of malignancy in myeloid lineage in older individuals (475, 
476). 
Aging in HSCs also affects gene expression through epigenetic regulation, increasing 
expression of genes involved in stress responses and inflammation (477). Expansion of these 
initial studies has also revealed decreases in multiple genes including those expressed in DNA 
repair and DNA replication, and differentiation. Through pathway analysis they identified that 
the increases in the transforming growth factor -Beta (TGF-β) pathway, a key pathway in the 
activation of proliferation and differentiation in HSCs, also occurs in aged HSCs (478). The 
authors found that these changes were mediated by alterations in epigenetic marks with increases 
in activating acetylation marks on genes involved in HSC identity and self-renewal, and overall 
decreases in inactivating methylation marks. The authors also found that expression of the 
enzymes important in adding/removing these marks were altered with a decrease in DNA 
methyltransferases and histone deacetylases suggesting that overall gene regulation was 
perturbed in ages HSCs. Taken together, these data suggest that overall gene expression is 
altered in aging HSCs and that it is likely changes in epigenetics that contribute to the 
characteristic changes in of older HSCs.  
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Clonal hematopoiesis 
Damage to HSCs may also confer increased ability to survive over other HSCs, leading 
to increased representation of these HSCs and its progeny in the hematopoietic population, a 
state known as clonal hematopoiesis (472). Clonal hematopoiesis primarily affects older 
individuals (479). This process is characterized by increased presence of the same “clone” of 
hematopoietic cells within the hematopoietic system containing certain acquired somatic 
mutations. Current studies focus on examination of the genomes and exomes of hematopoietic 
cells within the peripheral blood for mutations (479, 480). While many somatic mutations are 
present in individuals with clonal hematopoiesis, three genes are commonly mutated at a higher 
variant allele frequency, DNA (Cytosine-5)-Methyltransferase 3 Alpha (DNMT3A), Additional 
Sex Comb-like 1 (ASXL1), and Tet Methylcytosine Dioxygenase 2 (TET2) (479). These genes 
are associated with epigenetic control of gene expression in myeloid malignancies (481).  
The clinical significance of clonal hematopoiesis is not well understood. However, it is 
hypothesized that individuals with clonal hematopoiesis at an older chronological age are nearly 
13 times more likely to progress to hematologic malignancies such as myelodysplastic syndrome 
(MDS) or acute myeloid leukemia (AML) (480, 482). This process is hypothesized to primarily 
occur as a result of the increased likelihood that additional “driver mutations” will develop in 
these clonal cells (483, 484). Driver mutations are causally linked to malignancy development 
and drive the development of cancer. Several studies of populations of individuals demonstrate 
that mutations often found in individuals with AML and MDS often have mutations in the same 
genes commonly mutated in clonal hematopoiesis discussed above (485–487). The presence of 
these mutations and others in HSPCs that are still able to function normally are referred to as 
preleukemic HSPCs (488). Mutations in DNMT3A, ASXL1, and TET2 are considered to be 
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preleukemic due to their association with malignancy. However, few people with clonal 
hematopoiesis due to these mutations develop these hematologic malignancies, a distinction 
called clonal hematopoiesis of indeterminate potential (CHIP) (489). Some individuals 
additionally develop these malignancies but lack driver mutations, suggesting another random 
mutation likely stochastically occurs in order for malignancy to arise (464). This process of 
transformation is not well understood, as well as how other factors including the variant allele 
frequency of specific mutations and structural chromosomal mutations (e.g. inversion or 
translocation) affect the likelihood of transformation.  
 
Myelodysplastic Syndrome 
 MDS is a believed to be a group of chronic hematologic diseases characterized by 
cytopenias in at least one lineages, presence of dysplasia, and hypocellular bone marrow. The 
presence of hypocellular bone marrow is attributed to increased programmed cell death. For over 
20 years, studies of the type and cause of programmed cell death in MDS has concluded that 
apoptosis was the culprit of increased death within the bone marrow. However, the majority of 
these studies were completed during a time before another prominent type of cell death, 
necroptosis, was recognized in 2000. As such, while the findings presented during that time were 
sufficient to suggest an apoptotic death, reexamination of this data suggests that an apoptotic or 
necroptotic death could be occurring. Initial studies utilized a new technique at the time termed 
in situ end labeling (ISEL), which measured ends of nicked DNA. While DNA cleavage was 
purported to only occur in apoptosis, data also suggest that cleavage of DNA (although in a less 
ordered fashion) also occurs in necrosis (490, 491). These initial studies found that ISEL 
positivity was more prominent in the three lineages most affected by programmed cell death in 
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MDS samples and that this correlated with increased levels of TNFα (492–494). Later studies 
additionally demonstrate increased TNFR1 and FasR in MDS patient samples, suggesting 
increased death receptor signaling, which can have an outcome of both apoptotic and necroptotic 
death (495). With increased understanding of the apoptotic pathway, these studies next moved to 
understand the role of activation Caspase-3 in this process, and through in vitro studies found 
that cleaved Caspase-3, Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling 
(TUNEL), and Annexin V positivity were increased in MDS samples (496, 497). However, these 
studies were completed on cultured MDS samples, which likely have decreased viability as a 
result of being outside of their natural niche. Additionally, as previously mentioned, increased 
DNA presence of nicked ends (TUNEL) is not necessarily indicative of apoptosis.  
Current treatments for MDS include chemotherapeutics, demethylating agents, 
transfusions, and allogeneic bone marrow transplantation. While these treatments often palliate 
patient symptoms, many patients have no response or lack a sustained response to these 
interventions. The only potential cure for MDS is an allogeneic transplant, which often is 
difficult to receive as it requires the bone marrow donor to be closely related. As such, more 
therapeutics are needed to aid in the treatment of this disease. 
 MDS is hypothesized to be propagated by the accumulation of mutations within the HSC 
and progenitor populations, quite often within the same HSPCs which in turn propagate clonal 
hematopoiesis (489, 498). MDS is characterized by structural (Cytogenetic abnormalities) and/ 
or molecular (gene) mutations. Structural mutations often involve deletion of chromosomal arms, 
the most common of which is deletion 5q, (a loss of the long arm on chromosome 5) but may 
also include deletions of chromosome 7 and 20 (464, 482, 499). Molecular mutations are much 
more numerous and typically occur in not only DNMT3a, ASXL1, and TET2, but also Runt-
 86 
related transcription factor 1 (RUNX1), Splicing factor 3b Subunit 1 (SF3B1), Serine/Arginine 
Rich Splicing Factor 2 (SRSF2), U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1), Tumor 
protein 53 (TP53), Enhancer of Zeste Homolog 2 (EZH2), GATA-binding factor 2 (GATA2), 
Janus Kinase 2 (JAK2), Kirsten Rat Sarcoma Viral Oncogene Homolog  (KRAS), and Casitas B-
Lineage Lymphoma (CBL) (482, 500) .  
 MDS is currently classified according to recommendations from the World Health 
Organization (WHO) which considers morphologic, cytogenetic, hematologic, and molecular 
genetic findings (501). This group now utilizes a designation of MDS-qualifying description 
(e.g. Single lineage dysplasia, excess blasts). This replaces designations such as Refractory 
Anemia with Ringed Sideroblasts (RARS) or Refractory Anemia with Excess Blasts (RAEB-1) 
with MDS-RS and MDS- with excess blasts, respectively. This new designation was made 
because cytopenias are an essential quality of MDS and do not require designation, and 
understanding dysplasia and percent of blasts present is more pertinent in disease classification 
and treatment development. 
 
Table 1.6 Comparison of old and new WHO classifications of MDS. Adapted from (501, 502). 
WHO Previous Classification (2008) WHO New Classification (2016) 
Refractory Anemia (RA) MDS 
Refractory anemia with ring sideroblasts 
(RARS) MDS with ring sideroblasts 
Refractory cytopenia with unilineage dysplasia MDS with single lineage dysplasia 
Refractory cytopenia with multilineage 
cytopenia (RCMD) MDS with multilineage dysplasia 
Refractory anemia with excess blasts-1 (less 
than 10% blasts) (RAEB-1) MDS with excess blasts (% blasts) 
Refractory anemia with excess blasts-2 (10-
20% blasts) (RAEB-2) MDS with excess blasts (% blasts) 
Myelodysplastic Syndrome with del (5q) MDS with del (5q) 
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 My studies demonstrate that inflammatory cytokine signaling is increased in the bone 
marrow, and that death seems to particularly affect myeloid progenitor populations. Additionally, 
my own studies suggest that Annexin V, a protein that binds to phosphatidylserine, binds to both 
apoptotic and necroptotic cells, again suggesting this is not a marker specific to apoptosis. 
Studies presented within Chapter II implicate programmed necrotic death in the death of bone 
marrow in not only our mouse model of MDS, but also in samples of MDS. These findings 
suggest that further study of this process is needed to clarify the type of programmed death 
occurring in MDS and also provide a potential new therapeutic target for the treatment of MDS, 
blockage of programmed cell death. My studies contribute to this exploration through 
demonstration that necroptosis is a prominent source of death in both a mouse model of MDS 
and in MDS patient samples.  
 
Acute Myeloid Leukemia 
 Acute myeloid leukemia is a heterogeneous collection of diseases characterized by 
cytogenetic and molecular abnormalities that leads to overproduction of non-functional myeloid 
blasts which impedes normal hematopoiesis (503). This overproduction can occur within any cell 
of the myeloid lineage. AML is the most common of the acute leukemias and most often 
develops de novo, as a new malignancy (504). However AML can also occur after cytotoxic 
therapies, which is known as therapy-related AML (t-AML) or as a result of transformation from 
MDS (505, 506). This process occurs through “clonal evolution” the development of a new 
mutation within an existing clone that confers increased survival and allows for cancer 
development (507). AML primarily affects older individuals, and the risk for development 
increases with age. AML may additionally affect children. 
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 AML is diagnosed through examination of cytogenetics, peripheral blood counts, 
examination of the bone marrow for blasts, immunophenotyping, and examination of malignant 
cells for molecular mutations (508). Treatment consists of induction therapies with 
chemotherapy and in cases where a complete remission is achieved, patients often undergo 
consolidation therapy which may include further cytotoxic treatment or allogeneic hematopoietic 
cell transplant. While AML is quite treatable in younger patients (younger than 60), it becomes 
more difficult to treat in older patients as they are more likely to be resistant to standard 
treatments, suffer from therapy-related mortality, or to have a relapse of their disease (503, 508).  
 AML is characterized by several types of mutations, and similar to MDS these mutations 
tend to be structural cytogenetic or molecular genetic issues. As in clonal hematopoiesis and 
MDS, many of the same genes are mutated in AML. However, many of these genes are unique to 
AML, and are recognized driver mutations that develop as a result of clonal evolution. In 
addition to DNMT3A, RUNX1, ASXL1, TET2, and TP53, mutations in FLT3, Nucleophosmin 
(NPM1), CCAAT Enhancer-binding protein alpha (CEBPα), Kit (gene encoding c-Kit), 
Neuroblastoma Rat Sarcoma viral oncogene homolog (NRAS), and Isocitrate dehydrogenase 1 
and 2 (IDH1 and IDH2) are also common (501, 503). As with MDS, presence or absence of 
these mutations often predicts prognosis and additionally aids in classification of AML. 
Additionally, it was recently demonstrated that clonal evolution also comes into play with the 
relapse of AML in patients after achieving complete remission (509).  
 As a heterogeneous disease characterized by many structural and molecular mutations, 
AML is classified into a number of categories based upon specific genetic abnormalities as well 
as dysplasias (a rare occurrence), as well as the particular lineage of cell affected, and lastly 
myeloid sarcoma, an isolated myeloid extramedullary tumor (also rare) (501). The great number 
 89 
of structural and molecular mutations present in AML leads to a single classification category 
focused on recurrent mutations that commonly occur in AML 11 subtypes focus on 
chromosomal translocations, inversions, and deletions, t-AML related to cytotoxic therapies, as 
well as commonly mutated genes (510). AML is also classified according to the presence of 
myelodysplasia, as the association of these dysplasias with previously diagnosed MDS or 
myeloproliferative neoplasms (MPNs) has prognostic relevance for AML. Lastly, AML- not 
otherwise specified (NOS) covers AML with blasts at varying stages of differentiation, and 
blasts that tend to be rarer (e.g. acute basophilic leukemia). Classifications of AML utilizing 
these criteria aid in diagnosis and additionally aid in determination of treatment regimens.  
 
Table 1.7 WHO Classification of AML. Adapted from (501). 
Classification (# of subtypes) Description 
AML with recurrent genetic 
abnormalities (11) AML with structural and molecular mutations 
AML with myelodysplasia-related 
changes 
AML present in patients with previous diagnosis of 
myedysplasia  
Therapy-related AML 
Patient diagnosed with AML after cytotoxic therapy for a 
primary neoplasm 
AML, Not otherwise specified (9) 
AML characterized by more mature blasts (e.g. 
megakaryoblast) or immature blasts 
Myeloid sarcoma 
Solid tumor composed of myeloid blasts outside of the bone 
marrow 
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The Intestinal System 
 
Intestinal development in the mouse  
 The development and maintenance of the gastrointestinal system is crucial for the 
survival of an organism as it is key in breaking down and taking up nutrients necessary for the 
maintenance, growth, and restoration of the body. This complex system consists of the mouth, 
esophagus, stomach, cecum, small intestine, large intestine (i.e. colon), rectum, and anus. 
Development of the gastrointestinal system begins very early in fetal development and completes 
by two weeks postnatally. This process is characterized by constant proliferation and 
differentiation. Following gastrulation, the endodermal cells accumulate to form the hindgut and 
foregut. Through a folding wave these two sets of cells meet to form the primitive gut tube which 
includes the foregut, midgut, and hindgut (511). The foregut gives rise to esophagus, thyroid, 
trachea, lungs, stomach, liver, biliary system, and pancreas. The midgut gives rise to the small 
intestine and the hindgut gives rise to the colon. As the fetus continues to develop, the gut tube 
continues to grow through elongation and increasing girth. The once monolayer epithelium 
becomes pseudostratified and develops polarity (apical and basolateral poles) (512). 
Additionally, expansion of cells within the submucosa and layer of muscle expand to aid in 
expansion of the epithelial layer. In late development, the rostral to caudal wave promotes 
reorganization of the epithelium. The pseudostratified epithelial cells within the mid and hindgut 
become simple polarized columnar epithelium. Intraepithelial cavities form at the basolateral 
membrane of the pseudostratified epithelium and grow larger forming a secondary lumen that 
eventually fuses with the primary lumen (513). Around the same time, the mesenchyme 
invaginates into the epithelium to form de novo villi. These initial villi split to form more villi, a 
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process that is believed to be control by tension from the underlying muscle layer (514). This 
process similarly occurs in the colon, however the villi that form here are transient and are 
replaced by crypts as development continues. The colon additionally forms a multilayer 
epithelium that develops secondary lumina that fuse with the primary lumen as intervillous 
regions (513). By late gestation the small intestine and colon are composed of villi and 
intervillous regions. During the first two weeks of life the intervillous regions become crypts of 
Lieberkühn and the gastrointestinal system matures (514, 515). After maturation, further growth 
of the intestine occurs through fission of crypts throughout the lifetime of the organism (516).   
 
Adult intestinal system 
The mature gastrointestinal system plays two key roles in helping an organism to survive; 
breaking down and absorbing nutrients obtained from foods and maintaining a tight barrier to 
keep potential pathogens (e.g. microbes present on ingested food or commensals present within 
the intestinal tract) from infiltrating the body. There are four main layers of the intestine. The 
inner mucosa is the home of the intestinal epithelium which serves as a barrier from the intestinal 
lumen. The submucosa is a supportive layer of the mucosa and also contains the enteric neurons. 
The muscle layer contains several layers of muscle which are important for the movement of 
chyme (intestinal contents) through the intestine (517). The outer layer, the serosa, aids as a 
visceral membrane that covers the intestine and anchors it in place within the peritoneum (518). 
Within the intestinal epithelium there are four main types of terminally differentiated cell types 
that carry out these functions; enterocytes (colonocytes within the colon), goblet cells, 
enteroendocrine cells, and Paneth cells. Enterocytes make up the majority of the epithelial barrier 
within the intestinal barrier easily comprising 80% or more of the cells covering villi (519). 
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These highly polarized cells are responsible for the uptake of nutrients present in the digesting 
food moving through the small intestine and also secrete hydrolyzing enzymes that aid in 
digestion (520). These cells additionally participate in host defense against potential antigens 
through secretion of antimicrobial proteins (AMPs), expression of PRRs that allow for innate 
immune signaling, and through presentation of antigens to immune cells (519, 521, 522). Goblet 
cells are localized to both crypts and villi and secrete mucus within the lumen providing an extra 
barrier against potential antigens. Goblet cells primarily secrete mucin 2, a primary component 
of mucus, as well as trefoil factor 3 (TFF3), FC-gamma binding protein (FCGBP), and resistin-
like molecule β (RELMβ). TFF3 and FCGBP promote the cross-linking of mucins which is 
important in maintaining the stability of the mucus layer protecting the epithelium (523). While 
the role of RELMβ is not completely understood, it is known that its expression promotes 
increased mucin 2 expression and secretion, and it is induced when goblet cells are exposed to 
commensal bacteria, as well as within mouse models of helminth infection and inflammatory 
bowel disease (IBD) (523). These cells are also demonstrated to play a role in host defense 
through the presentation of antigens to dendritic cells (524). Enteroendocrine cells are hormone 
secreting cells that sense the luminal environment for nutrient uptake and monitor energy status 
and in turn secrete hormones in response to these stimuli. This is important in regulation of the 
enteric nervous system, facilitating communication between different portions of the 
gastrointestinal system as well as with other organs important for nutrition such as the pancreas 
(525). There are 10 distinct populations of enteroendocrine cells each secreting different types of 
hormones in response to various stimuli. For example, detection of energy sources such as 
glucose leads to the secretion of glucoinsulinotropic peptide (GIP) from enteroendocrine cells 
which targets β cells within the pancreas to produce insulin and promote glucose uptake (525). 
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Paneth cells serve as the primary host defense proteins within the intestine and are localized to 
the bottom of crypts alternating positions with intestinal stem cells (ISCs). These cells secrete 
AMPs such as lysozyme, cryptdins, and cathelicidins, which disrupt bacterial membranes (526). 
Paneth cells also secrete necessary factors for maintenance and survival of ISCs (520). Paneth 
cells are also implicated in the management of inflammation and intestinal homeostasis, as loss 
of these cells leads to increased inflammation in the intestine of mice and development of a 
phenotype similar to the IBD Crohn’s disease (527). Three other less common types of cells (cup 
cells, tuft cells, and microfold cells) exist within the intestinal system, however their function is 
less well understood. More recently, microfold cells, which are localized to Peyer’s patches in 
the small intestine, were demonstrated to sense antigens within the lumen and present these 
antigens to adaptive immune cells (528). Additionally, tuft cells which are chemosensory sensing 
epithelial cells, were shown to accumulate at site of infection with protozoa and helminth within 
the intestine (529).  
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Figure 1.14 Structure of the Intestine 
The intestine is an important site of nutrient absorption, and also serves to aid in the movement 
of intestinal contents throughout the gastrointestinal system. The intestinal mucosa is part of the 
intestinal epithelium which is important for nutrient absorption and serves as a barrier between 
the intestinal lumen and the gastrointestinal system. The submucosa serves as a supportive layer 
of the mucosa and also contains the enteric nerves. The muscle layers contain several layers of 
muscle which are important for the movement of the intestinal contents through the 
gastrointestinal system. Lastly, the serosa is an outer layer serving as a visceral membrane 
covering the intestine. This membrane also serves as an anchor for the intestine within the 
peritoneum. Adapted from (517).  
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Maintenance and homeostasis of the intestine 
 The intestinal lumen is an extremely harsh environment due to the high pH of the lumen, 
constant mechanical motion, and the presence of enzymes designed to aid in the breakdown and 
digestion of the contents moving through it. As a result, the turnover of the epithelial cells within 
the intestinal lumen is quite high with most lineages renewing every 3-5 days and as many as 
300 million cells being lost daily through anoikis (530). This great loss creates a need to replace 
cells quickly. Intestinal stem cells (ISCs) replace these lost cells by replenishing terminally 
differentiated populations through proliferation and self-renewal. Replicating ISCs differentiate 
into transit amplifying cells (TAs) an intermediate compartment within the crypt (531). Next, 
TAs divide 3-4 times, traveling up the crypt as they divide, before differentiating into all  
terminally differentiated epithelial cells with the exception of Paneth cells. Once this lining of 
cells reaches the base of the villus, proliferation ceases (530). Paneth cells renew every 3-6 
weeks and differentiate from dedicated progenitor cells which reside in the TA cell portion of the 
crypt. Once these cells differentiate they migrate downward toward the crypt bottom where they 
are interspersed between ISCs  (532).  
Maintenance of the intestinal epithelium relies on ISCs which are capable of generating 
all intestinal epithelial cells. Current studies have led to the development of a two stem cell zone 
model which posits the existence of at least two stem cell populations; the crypt base columnar 
(CBC) stem cells and the +4 stem cells which are present 4 cell diameters up from to the crypt 
base. This model arises from several studies suggesting that cells residing within the crypts 
proliferate and self-renew rapidly and function as short-term ISCs while +4 stem cells are more 
quiescent and function as long-term ISCs (530). While the identity of CBC stem cells is well-
established with the identification of Leucine-rich G protein-coupled receptor 5 (Lgr5) as a 
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marker, a +4 stem cell has not been firmly established (531). Several proteins are purported to be 
markers of the +4 stem cell population, including B-cell specific Moloney murine leukemia virus 
integrating site 1 (BMI1), Hop homeobox (HOPX), Leucine-rich Repeats and Immunoglobulin 
like domains 1 (Lrig1), and Telomerase reverse transcriptase (TERT) (533–537). However, 
while initial reporter and fate-mapping studies in mice suggested these proteins as markers of 
this population, further studies have fallen short in reliably marking this population, were not 
reliably being expressed in exclusively multipotent cells, or were expressed in highly 
proliferative cells (536, 538, 539). The fate of ISCs after differentiation into TAs and terminally 
differentiated cells is well understood, however many more studies are needed to understand 
stem cell biology within the intestine.  
The adult ISC population arises from early ISCs that are present during initial crypt 
development. These early ISCs rapidly expand through several self-renewing cycles, and then 
switch to a differentiating state to establish the adult stem cell pool (540). These cells further 
undergo a symmetric division that can result in either long-lived ISCs or TA cells. Through a 
stochastic event each crypt has a single remaining ISC, a process termed “neutral drift” (530). 
Overtime, each crypt becomes clonal, as this single long-term ISC remains after the cells 
dividing and differentiating are lost through normal cell turnover. The remaining ISC gives rise 
to all cells within the crypt, creating a clonal population.  
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Figure 1.15 Crypt and villi structure 
The epithelial layer of the small intestine is composed of villi and crypts which absorb nutrients 
and are the sites of intestinal cell generation, respectively. These structures provide increased 
surface area, increasing exposure of the contents of the intestinal lumen to chyme. Enterocytes 
are the principle absorptive cells. Goblet cells secrete protective mucus that coats all surfaces of 
the intestinal lumen and serve as the first line of defense against foreign antigens. Entero-
endocrine cells secrete hormones related to the presence or absences of certain nutrients and 
monitor energy status. Paneth cells serve as intestinal host defense cells, secreting antimicrobial 
peptides, and are also implicated in control of inflammation in the intestine. Transit amplifying 
cells serve as the precursors of each of these terminally differentiated cell types except Paneth 
cells. The cells of the intestine derive from intestinal stems cells (ISCs). The current model of 
ISC maintenance purports the existence of two types of ISCs; Lrg5+ and +4 ISCs. Lgr5+ cells 
are positive for this marker and reside at the bottom of crypts in alternating position between 
Paneth cells. Lgr5+ cells are believed to be short term ISCs that are highly proliferative. The +4 
ISC is located at position 4 within the crypt, however, there is controversy on which markers it 
expresses. The +4 ISCs are believed to be a more quiescent population that is long lived. The 
colon is made up of these same cells populations, but with enterocytes instead being termed 
colonocytes. Additionally, the colon primarily contains crypts, and villi are absent. Adapted from 
(530). 
 
 98 
 Inflammatory Bowel Diseases 
 Inflammatory Bowel Diseases (IBDs) are pathological states affecting the intestines 
characterized by chronic inflammation due to defective inflammatory signaling and is often 
driven by cytokine signaling (521). There are two major types of IBDs, Crohn’s Disease (CD) 
and Ulcerative Colitis (UC) (541). Other types include microscopic colitis, Behcet’s Disease, and 
indeterminate colitis, which are much less common (541, 542). While an exact etiology of IBDs 
is not known, it is believed to be caused by a combination of potential genetic susceptibility, 
issues with maintenance of epithelial cell barrier function, innate immune signaling, the status of 
the microbiota, and diet  (543–545). IBDs typically affect individuals between the ages of 15-30, 
but it is also diagnosed in children and is often more severe than adolescent and adult cases. 
Mouse models of IBDs suggest a major role for perturbed immune signaling and barrier 
function, as well as the microbiota, in the development of IBDs and as such are topics are of 
active research to develop and discover therapeutic targets (546). One of the new methods that is 
being utilized is the identification of biomarkers which can aid in the classification of IBDs and 
distinguish between CD and UC (547). 
 Crohn’s disease and ulcerative colitis, while being characterized by inflammation are two 
different diseases. CD can affect any tissue of the gastrointestinal system, but primarily affects 
the intestines, and is characterized by patchy presence of inflamed sites within healthy tissue. UC 
exclusively affects the colon and typically affects the distal portion and the rectum in continuous 
regions. Symptoms of both diseases include similar features; diarrhea, chronic abdominal pain, 
weight loss, and often a family history of IBD issues, as nearly 20% of patients have a family 
history of IBD (544, 545, 548). Patients may also display extraintestinal diseases such as 
osteoporosis, uveitis (inflammation of the uvea in the eye), or erythema nodsum (formation of 
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painful nodules under the skin) (544, 545).  Diagnosis of both diseases follows the same process 
which includes endoscopic and colonoscopic examination and biopsies, examination of tissue 
histology, magnetic resonance enterography, and blood serum examination and fecal 
examination for markers of inflammation such as C-reactive protein and calprotectin(544, 545). 
Additionally, while CD has clear mutations associated with its occurrence, UC does not (544, 
545).  
 Classification of inflammatory bowel diseases, particularly CD and UC, is based upon the 
age of onset, location within the gastrointestinal system, activity of the disease, and growth (544, 
545). In the treatment of IBDs, clinicians also measure the activity of the disease according to a 
score known as the Crohn’s Disease Activity Index in CD and the Truelove and Witts Severity 
Index for UC in adults (545, 549). Activity is characterized as being mild, moderate, or severe 
and give implication for the effectiveness of patient treatment.  
 There are a number of treatments utilized in patients with IBDs which target hormone, 
immune, or inflammatory/cytokine signaling (546). Steroids are a common treatment for IBDs 
and include corticosteroids and adrenocorticotropic hormones (550). These steroid often cause a 
complete remission in patients within a year. Immunosuppressants such as mercaptopurine and 
azathioprine are utilized in patients if steroids are ineffective, or for patients that are steroid-
dependent (551). Cyclosporine is another immunosuppressant that is specifically utilized in 
severe cases of UC that are steroid-refractory (552). Methotrexate is an anti-inflammatory drug 
utilized in patients with CD that are steroid-dependent. It is also used to maintain steroid-free 
remission, or to maintain remission (553, 554). Lastly, more recently, anti-TNFα therapy is 
demonstrated to be extremely effective in some patients with IBDs. As a pleiotropic cytokine the 
mechanism of action is not well understood, but may provide clues to understanding the 
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pathogenesis of IBDs (555). When drug therapies are ineffective, or if inflammation in the 
affected intestine is severe, patients may also receive surgery to remove affected portions of 
tissue or to bypass affected regions (556, 557). While many patients are successfully treated with 
these therapies, many are not, while others fail to have a sustained response. As such, the need 
for better understanding of IBDs and for more treatment options is needed in order to provide 
better treatment options for patients, and to prevent the progression of this disease which can 
lead to formation of fistulas, strictures, or intestinal malignancy (544, 545). 
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CHAPTER II 
 
 
LOSS OF BID-REGULATED NECROSIS INHIBITION LEADS TO MYELODYSPLASIA 
AND BONE MARROW FAILURE SIMILAR TO THE HUMAN DISEASE 
MYELODYSPLASTIC SYNDROME 
 
Introduction 
 
      Programmed cell death (PCD) is an essential process, required to craft distinct structures in 
early embryonic development (1), and to maintain homeostasis in dynamic systems such as 
hematopoiesis in adult organisms (102). The two main forms of PCD, apoptosis and necroptosis, 
result in markedly different outcomes with important implications for the cellular 
microenvironment: apoptotic cells are removed with minimal inflammation, whereas necroptotic 
cells release DAMPs which incite inflammation (15). In settings such as hematopoiesis, where 
cells are primed to respond to cytokine-directed environmental cues in order to maintain 
homeostasis, biasing cell death fate to necroptosis could seed chronic inflammation. 
Inflammation-driven cytokine production has the potential to alter the microenvironment to 
impact response to infections, myelosuppression from toxins (e.g chemotherapy), and 
transformation to leukemia. The potential impact of cell death fate on hematopoietic homeostasis 
is substantial and poorly understood.  
The Bcl-2 (B-cell lymphoma) family of proteins are situated at this central decision point 
of cell death fate, functioning downstream of death receptor signaling yet before activation of 
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executioner Caspases and cell death. While their central role in apoptotic cell death is well 
understood, the mechanistic link between the Bcl-2 family and necroptotic cell death has not 
been described. In particular, the BH3-only family member Bid, acts as a sensor and amplifier of 
signaling through death receptors, serving to activate mitochondrial outer-membrane 
permeabilization (MOMP) and initiate intrinsic apoptosis following interaction with and 
cleavage by Caspase-8 (113, 114). Importantly, Bid has been shown to function in a pro-survival 
role in which it acts to restrain cell death execution in certain contexts (7, 8, 173, 558). We 
propose that this pro-survival function of Bid extends to its role in actively restraining 
necroptosis, mediated through its modulation of Caspase-8 activity (discussed in Chapter III). 
Thus Bid acts at the central decision point between apoptotic and necroptotic cell death 
commitment.  
  In order to test whether Bid may influence cell death fate, we generated two mouse 
models. First, we conditionally deleted Bax using VavCre, and crossed this to a mouse model 
with germ line deletion of Bak in order to create hematopoietic-specific BaxBak double knockout 
(DKO) mice. This cross results in the loss of intrinsic apoptotic execution in hematopoiesis, 
however importantly leaves the upstream signaling pathway of interest intact. To specifically 
assess the role of Bid, we crossed these mice with Bid-/- mice to create BaxBakBid triple 
knockout (TKO) mice (121, 157). These models allow us to determine BaxBak independent roles 
of Bid at the central decision node upstream of the mitochondria yet still downstream of the 
receptors and immediate DISC complexes (47, 51).  
     We confirm that deletion of BaxBak completely blocks apoptotic cell death, but that this 
deficiency is not sufficient to initiate necroptotic cell death. Further deletion of Bid, however, 
leads to robust activation of necroptosis and specifically early death due to bone marrow failure 
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(BMF), manifest by a disproportionate anemia and thrombocytopenia. TKO mice display highly 
increased numbers of necrotic bone marrow cells, as assessed by Transmission Electron 
Microscopy (TEM). In addition, they display a dramatic depletion of progenitor cells 
accompanied by expansion of hematopoietic stem cell populations. Increased necroptotic death 
of bone marrow thus has a disproportionate effect on an early hematopoietic progenitor cell that 
give rise to erythrocytes and megakaryocytes. We have thus created genetic mouse models in 
which hematopoietic cells are protected from PCD (BaxBak DKO), and show that by removing 
Bid, a third pro-apoptotic Bcl-2 family member (BaxBakBid TKO), we switch cell death fate to 
necroptosis from apoptosis (wild type) under homeostatic conditions in mouse bone marrow. 
To further examine the function of hematopoietic stem and progenitor cells in our mouse 
models, we performed competitive reconstitution studies in which TKO or DKO whole bone 
marrow is transplanted in a 1:1 ratio with wild type bone marrow into lethally irradiated wild 
type (Bid +/+) recipient mice. Mice transplanted with TKO as well as mice transplanted with 
DKO bone marrow initially display increased competitive reconstitution compared to the wild 
type control, suggesting that early reconstitution requires restraint of BaxBak dependent 
apoptosis. Over time however, mice transplanted with TKO bone marrow develop progressive 
anemia and thrombocytopenia leading to early mortality despite the continued presence of wild 
type bone marrow. This suggests that the presence of necroptotic hematopoietic cells can impair 
hematopoietic function of normal cells. 
   Evaluation of hematopoietic stem and progenitor compartments in the transplant setting 
reveals significant differences between the impact of DKO versus. TKO bone marrow on 
homeostasis in this compartment. Whereas DKO stem and progenitor cell numbers are decreased 
relative to wild type, TKO cell numbers are preserved or even increased. This increased number 
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of TKO stem and progenitor cells is due to a disproportionate increase in LSK and SLAM-HSC 
cell numbers relative to wild type. In a secondary reconstitution experiment, TKO but not DKO 
bone marrow fails to reconstitute in a secondary transplant, demonstrating that increased 
necroptosis impacts hematopoietic stem cell repopulating ability. 
Necroptotic cell death elicits an inflammatory response that can impact hematopoietic 
differentiation and stem cell function. We note increased TNFα production in tissues of mice 
transplanted with TKO bone marrow, and increased TNFα production in response to LPS 
stimulation in TKO bone marrow. Importantly, treatment of TKO mice with the decoy TNFR, 
Enbrel, can partially rescue progenitor cells as well as TKO anemia and thrombocytopenia, 
further demonstrating that the preferential progenitor cell death and resultant cytopenias 
observed are driven at least in part by increased inflammatory cytokine production. Notably, we 
also demonstrate increased necroptotic signaling in the human bone marrow failure disorder, 
Myelodysplastic Syndrome (MDS), demonstrating the impact of necroptosis signaling on normal 
bone marrow function is relevant to human disease.  
 
Results 
 
VavBaxBakBid TKO mice die of bone marrow failure (BMF)  
As described above, our mouse models enable us to study apoptosis inhibition at the 
central decision node upstream of the mitochondria yet still downstream of the receptors and 
immediate DISC complexes (47, 51) (Figure 2.1A). VavCre efficiently deletes Bax in the bone 
marrow and spleen of DKO and TKO mice (Figure 2.2A). Consequently, there is no detectable 
mRNA by RT-PCR (Figure 2.1B) or protein by Western blot (Figure 2.1C). Phenotypes present 
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in VavCre TKO mice distinct from VavCre DKO mice indicate BaxBak- independent functions 
of Bid, allowing us to interrogate Bid-dependent upstream signaling events driving commitment 
to apoptosis versus necroptosis in hematopoiesis.  
As shown previously, BaxBak DKO mice die predominantly (89%) of lymphoid 
leukemia or myeloproliferative disease (MPD) that can be transferred to recipient mice, 
consistent with loss of mitochondrial –mediated death (Figure 2.1D, E, and G) (120, 559). In 
contrast, mice harboring loss of Bid in addition to Bax/Bak (TKO mice) display decreased 
survival relative to Bid+/+ (WT), Bid-/- (Bid KO), and BaxBak DKO mice (Figure 2.1D), with 
death predominantly due to overwhelming cell death in the bone marrow that results in bone 
marrow failure (BMF), in 66% of TKO mice. TKO mice manifested classical signs of BMF, 
including decreased hemoglobin concentrations (red blood cell (RBC) numbers) and platelet 
numbers (Figure 2.1F). Furthermore, TKO bone marrow demonstrates extensive myeloid 
dysplasia (abnormal differentiation and development) (Figure 2.1H): I) neutrophils (hyper-
segmentation), II) megakaryocytes (hypo-lobulation), and III) erythroid precursors (binucleation 
and intrachromosomal bridging) (560). Transformation to leukemia/MPD only occurs in 22% of 
TKO mice. This marked difference in hematopoietic phenotype with additional Bid deletion 
establishes that Bid can regulate hematopoietic homeostasis independent of its Bax/Bak activator 
role.  
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Figure 2.1 VavBaxBakBid TKO mice die of Bone Marrow Failure (BMF) 
A) Schematic and rationale for development of the BaxBakBid KO (TKO) mouse. (B) 
Examination of the deletion of Bax in bone marrow and spleen as determined by RT-PCR. (C) 
Immunoblot examining expression of Bax, Bak, and Bid, in Bid +/+, VavBaxBak DKO, and 
VavBaxBakBid TKO mice. (D) Survival curves of Bid +/+, Bid -/-, DKO, and TKO mice. 
Statistics demonstrate differences between DKO and TKO animals. ***= P< 0.001 Bid+/+ n=4 
Bid-/- n=4 DKO n=14 TKO n=22. (E) Cause of death in DKO and TKO mice was determined 
based on findings upon necropsy in DKO versus TKO mice. (F) Hemoglobin (a measure of red 
blood cell (RBC) numbers) and platelet counts from complete blood counts. Data are 
representative of mean +/- SEM from three and four Bid+/+ and TKO mice, respectively. *= P< 
0.05 (G) Examination of bone marrow and brain fluid from Bid +/+ mice transplanted with 
leukemic VavBaxBak DKO bone marrow after sub-lethal irradiation. Scale bar denotes 50 
microns. (H) Cytospins from the bone marrow of Bid +/+ and TKO mice denoting I) 
neutrophils, II) megakaryocytes, and III) erythroid precursors. Scale bars in I) and II) denote 50 
microns and in III) denotes 10 microns. 
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Figure 2.2 VavBaxBakBid TKO Bax allele organization and total bone marrow count 
A) Schematic of the Bax allele in VavBaxBak and VavBaxBakBid mice. B) Total cell number 
within the bone marrow (before sickness) in Bid +/+, Bid -/-, DKO, TKO Younger, and TKO 
Older mice. Bid +/+ n=5, Bid -/- n=5, DKO n=6, TKO Younger n=5, TKO Older n=9 
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TKO bone marrow dies by necroptosis  
The presence of markedly decreased cells in TKO blood despite preserved bone marrow 
cellularity (Figure 2.2B) strongly suggests that there is increased cell death in the bone marrow. 
To determine how the additional loss of Bid impacts bone marrow cell death in TKO mice, we 
performed transmission electron microscopy (TEM) to examine cellular morphology, a defining 
feature of both apoptosis and necroptosis. Image comparison of Bid+/+ and TKO cells reveal 
morphologies characteristic of apoptosis (e.g. pyknotic nuclei, cell membrane and organelle 
shrinkage) and necroptosis (e.g. membrane integrity loss, cell membrane and organelle swelling), 
respectively (Figure 2.3A). Image quantification reveals necroptotic morphology in nearly 25% 
of cells in TKO bone marrow versus 7% in Bid+/+ and 10% in DKO bone marrow (Figure 
2.3B). Necroptotic PCD signaling is executed by Rip1 and Rip3 (561). Accordingly, Rip1 levels 
are increased by immunofluorescence in TKO but not Bid+/+, Bid-/-, or DKO bone marrow 
(Figure 2.3C). No significant cleaved Caspase-3 was observed in DKO or TKO bone marrow 
(Figure 2.3D and E), inconsistent with apoptosis as the primary cell death mechanism in this 
setting. Immunofluorescence data further supports necroptotic PCD in TKO bone marrow, 
establishing that while loss of BaxBak prevents MOMP and apoptosis in the bone marrow, the 
additional loss of Bid induces necroptotic cell death, suggesting that Bid may function as a brake 
on necroptotic death in the bone marrow. 
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Figure 2.3 VavBaxBakBid TKO bone marrow dies by necrosis 
A) Bid +/+, DKO, and TKO bone marrow was prepared for transmission electron microscopy. 
Representative transmission electron microscopy images from Bid +/+ and TKO mice. (Upper: 
Scale bar indicates 2 microns, Lower: Scale Bar indicates 500 nanometers). **= P< 0.01 B) 100 
cells with a nucleus from lower magnification images (Upper) were scored as being either 
apoptotic, necroptotic, or live based on cell and organelle morphology.  Quantification of 
transmission electron microscopy of Bid +/+, DKO, and TKO bone marrow. C) Fluorescent 
immunohistochemistry was performed on paraffin-embedded bone marrow sections from Bid 
+/+, Bid -/-, DKO, and TKO mice were for Rip1. Experiment was performed three independent 
times. Scale bar indicates 50 microns. D) Fluorescent immunohistochemistry was performed as 
above for cleaved Caspase-3. Scale bar indicates 100 microns. E) Fluorescent 
immunohistochemistry on Bid +/+ liver after tail vein injection with Fas ligand as a positive 
control for cleaved Caspase-3 staining.  
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Unrestrained bone marrow necrosis disrupts hematopoietic homeostasis 
Hematopoiesis is a highly dynamic biological process that is tightly regulated by 
proliferation and death. In response to stress, terminally differentiated cells are removed through 
PCD and normally quiescent hematopoietic stem cells (HSCs) proliferate and differentiate, 
expanding the progenitor cell pools, which then rapidly proliferate to restore hematopoiesis 
(364). Programmed cell death serves to reset homeostasis once the stress is resolved. 
Long-term hematopoietic homeostasis therefore depends on proper regulation of 
programmed cell death. We asked whether the mechanism of cell death (apoptosis versus 
necroptosis) may also impact long-term hematopoietic homeostasis, as necroptotic cells create an 
inflammatory microenvironment by releasing DAMPs and cytokines such as TNFα and IL-1β 
into the extracellular space (562).  Inflammatory cytokines have been shown to impair HSC 
function (445), suggesting the possibility that bone marrow necroptosis may impair HSC 
function and hematopoietic homeostasis.  
To evaluate the effect of increased necroptosis on hematopoietic homeostasis in our TKO 
mice, we examined hematopoietic stem and progenitor cells (HSPCs).  LSK (Lin- Sca1+c-Kit+) 
cell populations were expanded in TKO but not Bid+/+, Bid -/-, or DKO mice (Figure 2.4A). 
The signaling lymphocyte activating molecule-HSC (SLAM-HSC, LSK Flt3LoCD48-CD150+) 
population (377), more highly enriched for HSCs, continues to expand in TKO but not DKO 
mice with age. Accordingly, TKO but not DKO SLAM-HSCs displayed increased BrdU 
incorporation, consistent with an appropriate response to bone marrow stress (Figure 2.4B). LT-
HSC (Lin- Sca1+c-Kit+CD135Lo) populations were not significantly changed between genotypes 
(Figure 2.5A). The above results are consistent with an appropriate SLAM-HSC response to 
bone marrow stress. 
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Given the apparent bone marrow stress noted in TKO SLAM-HSCs, we anticipated that 
progenitor populations would be similarly expanded with increased BrdU incorporation. In 
contrast, we found that both TKO and DKO myeloid progenitor (Lin- Sca1-c-Kit+) populations 
are decreased (Figure 2.4C) and display significantly decreased BrdU incorporation as compared 
to Bid+/+ mice (Figure 2.4D). The expanded SLAM-HSCs with decreased progenitors in TKO 
mice are consistent with increased sensitivity of the progenitor population to cell death with 
compensatory HSC proliferation. Importantly, DKO mice do not display increased SLAM-HSC 
proliferation despite decreased progenitor cell proliferation (Figure 2.4B and D), suggesting a 
distinct defect in hematopoietic homeostasis in DKO versus TKO mice.   
Consistent with the increased programmed cell death noted in myeloid cells, TKO but not 
Bid+/+, Bid-/-, or DKO mice display splenomegaly with increased Ter119+ cells (erythroid), 
indicative of extramedullary hematopoiesis that is progressive with age (Figure 2.5B and C). 
Notably B cell and monocyte populations are not significantly different between genotypes at 
necropsy, but TKO T cell populations are expanded (Figure 2.5D). Examination of erythroid 
progenitor populations including the Pro-erythrocyte and erythroblast populations before 
phenotype manifestation and at death reveal significant decreases in the basophilic erythroblast 
populations in both DKO and TKO mice (Appendix A). 
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Figure 2.4 VavBaxBak DKO and VavBaxBakBid TKO bone marrow displays altered 
hematopoietic homeostasis 
A) Immunophenotyping analysis by flow cytometry of bone marrow to examine LSK (Lineage-, 
Sca-1+, c-Kit+) and SLAM-HSC (Signaling lymphocyte activating molecule- hematopoietic stem 
cell) populations. Mice were examined before onset of sickness. Younger mice were 11-15 
weeks old and older mice were 15-20 weeks of age. Bid +/+ n=5, Bid -/- n=5, DKO n=6, TKO 
Younger n=5, TKO Older n=9 B) Examination of the number of BrdU+ SLAM-HSCs in bone 
marrow as determined from BrdU assay in mice were injected with a total of 4mg of BrdU in 
three doses over the course of 36 hours. Bone marrow was collected, depleted for terminal 
lineages, and then stained for flow cytometry. All remaining cells were analyzed by flow 
cytometry. Mice were 18-20 weeks of age. C) Numbers of myeloid progenitors (Lineage-, Sca-1-, 
c-Kit+) as in (B). Mice were 18-20 weeks of age. D) Examination of the number of BrdU+ 
myeloid progenitors. BrdU positivity in the myeloid progenitor population was examined in mice 
treated as above. For (A) Bid+/+ n=5, Bid -/- n=5, DKO n=6, TKO Younger n=5, TKO Older= 
9. For (B), (C), and (D) Bid+/+ n=8, Bid -/- n=7, DKO n=8, TKO n=7.  
Ns= not significant (p>0.05) *= P<0.05 **=P<0.01 ***=P<0.001 ****=P<0.0001 
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Figure 2.5 Unrestrained bone marrow necrosis does not significantly impact LT-HSC, B 
cell, or monocytic populations 
A) Examination of the LT-HSC population in Bid +/+, Bid -/-, DKO and TKO mice before 
sickness (11-20 weeks old). Younger TKO mice are aged 11-15 weeks, and Older TKO mice are 
15-20 weeks old. Bid+/+ n=5, Bid-/- n=5 DKO n= 6 TKO Younger n=5, TKO Older n=10 B) 
Spleen weights of Bid +/+, Bid -/-, DKO and TKO mice before sickness as in (A) Bid+/+ n=11, 
Bid-/- n=9 DKO n= 15 TKO Younger n=10, TKO Older n=10. C) Examination of Ter119+ cells 
in the bone marrow and spleen of mice at death (At time of phenotype manifestation in DKO and 
TKO mice) In examination of spleen, TKO younger mice are 12 months old or younger, and 
TKO older mice are 12 months or older in age. Bid+/+ n=6, Bid-/- n=5 DKO n= 13 TKO n=22 
D) Examination of T, B, and myeloid cells in the bone marrow of mice at death (At time of 
phenotype manifestation in DKO and TKO mice). Populations examined by flow cytometry for 
CD3 (T cells), B220 (B cells), and CD11b and Gr-1 double positivity (Myeloid cells). Bid+/+ 
n=6, Bid-/- n=5 DKO n= 13 TKO n=22 
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TKO cells outcompete Bid+/+ cells, but fail to maintain hematopoiesis in competitive 
repopulation experiments 
The BMF noted in TKO mice strongly indicates abnormal hematopoietic stem cell 
function. To stringently evaluate TKO HSPC function, we required test (TKO) bone marrow to 
compete with normal bone marrow to repopulate a lethally irradiated congenic mouse 
(competitive repopulation). Accordingly, we injected a 1:1 ratio of TKO (Ly45.2+) to wild type 
(Bid +/+) (Ly45.1+) bone marrow into lethally irradiated wild type (Bid +/+) (Ly5.1+) mice, 
and evaluated peripheral blood for Ly45.2+ and Ly45.1+ mononuclear cells. Two additional 
cohorts of mice were examined in which a 1:1 ratio of wild type (Ly5.2+) to wild type (Ly5.1+) 
or a 1:1 ratio of DKO (Ly5.2+) to wild type (Ly5.1+) marrow was transplanted into lethally 
irradiated wild type (Ly5.1+) mice.  Surprisingly, both DKO and TKO bone marrow displayed 
increased repopulating ability relative to Bid+/+ marrow (Figure 2.6A). However, peripheral 
blood counts reflected the presence of bone marrow stress that was more severe in TKO mice, 
with decreasing RBC counts (anemia) and platelets (thrombocytopenia) and increasing platelet 
size (Mean platelet volume) (Figure 2.6B, C, and D). 
 
Hematopoietic stem and progenitor compartments reflect a distinct phenotype between DKO and 
TKO HSPCs 
To further explore how altered cell death mechanism impacts non-cell autonomous 
interactions in the HSPC and progenitor compartment, we evaluated progenitor, LSK, and 
SLAM HSC populations post 20 weeks in primary competitive repopulation experiments. 
Similar to untransplanted mice, DKO and TKO-transplanted progenitor cell numbers were 
similar, and markedly decreased relative to Bid +/+ (wild type) transplanted mice. Strikingly, 
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whereas DKO and wild type LSK cell numbers are similar, TKO bone marrow displays a 
substantial increase in LSK (~7x) and SLAM HSC (~2x) numbers. This increase in TKO LSK 
and SLAM HSCs results in an expansion in the HSC population overall, despite a relative 
decrease in progenitor cells- consistent with stress hematopoiesis. In contrast, DKO HSPCs are 
~2 fold decreased relative to wild type HSPCs, consistent with bone marrow crowding due to 
increased mature cells that did not die (Figure 2.6E).  Beginning at 20 weeks, mice transplanted 
with both DKO and TKO bone marrow but not Bid+/+ bone marrow alone, began to die (Figure 
2.6F). In addition, TKO but not DKO-transplanted mice displayed evidence of BMF (Appendix 
B, A and B), increased bone marrow debris. Examination of blood and bone marrow from mice 
transplanted with TKO bone marrow reveals dysplasia and bone marrow cell death similar to that 
observed in TKO mice. At the time of death, TKO cells represented 80-90% of the bone marrow. 
Despite the presence of 10-20% wild type bone (Bid +/+) marrow, hematopoiesis was not 
maintained, suggesting a cell-extrinsic effect of TKO bone marrow on wild type HSPCs.  
 
Secondary transplantation reveals defective TKO HSPC repopulating ability  
To further evaluate HSPC function, and to compare DKO and TKO bone marrow 
reserve, we performed a secondary transplant. DKO bone marrow continues to out-compete wild 
type bone marrow even in secondary transplant conditions, indicating continued HSPC self-
renewal capacity. In contrast, TKO bone marrow displays strikingly decreased competitive 
repopulating ability, consistent with decreased HSPC self-renewal capacity (exhaustion) in 
secondary transplant conditions (Figure 2.6G). We thus demonstrate that increased necroptosis 
impairs long-term HSPC function.  
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Mice transplanted with TKO bone marrow display increased TNFα production 
As increased necroptosis promotes an innate immune response, we evaluated our 
transplanted mice for evidence of increased inflammation and inflammatory cytokine production. 
Notably, mice transplanted with TKO but not wild type (Bid +/+) bone marrow displayed 
marked inflammation in the lungs, kidney, and liver upon necropsy. Immunofluorescence 
revealed increased TNFα expression in lungs from mice transplanted with TKO but not wild type 
or DKO bone marrow (Figure 2.6H), suggesting that transplantation of TKO but not wild type 
cells promotes inflammatory cytokine production. Accordingly, TKO but not wild type or DKO 
bone marrow displayed significantly increased TNFα expression on the lower side scatter 
population but not the middle side scatter population, as measured by intracellular flow 
cytometry, following LPS stimulation (200 ng/mL) (Figure 2.6I and Appendix B, C.). The above 
results are consistent with inflammation induced by dying TKO cells leading to increased TNFα, 
which kills wild type and TKO HSPCs, producing BMF.  
 
Treatment with TNF decoy receptor (Enbrel) restores HSPCs and improves cytopenias in TKO 
mice 
Given the marked increase in TNFα observed in TKO transplanted mice as well as TKO 
bone marrow, we sought to determine whether inhibiting TNFα could improve TKO cytopenias.  
We treated a cohort of Bid+/+, DKO and TKO mice with Enbrel to inhibit TNFα. Enbrel 
treatment increased the number of myeloid progenitor cells and BrdU+ myeloid progenitor cells 
such that were not significantly different from Bid +/+ myeloid progenitor cell and BrdU+ 
myeloid progenitor cell numbers (Figure 2.6J). In addition to rescuing progenitor cell numbers 
and proliferation, Enbrel treatment also improved peripheral cytopenias in TKO mice. Both RBC 
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and platelet counts in Enbrel-treated TKO mice (Fig. 2.6K) increased, further demonstrating that 
increased TNFα elicited by necroptosis impairs hematopoiesis. Significantly, TNFα inhibition 
can improve bone marrow function to improve peripheral blood counts. 
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Figure 2.6 VavBaxBakBid TKO bone marrow outcompetes Bid +/+ bone marrow but fails 
to maintain hematopoiesis in competitive reconstitution experiments 
A) Percent CD45.2+ cells in Bid +/+, DKO, and TKO transplant mice at 8,12,16, and 20 weeks 
after transplantation. Mice were transplanted with experimental and control bone marrow at a 1:1 
ratio. Bid +/+ n=7 DKO n=7 TKO n=6. Statistics demonstrate differences between Bid +/+ and 
TKO animals. B) Examination of red blood cell counts in transplanted Bid +/+, DKO, and TKO 
mice at 8, 12, 16, and 20 weeks after transplantation. Bid +/+ n=5 DKO n=8 TKO n=8. Statistics 
demonstrate differences between Bid +/+ and TKO animals. C) Examination of platelet counts 
in transplanted Bid +/+, DKO, and TKO mice at 8, 12, 16, and 20 weeks after transplantation. 
Bid +/+ n=5 DKO n=8 TKO n=8. Statistics demonstrate differences between Bid +/+ and TKO 
animals. D) Examination of mean platelet volume in transplanted Bid +/+, DKO, and TKO mice 
at 8, 12, 16, and 20 weeks post transplantation. Bid +/+ n=5 DKO n=8 TKO n=8. Statistics 
demonstrate differences between Bid +/+ and TKO animals. E) Examination of the distribution 
of myeloid progenitor, LSK, and SLAM-HSC populations in Bid +/+, DKO, and TKO 
transplanted mice. Bid +/+ n=5 DKO n=7 TKO n=6. F) Survival of Bid +/+, DKO, and TKO 
transplanted mice. Bid +/+ n=10 DKO n=10 TKO n=10. Statistics demonstrate differences 
between Bid +/+ and TKO animals. G) Secondary transplantation of DKO and TKO bone 
marrow completed through transplantation of bone marrow from primary transplant in a 1:1 ratio 
with Bid +/+ to stringently test HSC function. DKO n=8 TKO n=7.  H) Fluorescent 
immunohistochemistry of TNFα expression in lung of Bid +/+, DKO, and TKO mice. Scale bar 
indicates 50 microns. Experiment was completed two independent times. I) Examination of 
TNFα expression in the low side scatter population of bone marrow of Bid +/+ and TKO mice 
following 5 hours of in vitro stimulation with 200ng/mL LPS. Data are represented as mean +/- 
SEM. Experiment was completed four independent times. J) Examination of myeloid progenitor 
populations and BrdU incorporation within this population in Bid +/+ and TKO mice after 
treatment with Enbrel, a TNF inhibitor. K) Examination of red blood cell and platelet counts in 
Bid +/+ and TKO mice. Bid +/+ n=4 TKO n=4 
ns= P>0.05 *= P<0.05 **=P<0.01 ***=P<0.001 ****=P<0.0001 
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The human disease MDS demonstrates increased Rip1 and Phospho-MLKL expression, 
consistent with increased necroptotic signaling 
We demonstrated above that increased necroptosis in mouse bone marrow results in BMF 
with a cellular bone marrow, prominent dysplasia, and a small frequency of transformation to 
leukemia, phenocopying the human BMF disorder, Myelodysplastic Syndrome (MDS). 
Increased cell death in MDS bone marrow has been attributed to apoptosis. However, review of 
the published data in light of current knowledge reveals that early studies measured cell death 
using techniques that do not distinguish between apoptotic and necroptotic cells (563): increased 
in situ end labeling, increased TUNEL staining, or increased DNA laddering on gels (392, 492, 
493, 564). Increased Caspase-3 activity was seen in cultured MDS bone marrow (496), but in 
only 10% of MDS samples when measured directly ex vivo (565). Thus evidence to date does not 
distinguish between apoptotic and necroptotic cell death in MDS bone marrow in vivo.  
As the salient features of MDS are recapitulated in our Vav TKO mice, we investigated 
necroptosis and apoptosis in MDS patient bone marrow samples. Rip1 staining revealed 
increased expression in all samples of RCMD, and 50% of RAEB-1 and -2 subtypes of MDS in 
our 22-patient cohort (Figure 2.8A) consistent with increased necroptosis signaling in MDS bone 
marrow. Conversely, staining for cleaved Caspase-3 reveals modest staining in only a few 
samples, including controls (Figure 2.8B), inconsistent with significant apoptosis in our cohort of 
patients. We further stained samples from our MDS patient cohort with anti-phospho MLKL. We 
find increased phospho-MLKL staining in several subtypes of MDS patient samples, 
corresponding to those in which we find increased RIP1 kinase staining (Figure 2.8C and D). 
Furthermore, we observed an inverse correlation between Rip1 and Bid expression in MDS but 
not control patient samples: we observed a decrease in Bid expression, but an increase in Rip1 
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expression in MDS (Figure 2.8E). This correlation corresponds to the pattern of expression seen 
in myeloid progenitor cells (MPCs) in mechanistic studies (Chapter III). While this study does 
not rule out a role for apoptosis in a subset of MDS patients, our study clearly implicates 
necroptosis signaling in MDS. 
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Figure 2.7 The human disease MDS demonstrates increased Rip1 and phosphor-MLKL 
expression, consistent with increased necroptotic signaling 
(A) Rip1 staining on paraffin-embedded human bone marrow aspirate with Dapi as a nuclear 
stain. Scale bar indicates 100 microns. Experiment was performed three independent times. (B) 
Caspase-3 staining on paraffin-embedded human bone marrow aspirate with Dapi as a nuclear 
stain. Experiment was performed three independent times. Scale bar indicates 50 microns. (C) 
Phospho-MLKL staining on paraffin-embedded human bone marrow aspirate with Dapi as a 
nuclear stain. Experiment was performed two independent times. Scale bar indicates 50 microns. 
(D) Table demonstrating positivity of human samples for Rip1 and Phosph-MLKL by subtype. 
E) Lysate from control and MDS patient bone marrow examining Rip1 and Bid levels by 
immunoblot. Demonstrates a similar relationship between these proteins, with increased Rip1 
expression and decreased Bid expression in MDS samples as seen in TKO myeloid progenitor 
cell lines. Experiments in A-E were performed by Qiong Shi.  
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Discussion 
 
Using our mouse models in which we altered programmed cell death fate in 
hematopoiesis, we demonstrate that increased necroptotic cell death in the bone marrow, as 
demonstrated in our TKO mice, leads to bone marrow failure with prominent dysplasia, and a 
hyper/normocellular bone marrow. We further show that this bone marrow failure is driven by 
loss of the progenitor cell populations: SLAM-HSCs show expansion over time, consistent with 
a stress response. Competitive repopulation experiments demonstrate that necroptotic cells can 
cause bone marrow failure, even in the presence of normal hematopoietic cells, suggesting that 
necroptotic cell death results in a cell extrinsic impairment of both normal and mutant 
hematopoietic stem cells. We postulate that this cell extrinsic effect is mediated by the release of 
DAMPS, which promotes the release of TNFα, and show increased TNFα in organs of TKO 
transplanted mice as well as increased TNFα production by TKO bone marrow. Hematopoiesis is 
a dynamic system that responds to environmental cues transmitted through cytokines such as 
TNFα, to promote proliferation and PCD function to remove damaged cells and to reset 
homeostasis. Our data demonstrate that, in addition to the degree of cell death, the mechanism by 
which cells die can have a dramatic impact on bone marrow homeostasis, and that skewing death 
to necroptosis results in BMF. 
 Studies focused on BaxBak DKO MEFs and cardiac myocytes have implicated Bax and 
Bak in necroptosis execution as BaxBak DKO cells are protected from necroptotic stimuli (566). 
Our studies in hematopoietic cells are in agreement with the finding that BaxBak DKO cells do 
not undergo necroptosis. However, we clearly demonstrate that necroptosis can be executed in 
the absence of Bax and Bak both in vitro as well as in vivo in hematopoietic cells following the 
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additional loss of Bid. Further studies will be required to determine the molecular mechanism of 
necroptosis execution in hematopoietic cells versus fibroblasts and cardiac myocytes, and to 
clarify the requirement for Bax and Bak. 
The bone marrow failure phenotype of our TKO mice phenocopies the human BMF 
disorder, MDS, and we demonstrate increased necroptosis signaling in primary MDS bone 
marrow. Our results thus shed light on how increased programmed necrotic cell death can 
amplify bone marrow cell death and lead to BMF. The ability to restore hematopoietic progenitor 
function by inhibiting the inflammatory cytokine TNFα raises the possibility that inhibiting 
inflammatory cytokines (TNFα or other inflammatory cytokines) may provide therapeutic 
benefit in BMF disorders such as MDS. Clinical trials targeting TNF in  MDS suggest that TNF 
signaling can drive cytopenias in this disease (567). However the disappointing results of the 
randomized phase 2 trial suggest that targeting TNFα at the receptor level is not sufficient (568). 
Additional studies will be required to determine whether combining necroptosis and 
inflammatory cytokine inhibition can provide additional benefit.  
Two recent studies demonstrate BMF due to HSC dysfunction in mice harboring a 
kinase-inactive form of Rip1 (248), and impaired engraftment of fetal liver hematopoietic cells 
from Rip1 -/- mice (569) demonstrating that signaling through Rip1 kinase is required for proper 
HSC function. However, the loss of stem cell function in these studies precluded further 
evaluation of the impact of Rip1 kinase on hematopoiesis as no blood cell development beyond 
HSCs ensues. In contrast, our study designed to interrogate increased necroptosis signaling, 
demonstrates an expanded HSC population with increased repopulating ability, further 
highlighting the importance of Rip1 kinase signaling in HSC function. As our system allows 
differentiation beyond the HSC, we show that in contrast to HSCs that appear to require RIP1 
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activity for proper function, myeloid progenitors are sensitive to increased Rip1 signaling and 
undergo necroptosis that results in bone marrow failure through both cell intrinsic as well as cell 
extrinsic mechanisms. Our study has important implications for settings in which an insult such 
as infection or chemotherapy is delivered to the entire bone marrow and induces necroptotic cell 
death. The ability to intervene to inhibit necroptosis in these settings may provide a mechanism 
to ameliorate myelosuppression.   
In summary, we have developed a novel set of mouse models tuned to undergo apoptosis 
(wild type) or necroptosis (TKO), to explore the impact of necroptotic PCD on hematopoiesis. 
Although the impact of necroptosis signaling on early embryonic development has been carefully 
dissected using genetic mouse models, the role of necroptosis in dynamic systems such as 
hematopoiesis under homeostatic conditions has not been determined. Our mouse models 
provide insights into how increased necroptosis impacts hematopoietic homeostasis and HSC 
function leading to BMF. We further demonstrate how aberrant bone marrow necroptosis 
contributes to bone marrow failure disorders such as MDS. Substantial data have established the 
presence of increased cell death and increased inflammation in MDS bone marrow. We now 
demonstrate increased necroptosis in MDS bone marrow, and elucidate how aberrantly increased 
bone marrow necroptosis may contribute to the pathogenesis of bone marrow failure disorders 
such as MDS.  
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CHAPTER III 
 
BID MODULATES CASPASE-8 ACTIVITY TOWARDS RIP1 
 
Introduction 
 
The two main forms of PCD, apoptosis and necroptosis, result in markedly different 
cellular outcomes as a result of similar methods of upstream stimulation. The upstream 
molecular signaling machinery through death receptors such as TNF (Tumor necrosis factor 
receptor), FAS, and DR4/5 (Death receptor 4/5) is shared among apoptosis and necroptosis, but 
diverges prior to activation of effector Caspases or Rip kinases culminating in apoptotic or 
necroptotic death, respectively. Seminal studies of genetic mouse models further demonstrate 
that the upstream activators of apoptosis, FADD and Caspase-8, act as key inhibitors of 
necroptotic cell death during embryonic development. The embryonic lethality of Caspase 8-/-, 
and FADD -/- mice can be rescued by additional loss of the necroptosis effectors Rip1/Rip3. 
(230, 569–574). These data strongly suggest that the molecular interactions that commits a cell to 
necroptosis through Rip1 kinase activity or to apoptosis through Caspase-8 activity lie 
downstream of receptor-ligand interactions, yet must take place before the preferential activation 
of either effector Caspases or Rip kinases. 
    The Bcl-2 family of proteins are key regulators of apoptosis, required for execution of 
through the intrinsic mitochondrial apoptotic pathway. Despite their central role in cell death 
signaling, the mechanistic link between the Bcl-2 family and necroptotic cell death has not been 
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described. The BH3-only family member Bid, acts as a sensor and amplifier of apoptotic 
signaling through death receptors, serving to activate mitochondrial outer membrane 
permeabilization (MOMP) and initiate intrinsic apoptosis following interaction with and 
cleavage by Caspase-8 (113, 114). Furthermore, Bid has been shown to play a cell death or a 
survival role depending on the context, suggesting the possibility that it can act as a brake on cell 
death (8, 9, 149, 558). Bid thus is situated at the nexus between apoptosis and necroptosis 
commitment, well positioned to serve as a mediator between these two pathways.   
Our previous studies (See Chapter II) with mice deficient for the upstream regulators of 
apoptosis activation (VavBaxBak DKO) as well as mice deficient for these proteins plus Bid 
(VavBaxBakBid TKO) suggests that loss of Bid in the setting of loss of apoptosis execution 
promotes increased necroptotic signaling. In this work we show that the Bcl-2 protein Bid, 
traditionally associated with apoptosis execution, plays a previously unrecognized regulatory 
role early in cellular commitment to necroptosis. We found that Bax/Bak deletion completely 
blocks apoptotic cell death upon treatment of hematopoietic progenitor cells with TNFα but this 
knockout is not sufficient to shift the balance toward necroptotic cell death. Further deletion of 
Bid, however, leads to robust activation of necroptosis. The presence of Bid correlates with Rip1 
degradation and apoptosis execution through a non-canonical role to modulate Caspase-8 
activity. This occurs through an IETD-inhibitable activity mediated by Caspase-8 in myeloid 
progenitor cells. We thus show that Bid, a Bcl-2 protein typically linked to MOMP and apoptosis 
plays a central role in apoptotic versus necroptotic cell death outcome by pushing the “brake” on 
necroptosis.  
 As necroptosis causes inflammation that alters hematopoietic differentiation, and stem 
cell function, and causes additional tissue damage that can drive bone marrow failure, 
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understanding the key signaling components that determine whether a cell will die by apoptosis 
or necroptosis provides a first step towards therapeutic intervention in diseases such as 
Myelodysplastic Syndrome (MDS), driven by dysregulated cell death.  
 
 
Results 
 
TKO myeloid progenitors die by necroptosis 
In our previous studies with mice deficient for Bax, Bak, and Bid we found that the 
myeloid progenitor populations were particularly affected as a result of unrestrained necrosis of 
the bone marrow. Our studies suggest that this population is particularly susceptible to TNFR 
signaling, and likely as a result undergoes increased necroptosis as a result. To interrogate cell 
death signaling in these hematopoietic progenitor cells, we generated Hox11 immortalized 
myeloid progenitor cells (MPCs), from the bone marrow of Bid +/+, Bid -/-, MxBaxBak DKO, 
and MxBaxBakBid TKO mice, as previously discussed (8). We then treated these MPCs with 
TNFα plus Actinomycin D (TNFα/ActD) to activate TNFR signaling and block survival 
signaling, and utilized Annexin V/ PI staining by flow cytometry to examine viability. As 
expected for Type II cells, Bid-/- and DKO cells exhibited less death in response to TNFα/ActD 
(133). Notably, DKO MPCs do not undergo necroptosis following TNFα/ActD, suggesting that 
inhibiting apoptosis is insufficient to elicit necroptotic cell death. TKO and Bid+/+ cells display 
similar death kinetics (Figure 3.1A, I), and Bid+/+ but not TKO MPCs displayed increased 
cleaved Caspase-3 (Figure 3.1A, II). Additionally, TKO MPCs that are positive for Annexin V 
following TNFα/ActD exhibit increased size (Figure 3.2A), consistent with necroptotic cell 
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death. TEM of MPCs treated with TNFα/ActD reveals predominantly apoptotic morphology in 
Bid+/+ cells, whereas TKO cells display overwhelmingly necroptotic cell morphology (Figure 
3.1B). Untreated MPCs show minimal cell death (Figure 3.2B). Our MPCs therefore behave in a 
manner consistent with death receptor signaling: Bid+/+ (wild type) MPCs undergo apoptosis in 
response to TNFα/ActD; removal of Bax and Bak prevents cell death; and removal of Bid in 
addition to Bax and Bak results in necroptotic cell death in response to TNFα/ActD, consistent 
with a role for Bid’s inhibition of necrosis. 
 
TKO MPCs display increased necroptotic signaling 
The above studies suggest that TKO bone marrow and MPCs do not die by apoptosis 
based on absence of activated Caspase-3. This instead suggests the possibility that TKO MPCs 
may die by necroptosis. To establish if TKO MPCs also display increased necroptosis signaling, 
we examined kinetics of Rip1 phosphorylation after LPS and TNFα stimulation. Phosphorylation 
of Rip1 has been shown to stabilize its association with a pro-necroptotic complex, and activate 
necroptotic kinase activity (24). TKO but not Bid+/+, Bid-/-, or DKO MPCs displayed 
constitutive and increased kinetics of Rip1 phosphorylation in response to LPS or TNFα, 
manifested by a phosphatase-sensitive shifted band (575) (Figure 3.1C and Figure 3.2C and D). 
Interestingly, Bid levels were inversely correlated with Rip1 phosphorylation: DKO MPCs have 
more Bid than Bid+/+ cells (Figure 3.2E), and no detectable phospho-Rip1. TKO MPCs (lacking 
Bid) display constitutive Rip1 phosphorylation. We further examined necroptotic execution by 
probing MLKL trimerization (203). TKO MPCs display increased MLKL trimerization with or 
without LPS stimulation, while Bid+/+ and DKO MPCs display minimal trimerization further 
supporting constitutive necroptosis signal execution in TKO MPCs (Figure 3.1D). These results 
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suggest that loss of Bid in addition to Bax and Bak is sufficient to stimulate necroptotic signal 
execution, consistent with release of a Bid-directed brake on necroptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 134 
 
 
Figure 3.1 MxBaxBakBid TKO myeloid progenitor cells (MPCs) die by necroptosis 
A) Examination of death in myeloid progenitor cells (MPCs). I) MPCs were treated with 
25ng/mL TNFα + 50ng/mL Actinomycin D. Viability was determined by Annexin V/ PI 
staining. II) MPCs treated with TNFα/ ActD were stained for cleaved Caspase-3 by intracellular 
flow. Experiment was performed three independent times. Data are represented as mean +/- 
SEM. Statistics indicate differences between Bid +/+ versus Bid -/-, DKO, and TKO. B) Bid +/+ 
and TKO MPCs treated with TNFα + Actinomycin D were examined by transmission electron 
microscopy (TEM). 50 cells with a nucleus were examined and characterized as being apoptotic, 
necrotic, or live. Arrows indicate apoptotic cells, and asterisks indicate necrotic cells. Scale bar 
indicates 2 microns. Graph with death quantification below. ***= P< 0.001 **=P< 0.01. C) 
MPCs were stimulated with 250 ng/mL LPS and status of Rip1 was examined. Experiment was 
performed four times. D) Examination of trimerization of MLKL in Bid +/+, DKO, and TKO 
MPCs following stimulation with LPS as in (C). Experiment was performed three times. 
Experiments in C) and D) were performed by Qiong Shi.  
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Figure 3.2 MxBaxBakBid TKO can also be stimulated by TNFα and increase in size 
following stimulation 
A) Examination of Size of Bid +/+, Bid -/-, DKO, and TKO myeloid progenitor cells (MPCs) in 
response to stimulation with TNFα + Actinomycin D by utilizing forward scatter measurements 
from flow cytometry. Experiment was performed three independent times. B) TEM of Bid +/+ 
and TKO MPCs without stimulation with quantification. 50 cells with a nucleus were scored as 
being live, apoptotic, or necroptotic. Scale bar indicates 2 microns. C) Examination of Rip1 
phosphorylation by immunoblot following stimulation of Bid +/+, Bid -/-, and TKO MPCs with 
TNFα. Experiment was performed two independent times. D) Examination of Rip1 state by 
immunoblot after phosphatase pre-treatment (CIAP) of lysates after trail stimulation. Experiment 
was performed two independent times. E) Bid expression in MPCs after stimulation with LPS. 
Experiment was performed two independent times. Experiments in C), D), and E) were 
performed by Qiong Shi.  
 
 136 
Bid inhibits association of Rip1 with Complex IIB 
Rip1 recruitment to a complex with FADD (Complex IIB), is associated with Rip1 kinase 
activity and this association is correlated with necroptosis execution (24). We next examined the 
effect of Bid on Rip1 recruitment to Complex IIB (FADD: Rip1: Caspase-8: cFlipL) through 
FADD immunoprecipitation (IP) following TNFα or LPS stimulus (24, 576, 577). IP for FADD 
following LPS or TNFα stimulation of TKO MPCs, revealed a marked increase in association of 
Rip1, cFlipL, and Caspase-8 with Complex IIB relative to Bid+/+ MPCs (Figure 3.3A, B, and C 
and Figure 3.4A, B, and C) suggesting increased necroptotic signaling in TKO MPCs. FADD IP 
of VavBaxBak DKO and VavBaxBakBid TKO MPC lysates yielded similar results (Figure 3.4D), 
establishing that the observed signaling is not a reflection of the Cre utilized to delete Bax. 
Retroviral reintroduction of Bid into MxTKO MPCs completely abrogated Rip1 presence in this 
complex (Figure 3.3D and Figure 3.4E), demonstrating that the association of Rip1 in Complex 
IIB was inhibited by Bid. 
 
Bid regulates Rip1 stability through modulation of Caspase-8 activity 
Our previous studies with MPCs reveal that the levels of Rip1 vary between genotypes 
(Figure 3.1C and 3.3D). In particular we note that Rip1 levels in DKO MPCs, which express 
increased levels of Bid (Figure 3.2D), are markedly decreased relative to TKO MPCs (Figure 
3.1C). Importantly, reintroduction of Bid into TKO MPCs by retroviral transduction results in 
decreased Rip1 levels (Figure 3.3D), demonstrating that the decreased Rip1 observed in DKO 
MPCs is due to the presence of Bid. 
 Rip1 can be ubiquitylated or cleaved by proteases such as Caspase-8 (97), and 
Cathepsins (578) to promote its degradation. Treatment with MG132 (proteosome inhibitor) or 
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Z-VAD-FMK (pan-caspase inhibitor) did not recover full length Rip1 in Bid+/+, DKO, or TKO 
MPCs (Figure 3.4F). Pretreatment with IETD (Caspase-8 inhibitor) following LPS stimulation 
completely recovered full length Rip1 in DKO MPCs and decreased truncated Rip1 in Bid+/+ 
and TKO MPCs, indicating that an IETD-inhibitable enzyme cleaves Rip1 (Figure 3.3F). Similar 
recovery of full-length levels of another Caspase-8 substrate, Cylindromatosis (CYLD), was also 
observed (Figure 3.4G). Additionally, Rip1 presence was recovered in Complex IIB in 
VavBaxBak DKO MPCs pretreated with IETD followed by FADD IP (Figure 3.4D).  
Furthermore, deletion of Caspase-8 using CRISPR/CAS9 with 2 independent gRNAs, results in 
an increase in Rip1 levels in Bid +/+ MPCs (Figure 3.3F) that is proportional to the degree of 
Caspase-8 knockdown achieved. While the above results are consistent with a role for Caspase-8 
in mediating Rip 1 levels, the inability to restore RIP1 levels with ZVAD is inconsistent with a 
singular role for Caspase-8 in modulating of Rip1 stability, suggesting another protease may be 
involved in this process. 
Another protease containing an IETD active site is Granzyme B. Our studies with a 
protein inhibitor of Granzyme B suggest that it may also play a role in the degradation of Rip1 
(Figure 3.3G). Permeabilization of MPCs with digitonin and addition of this protein to the 
culture medium, followed by treatment with LPS rescued full length levels of Rip1 in Bid +/+ 
MPCs. Presence of the Granzyme B inhibitor in MPCs was confirmed by immunofluorescence 
for chymotrypsin, the backbone of the inhibitor (Figure Previous studies suggest that Granzyme 
B may play a role in the restraint HSC function, as Granzyme B -/- HSPCs display increased 
competitive repopulating ability mediated through NF-κB signaling (579). However, whether 
Granzyme B exerts its HSPC effect through RIP1 kinase will require further investigation. 
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Bid forms an intermediate complex with Rip1, Caspase-8, and cFlipL 
 We next sought to understand where in the necroptotic pathway Bid functioned to toggle 
the switch between apoptosis and necroptosis. Because we saw dramatic changes in Rip1 in 
Complex IIB, we first examined this complex to determine if Bid could function within this 
complex to block Rip1’s association. However, upon multiple examinations of this complex, we 
were unable to detect the presence of Bid in this complex (Figure 3.4H). To probe Bid’s role in 
necroptosis directly, we next performed an IP for Bid with and without LPS stimulation. As 
shown in Figure 3.3I, we found an association of Bid with Rip1, Caspase-8, and c-FlipL with 
stimulation, suggesting the possibility that this complex could be involved in Rip1 degradation. 
Therefore, our work suggests that Bid plays a central role in PCD outcome through modulation 
of an IETD- inhibitable activity, and can serve as an alternate switch that determines whether a 
hematopoietic cell will execute apoptosis or necroptosis. However further study is needed to 
understand the interaction between these proteins and the activity of this complex.  
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Figure 3.3 Bid inhibits association of Rip1 with Complex IIB through modulation of 
Caspase-8 activity towards Rip1 in MxBaxBakBid MPCs 
A) Immunoprecipitation (IP) for FADD following stimulation with 250 ng/mL LPS for 10 
minutes, and immunoblotted for Rip1 and FADD. *Indicates light chain IgG. Experiment was 
performed four independent times. B) IP for FADD as in (A) with MPCs stimulated with 
10ng/mL TNFα for 10 minutes. Experiment was performed three independent times. C) Repeat 
of IP for FADD as in (A) with MPCs stimulated with 250ng/mL LPS to examine the status of 
Caspase-8 and CFlipL. Experiment was performed two independent times. D) IP for FADD as in 
(A) with TKO MPCs that had Bid reintroduced. Experiment was performed two independent 
times. All samples were stimulated with LPS as in (A). *Indicates light chain IgG. E) 
Examination of Rip1 in Bid+/+, DKO, and TKO MPCs by immunoblot following stimulation 
with LPS (as in A) and pre-treatment with an IETD inhibitor to Caspase-8 (20μM). Experiment 
was performed three independent times. F) Examination of Rip1 levels by immunoblot after 
deletion of Caspase-8 utilizing the Crispr-Cas9 system in Bid +/+ cells. Experiment was 
performed two independent times. G) Examination of Rip1 following addition of Granzyme B to 
Bid +/+ MPCs. Experiment was performed two independent times. H) Immunofluorescence for 
chymotrypsin (the backbone of the Granzyme B inhibitor) to examine the presence of the 
Granzyme B inhibitor in MPCs. I) IP for Bid following LPS stimulation and immunoblot for 
Caspase-8, Rip1, and cFlipL. MPCs were untreated or stimulated with 250ng/mL LPS. * 
indicates IgG. Experiment was performed three independent times. Experiments in A-I 
performed by Qiong Shi.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 141 
 
 
 142 
Figure 3.4 Bid inhibits association of Rip1 with Complex IIB in VavBaxBakBid MPCs 
B) Input from IP for FADD before and after LPS (250ng/mL) stimulation in Bid +/+, Bid -/-, 
DKO, and TKO MPCs. WB for FADD demonstrates equal loading. Experiment was performed 
four independent times. C) Input from IP of FADD from MPCs stimulated with 10ng/mL TNFα 
immunoblot for Actin demonstrates equal loading. *denotes IgG. Experiment was performed 
three independent times. D) IP of FADD from MPCs developed from VavBaxBakBid TKO mice 
with and without Caspase-8 inhibitor (IETD, 20M). MPCs were pre-treated with IETD and/or 
stimulated with LPS (250 ng/mL). *denotes IgG. Experiment was performed two independent 
times. E) Examination of Bid expression by immunoblot in MPCs after retroviral reintroduction 
of Bid into TKO MPCs and LPS stimulation to demonstrate Bid overexpression after retroviral 
reintroduction. Experiment was performed two independent times. F) Effect of MG132 
(proteosome inhibitor) and Z-Vad-FMK (Pan-caspase inhibitor) on Rip1 levels; MPCs were 
stimulated with LPS and/ or pre-treated with MG132 or Z-Vad-FMK and Rip1 was examined by 
immunoblot. Experiment was performed three independent times. G) Effect of IETD on CYLD; 
MPCs were pre-treated with IETD (20M) and/or stimulated with LPS (250ng/mL) and CYLD 
was examined by immunoblot. Experiment was performed two independent times. (H) 
Immunoblot for Bid following IP for FADD in Bid +/+, Bid -/-, DKO, and TKO MPCs 
demonstrating Bid is not found in Complex II. * Indicates IgG. Experiment was performed 
twice, independently. Experiments in A-H were performed by Qiong Shi.  
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Discussion 
 
A key unknown in the field of cell death is understanding what determines an outcome of 
apoptotic versus necroptotic death. The Rip kinases are important in the activation of 
necroptosis, whereas the Caspases are important in the activation of apoptosis. Additionally, 
multiple lines of evidence demonstrate that both Rip1 and Caspase-8 are important factors in 
upstream signaling pathways. Our studies in the context of hematopoiesis indicate that Rip1 and 
Caspase-8, in the presence or absence of Bid in the context of Bax/Bak deletion, determines the 
downstream cell death outcome. This occurs through the formation of a complex with Rip1, 
Caspase-8, cFlipL, and Bid that likely promotes the degradation of Rip1. In the absence of Bax, 
Bak, and Bid Rip1 levels are increased, and necroptosis is enhanced. Our data demonstrates that, 
in addition to blocking apoptosis, necroptosis in hematopoiesis must be activated by releasing the 
constraint imposed by Bid on Caspase-8-mediated Rip1 degradation.  
Consistent with previous studies, we show that cells in which both Bax and Bak are 
deleted are resistant to apoptotic stimuli, and also do not die by necroptosis. This indicates that it 
not sufficient to block apoptosis to promote necroptosis. We find that Rip1 levels in BaxBak 
DKO MPCs (which also have increased Bid levels) are markedly diminished, due to Caspase-8 
activity. Rip1 levels are completely restored upon additional loss of Bid, demonstrating that in 
this setting, Bid functions to modulate Rip1 levels through Caspase-8 (Figure 3.3E). 
Collaboration with a mathematical modeling group, suggests that this occurs through the 
modification of Bid. Leveraging cell lines from our mouse models that are tuned to undergo 
apoptosis or necroptosis, we demonstrate that in addition to activating apoptosis, Bid restrains 
necroptosis through a Bid:Caspase-8 axis, that cleaves and inactivates Rip1.  
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CHAPTER IV 
 
 
ROLE OF BID IN INTESTINAL HOMEOSTASIS AND INFLAMMATION 
 
 
Introduction 
 
Multicellular organisms remove damaged or superfluous cells through a highly regulated 
cellular process known as programmed cell death. There are two main forms of programmed cell 
death, apoptosis and necroptosis. Apoptosis, a highly regulated process, was for many years 
purported to be the only type of programmed cell death. Conversely, programmed necrosis 
(necroptosis), previously thought to be an unregulated death pathway, was recently found to be 
highly regulated. Necroptosis results in swelling of the cell and organelles, and is mediated by 
RIP kinases. While most of the activators and transducers of apoptosis have been identified, the 
necroptotic pathway is not well understood, but genetic evidence implicates upstream apoptotic 
proteins in necroptosis inhibition.  
In the setting of intestinal homeostasis and disease, programmed cell death balances with 
proliferation to maintain the integrity of the intestinal barrier and to limit inflammation (580). 
This process is intricately controlled, with deviations leading to pathologies such as malignancy 
or inflammatory bowel diseases (IBDs) (581). While apoptosis is a normal feature of cells within 
the crypt and anoikis of cells at the tips of villi, too much apoptotic death is detrimental and has 
been implicated in inflammation and pathology of IBDs (582–584). Similarly, necroptosis 
recently was implicated in maintaining intestinal homeostasis through inhibition of programmed 
cell death. Intestinal epithelial cell-specific deletion of Caspase-8 and FADD promotes increased 
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inflammation and necrosis of the intestinal epithelium in mice (585, 586). Additionally, necrosis 
is also implicated in the pathogenesis of IBDs, as it was reported in Crohn’s Disease with 
necrotic cells being visualized in portions of involved and uninvolved tissue (587, 588). The 
increase in death in this setting is likely mediated through increased inflammatory signaling, as 
increases in inflammatory cytokines, including TNFα, is a common finding in patients with IBD 
(393). These findings demonstrate the importance of programmed cell death in the intestine. 
The BCL-2 family has been demonstrated to regulate apoptotic cell death with the 
capability to promote or inhibit apoptosis execution. We recently identified a role for the BH3-
only member Bid in the inhibition of programmed necrosis in hematopoiesis (Chapters II and 
III). Because programmed cell death is also an important factor in maintaining intestinal 
epithelial homeostasis, and is likely a factor in the IBD pathological state, we wanted to 
understand what role Bid might also play in programmed cell death in the intestine independent 
of its apoptotic function.  
To interrogate this role for Bid, we generated a mouse model with a triple knockout 
(TKO) of the apoptotic proteins Bax, Bak, and Bid. In knocking out all three proteins we 
removed not only Bid, but also the apoptotic branch of Bid’s function (Bax and Bak). To 
compare and contrast the impact of loss of apoptosis (MxBaxBak DKO mice) versus increased 
necrosis (MxBaxBakBid TKO mice) in intestinal epithelial injury, we subjected our mice to DSS 
colonic injury model for 6 days. We hypothesized that mice with unrestrained necrosis 
(BaxBakBid TKO) would have increased epithelial injury as compared to Bid +/+ (wild type). 
We saw differences between Bid +/+ and Bid -/- versus DKO and TKO colons, suggesting 
increased inflammation in DKO and TKO colons. Further study is needed to understand the role 
of inflammatory signaling in settings of lack of apoptosis and increased necroptosis.  
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Results 
 
MxBaxBakBid TKO mice display fulminant liver necrosis  
 We began our studies with the development of MxBaxBakBid TKO mice to understand 
what function Bid might play intestinal homeostasis. We utilized Mx1Cre to induce the deletion 
of Bax in the setting of a Bid and Bak germline deletion. Mx1Cre is induced through injection 
with Poly Inosinic: Cytidylic (Poly (I;C), a dsRNA mimic that promotes a type I interferon 
response inducing Cre expression (589). Mice were given three doses every other day to induce 
Cre recombination. Following induction with Poly I;C a small percentage of TKO mice became 
moribund after a single injection. Upon necropsy we noted that these mice seemed to have livers 
and kidneys devoid of blood, as well as hemolysis of the peripheral blood. This effect did not 
occur in MxBaxBak DKO, Bid +/+, or Bid -/- mice when injected with Poly (I;C). We examined 
paraffin-embedded sections of liver, and found that the hepatocytes from TKO mice were 
increased in size, with some having a swollen appearance, along with increased size of the nuclei 
(Figure 4.1A). The morphology and size of hepatocytes of Bid +/+, or Bid -/-, and MxBaxBak 
DKO were normal, even with (Poly I;C) injection, suggesting that this effect was not due solely 
to the induction of an interferon response. Next, we wanted to examine the type of death 
occurring in the liver of TKO mice. Utilizing fluorescent immunohistochemistry, we examined 
the status of cleaved Caspase-3 in paraffin-embedded liver sections from our mice. We observed 
no significant staining for cleaved Caspase-3 in liver sections from Bid +/+, or Bid -/-, DKO, or 
TKO mice as compared to a positive control for cleaved Caspase-3, a Bid +/+ mouse tail-vein 
injected with Fas ligand, which stimulates liver apoptosis (Figure 4.1B). From this finding and 
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previous studies, we hypothesized that Bid was functioning to inhibit necrotic death, a process 
that often leads to increased inflammatory signaling. We next wanted to understand what role 
Bid might play in inflammatory diseases/ conditions in which necrosis and inflammation cause 
pathology. As discussed previously, necrosis and inflammation are both involved in the 
pathology of IBDs, and as such we subjected our mice to a model of colitis to understand what 
role Bid might play in this setting.  
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Figure 4.1 MxBaxBakBid TKO mice display fulminant liver necrosis 
A) We utilized Mx1Cre to promote the deletion of Bax in the setting of a Bid and Bak germline 
deletion to generate TKO mice (or Bak deletion for MxBaxBak mice). Liver sections from TKO 
mice demonstrate the classic feature of necrosis including loss of cell membrane integrity and 
swelling of nuclei. B) Fluorescent immunohistochemistry on sections of liver for Cleaved 
Caspase-3 to examine if dying cells in the TKO liver were undergoing apoptosis. Animals tail-
vein injected with Fas ligand as a positive control.  
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TKO mice have increased inflammation and damage in response to DSS model of colonic injury  
 To examine the role of programmed cell death in the setting of inhibited apoptosis and 
uninhibited necrosis on inflammatory signaling in the intestine, we subjected our Bid +/+, Bid -/-
, DKO, and TKO mice to the acute Dextran Sodium Sulfate (DSS) colitis model (590). 
Treatment with DSS is toxic to intestinal epithelial cells and disrupts the intestinal epithelial 
barrier in the colon promoting inflammation through innate immune signaling. Mice were treated 
with H2O or 4% DSS for 6 days and weighed each day. On day 6, mice were sacrificed, and 
tissues prepared for histologic analysis. Hematoxylin and Eosin stained sections of colon were 
scored for pathologic criteria including inflammation, percent involvement of inflammation, 
distortion of intestinal epithelium, crypt damage, and percent involvement of crypt damage. Each 
of these criteria may be scored from 0 to 4, and the total from all criteria is added together as a 
pathological score. While TKO mice treated with DSS have a pathological score that trends 
higher than Bid +/+, or Bid -/-, and DKO mice treated with DSS, this finding was not 
statistically different from the other genotypes (Figure 4.2A). Surprisingly, examination of 
weight loss in mice treated with DSS revealed less weight loss in TKO mice which was 
significantly different from Bid -/- and DKO mice (Figure 4.2B). The colons were further 
examined on Day 5 of the DSS treatment by endoscopy. Interestingly, upon examination of 
colons by endoscopy, both DKO and TKO mice appeared to have the greatest pathology with 
increased inflammation and an ulceration in the colon of the TKO (Figure 4.2C). These findings 
suggest that loss of Bid and its apoptotic arm of function may potentiate inflammation in the 
acute DSS model.  
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Figure 4.2 MxBaxBakBid TKO mice demonstrate increased inflammation and damage in 
the colon in response to intestinal injury 
A. Pathological scoring evaluating the degree of inflammation, distortion of the intestinal 
epithelium, crypt damage, and percent involvement of damage and inflammation in Bid +/+, Bid 
-/-, DKO, and TKO mice treated with H2O or DSS. B) Normalized weights of mice each day 
during H2O or DSS treatment in each genotype. C) Endoscopy images from mice treated with 
H2O and DSS on day 5 of DSS treatment. Pathological scoring in (A) completed by Mary Kay 
Washington. Endoscopy in (C) performed by Amber Bradley.  
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TKO mice treated with DSS have increased Rip1 expression in the colon following DSS 
 The toxicity of DSS to the intestinal epithelial cells promotes disruption of the intestinal 
epithelium, likely through programmed cell death. As discussed previously, there is a delicate 
balance between cell production and death in the intestine, and pathologies arise in settings in 
which this balance is perturbed. Additionally, previous studies implicate increased apoptosis and 
necroptosis in intestinal pathologies such as IBDs. We next wanted to explore if cell death was 
occurring in the intestine of Bid +/+, or Bid -/-, DKO and TKO mice, and to determine if this 
death was occurring through apoptosis or necroptosis. To explore this, we first examined whole 
cell lysate from colons of Bid +/+, or Bid -/-, DKO and TKO mice treated with H2O or DSS. We 
examined the status of Rip1 to determine levels of expression, as well as differences in mobility 
which would be indicative of phosphorylation, demonstrating activation of Rip1. Examination of 
Rip1 revealed increased expression and some lower mobility species in Bid+/+, Bid -/-, and 
TKO colons with H2O and/or DSS treatment. This finding correlates with the previous 
observation of an inverse relationship between Bid and Rip1 expression, as previously seen in 
MPCs (Figure 3.3C). While the Bid +/+ colon demonstrates about half the level of Rip1 
expression with H2O treatment, it interestingly is diminished and is of a lower mobility with DSS 
treatment. Interestingly, there is also dramatic loss of full length Rip1 in DKO colons treated 
with DSS, similar to the trend we note in our DKO MPCs following stimulation with LPS or 
TNFα. This finding suggests that any death occurring in DKO is likely not occurring through 
necroptosis (Figure 4.3A). While there are differences in Rip1 expression between our different 
genotypes of mice and with DSS treatment, further study is needed to interpret these differences. 
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Our western blot only contains lysate from a single mouse, however variability between mice, as 
well as random sampling of colons taken from mice at sacrifice could cause sampling error.  
 We additionally examined the status of cleaved Caspase-8, a marker of apoptosis activation. 
While there is only a modest activation in Bid +/+ colon, Bid -/- colon demonstrates robust 
cleaved Caspase-8 expression that decreases with DSS treatment, suggesting apoptotic signaling 
occurs in homeostatic conditions (H2O), but that with DSS treatment any death within the colon 
does not occur through apoptosis. While examination of Rip1 and Caspase-8 by Western blot 
was informative regarding levels of expression of these proteins, further study is needed to 
understand the effect of DSS on the mobility/modifications within the colon.  
While examination of whole cell lysate provided some understanding of the overall status 
of cell death in our different genotypes of mice, it did not provide information regarding where 
within the colon this expression was occurring. Inflammation from DSS treatment primarily 
affects the intestinal epithelium, however examination of lysate from the whole colon includes 
this layer as well as the underlying submucosa, muscle layer, and serosa. To understand what 
type of programmed cell death was occurring specifically within certain portions of the colon we 
examined paraffin-embedded sections of colon for Rip1 and cleaved Caspase-3, a more 
definitive marker of apoptosis. Examination of Rip1 in colons treated with H2O or DSS revealed 
a strong increase in Rip1 expression in the colon of TKO mice following DSS suggesting death 
of the epithelium by necroptosis. TKO mice also demonstrate increased Rip1 on the tips of the 
villi as compared to Bid +/+, Bid -/-, and DKO mice with H2O treatment, suggesting increased 
necrotic signaling in the TKO colon even without stimulation. While the Bid +/+ colon has 
increased Rip1 expression as well with DSS, the extent of this increase is not quite to the level 
seen in TKO. Interestingly, Bid -/-  had only modest increases in Rip1 expression with DSS 
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within the villi, while the DKO colon demonstrates minimal staining in the villi (Figure 4.3B). 
Next we examined apoptosis signaling through cleaved Caspase-3 staining. The positivity for 
cleaved Caspase-3 was modest and uniform between genotypes with both H2O and DSS 
treatment, at the tips of the villi within the colon, suggesting death by anoikis. The minimal 
positivity also suggests that minimal apoptotic death is occurring within the intestinal epithelium 
(Figure 4.3C). Increased Rip1 expression in TKO but not DKO colons with a corresponding lack 
in increase of cleaved Caspase-3 suggests that death in the TKO but not DKO colons is mediated 
by programmed necrotic death. 
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Figure 4.3 MxBaxBakBid TKO mice have increased Rip1 expression in the colon following 
DSS treatment 
A) Western blot examining expression of Rip1 as a marker of programmed necrosis and cleaved 
Caspase-8 as a marker of apoptosis activation. B) Examination of Rip1 expression in mice 
treated with H2O and DSS by fluorescent immunohistochemistry. C) Examination of cleaved 
Caspase-3 as a marker of apoptosis activation in mice treated with H2O and DSS by fluorescent 
immunohistochemistry. Experiments in A-C were performed by Qiong Shi.  
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Cytokine signaling following DSS stimulation is similar between DKO and TKO mice  
 The differences between Rip1 staining between DK0 and TKO colons after DSS, despite 
the presence of inflammation in both suggested that inflammatory and innate immune signaling 
pathways could differ between these two genotypes. These pathways are mediated by the release 
of cytokines which promote responses from epithelial and hematopoietic cells to attract immune 
cells, promote proliferation, differentiation, and programmed cell death. We examined the status 
of cytokine signaling within the colons of to Bid +/+, Bid -/-, DKO, and TKO mice following 
H2O and DSS through examination of lysate from these tissues. Utilizing a Luminex multiplex 
ELISA assay, the expression of several cytokines was examined. Comparison between genotypes 
and treatments reveals a similar pattern of cytokine expression between Bid +/+ and Bid -/- 
colon, as well as similarities in DKO and TKO colons (Figure 4.4A). Interestingly, while DKO 
and TKO colons have increases in similar cytokines, the TKO colons demonstrate slightly 
increased expression as compared to DKO colons (more intense red), suggesting loss of Bid on 
top of Bax and Bak further potentiates cytokine signaling. Examination of graphs of cytokines 
with substantial increases following DSS treatment reveals significant increases in TNFα and G-
CSF in TKO colons treated with DSS, suggesting increased inflammatory and innate immune 
signaling occurs in TKO colons following acute DSS injury (Figure 4.4B). 
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Figure 4.4 MxBaxBakBid TKO colons treated with DSS have increased inflammatory 
cytokine expression 
Examination of protein from colons of mice treated with H2O and DSS for expression of 
inflammatory and innate immune signaling cytokines. A) Heatmap of cytokine expression for 
inflammatory and innate immunity signaling cytokines. B) Graphs of cytokines with greatest 
change in expression in colons of mice treated with H2O and DSS. Experiments in (A) and (B) 
were performed in collaboration with the lab of Keith Wilson and with the help of Qiong Shi.  
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Rip1 expression is decreased in transformed samples of IBD 
 As discussed previously, programmed cell death has been implicated in the pathology of 
IBDs. While the role of increased apoptosis is established in this process, the studies on the role 
of necroptosis are preliminary, with few studies investigating the role of necroptosis in this 
disease and more recent studies completed in mice (583, 585, 586). As such, we wanted to 
understand if necroptotic signaling might be increased in samples of involved tissue from 
Crohn’s Disease (CD) and Ulcerative Colitis (UC). To do this, we acquired two tissue 
microarrays (TMAs) with samples of Control intestine, CD involved and uninvolved tissue, CD 
tumor, UC involved and uninvolved tissue, and UC tumor. We stained these microarrays for 
Rip1 and quantified expression through scoring for positivity. Representative images 
demonstrate increases in Rip1 staining in both Control and involved samples of CD and UC, but 
a striking lack of positivity in tumor samples (Figure 4.5A). Scoring of UC samples revealed 
significantly decreased Rip1 levels in uninvolved and tumor samples as compared to involved 
samples. Interestingly, in Crohn’s Disease, both the involved and uninvolved samples had 
increased Rip1 levels as compared to tumor samples. These data suggest that the transformation 
of IBDs to a malignant state decreased Rip1-mediated necrotic signaling. Further study to 
understand the activation of necroptotic signaling is needed to better understand the role of Rip1- 
necroptotic signaling in IBDs. 
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Figure 4.5 Rip1 levels are decreased in tumor samples of IBDs 
A) Representative samples of tissue from a tissue microarray (TMA) of IBD samples. B) Rip1 
score of UC samples of from two TMA arrays. C) Rip1 score of Crohn’s Disease samples from 
two microarrays. Experiments in A-C were performed in collaboration with the laboratory of 
Chris Williams. Staining in (A) was performed by Qiong Shi.  
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Discussion 
Through my studies with mice utilizing the acute DSS injury model I sought to 
understand if Bid-mediated programmed necroptotic death might play a role in inflammatory 
processes within the intestine. These studies suggest that inhibition of apoptosis (MxBaxBak) and 
loss of three proapoptotic proteins (MxBaxBakBid) within the colon causes increased pathology 
within the colon. My studies suggest this is mediated by increased inflammation through 
increased cytokine expression, but may be due to other factors such as programmed cell death. 
Increases in Rip1 expression in the colons of TKO mice as compared to DKO suggests that 
necroptotic death may be a factor in this process. Both necroptotic and increased apoptotic death 
can promote increased inflammation in the intestine (583, 588). Activation of similar cytokines 
to varying extents in DKO and TKO colons suggest that inflammatory signaling could be the 
result of activation of different upstream pathways. While our studies do not definitively 
delineate a role for Bid-mediated programmed cell death in intestinal inflammation, they do 
suggest that modulation of programmed cell death affects intestinal inflammation. Further study 
is needed to clarify what role Bid might play in this process. 
 Inflammatory bowel diseases are mediated by increased inflammatory signaling within 
the intestine. Several studies implicate increased cytokine signaling in patients with IBDs 
including through increased expression of TNFα, IL-6, and IL-1β. Signaling through TNFα can 
promote both an apoptotic and necroptotic death. Additionally, both apoptotic and necroptotic 
death is implicated in the pathology of IBDs suggesting that understanding how programmed cell 
death functions in IBD pathology may be a plausible target in treatment of this disease. Our 
studies with IBD samples suggest that necroptotic signaling may play a role in involved tissues 
in Crohn’s Disease and Ulcerative Colitis that is lost with transformation to malignant state. 
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However, further study to understand if this is an activation of Rip1 and if necroptotic signaling 
is occurring is needed to understand that status of necrotic signaling in these samples.  
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary of findings 
 
Loss of Bid removes restraint of programmed necrosis perturbing hematopoietic homeostasis 
 The canonical role of Bid as a potent activator of apoptosis is well-established in the field 
of apoptosis, however my studies suggest that Bid also functions to inhibit the activation of 
necroptosis. This finding of an alternative role for Bid is not unprecedented, as previous studies 
from our lab and others suggest alternative functions for Bid in the DNA damage response and in 
innate immune signaling (7, 9, 10, 150, 173). Through investigation of VavBaxBakBid mice, 
which removed Bid as well as its apoptotic arm of function, I found that Bid restrains necroptosis 
in hematopoiesis leading to a bone marrow failure phenotype and decreased survival in mice. 
This phenotype is distinct from VavBaxBak mice, which have hematopoietic cells that lack the 
ability to undergo apoptosis and as a result develop lymphoid leukemia and lymphoproliferative 
disease. This previously unknown function implicates a novel role for Bid in determining the cell 
death fate following stimulation of death and Toll-like receptors.  
 Characterization of Vav TKO mice through complete blood counts, pathological 
characterization, immunophenotyping, and competitive bone marrow transplantation revealed 
their phenotype was very similar to the human disease myelodysplastic syndrome (MDS). 
Complete blood counts revealed decreases in red blood cell/ hemoglobin and platelet counts 
suggesting deficiencies in hematopoiesis. Additionally, examination of the bone marrow 
revealed increased necrosis in the bone marrow of TKO mice through examination of Rip1 
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expression and morphological characteristics through transmission election microscopy. This 
creates a hostile environment with the release of DAMPs and inflammatory cytokines within the 
bone marrow milieu. TKO mice additionally demonstrate dysplasia within several myeloid cell 
types similar to those seen in MDS, which include hypersegmentation of neutrophils, and 
hypolobulation of megakaryocytes suggesting this environment additionally perturbs 
differentiation.  I further examined the hematopoietic system through characterization of 
hematopoiesis by immunophenotyping by flow cytometry. Examination of terminally 
differentiated cell types revealed minimal perturbation, as only T cell populations were 
significantly increased in DKO and TKO mice, whereas B cell, monocyte, and erythroid 
populations were not significantly different. However, examination of less mature populations 
revealed stark differences between TKO mice and Bid +/+, Bid -/-, and DKO mice. The 
hematopoietic system is highly responsive to insults, and as a result the HSC and progenitor 
populations are perturbed in TKO mice. The hematopoietic stem cell (HSC) populations were 
significantly increased in TKO mice as a result of compensatory proliferation as expected due to 
increased necrosis of the bone marrow. Surprisingly, the myeloid progenitor populations were 
significantly decreased in both DKO and TKO populations, however lack of a corresponding 
increase in the HSC population in DKO mice suggests a different hematopoietic defect. The 
decrease in TKO myeloid progenitor populations suggests that this population is particularly 
susceptible to the hostile environment created by the increased necrosis of the bone marrow.  
Reconstitution assays revealed that the presence of TKO cells in a Bid +/+ mouse promotes 
increased inflammation particularly in the lungs mediated by TNFα. My studies further revealed 
that TKO cells produced increased TNFα following necrotic stimulation, suggesting TKO cells 
have increased signaling through this pathway.  
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 I utilized competitive transplant assays to examine the ability of TKO cells to function 
and reconstitute the hematopoietic system in competition with Bid +/+ cells. Because TKO mice 
die of bone marrow failure without any stimulation, I hypothesized that TKO cells would fail to 
compete against Bid +/+ cells within a Bid +/+ mouse. Surprisingly, TKO cells outcompeted 
these cells and continued to do so throughout the course of the experiment for 5 months. 
Immediately after this time period, these mice began to die of bone marrow failure phenotype 
which also demonstrated increased inflammation. This result was surprising at the time, but was 
consistent with the original TKO phenotype which promotes increased TNFα signaling. 
Immunophenotyping of transplanted mice revealed similar perturbations seen in the bone 
marrow of TKO mice. HSC populations were increased within the transplanted TKO population, 
and progenitor populations were decreased as compared to Bid +/+ derived populations.  
Additionally, a secondary transplantation reveals that TKO HSCs have decreased function, as 
TKO bone marrow fails to outcompete Bid +/+ cells a second time, while DKO bone marrow 
continues to outcompete Bid +/+ bone marrow. From these findings we hypothesized that 1) 
myeloid progenitors are susceptible to increased TNFα signaling in the bone marrow, 2) that 
increased necrosis in the bone marrow propagates a feed-forward TNFα signaling increase, as a 
result of increased TNFα production by TKO cells, and 3) TKO mice likely die of bone marrow 
failure resulting from stem cell exhaustion due to increased cycling in order to replace cells lost 
by necrosis, and that this is distinct from the defect in hematopoiesis in DKO mice. 
 The phenotype of TKO mice was very similar to the human disease MDS, in particular 
the refractory cytopenias with multilineage dysplasia (RCMD) subtype. MDS is characterized by 
unrestrained programmed cell death in the bone marrow leading ineffective hematopoiesis and 
potential transformation to acute myeloid leukemia. For more than two decades, the death in 
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MDS has been implicated as an apoptotic death. However, my studies very clearly implicate 
necrotic death in the bone marrow failure phenotype of TKO mice. In examination of the type of 
cell death occurring in MDS patient samples, I found significant expression of Rip1 and 
phospho-MLKL in several subtypes of MDS samples, particularly the RCMD subtype. Every 
sample of RCMD within our cohort stained positively for both Rip1 and phospho-MLKL, 
suggesting that these proteins could serve as markers for these subtypes in diagnosis. 
Conversely, staining for cleaved Caspase-3 was minimal, with one to two positive cells in few 
samples. These findings suggest that there is increased necroptotic signaling in MDS samples, as 
opposed to apoptotic signaling. One limitation of this finding is that I have only examined 
expression of Rip1 instead of phospho-Rip1, the activated form. While the degree of Rip1 
staining suggests that necroptotic death is occurring, this staining must be repeated with a 
phospho-Rip1 antibody to definitively show this.  
 In summary, my studies demonstrate the effect of unrestrained necrosis on hematopoietic 
homeostasis, a context previously uncharacterized within the literature. I show that loss of Bid in 
addition to Bax and Bak (TKO mice), but not Bax and Bak alone (DKO mice), promotes 
unrestrained necrosis of the bone marrow in mice. My studies implicate a role for Bid 
independent of Bax and Bak in the restraint of programmed necrosis. This finding places Bid at 
the crossroads of apoptosis and necroptosis execution, much like other apoptotic proteins such as 
Caspase-8 demonstrated to play a role in necroptosis inhibition (78). It additionally is the first 
implication of a member of the BCL-2 family in the regulation of necroptotic death, a novel 
noncanonical function distinct from their canonical role in apoptotic death. My studies also 
implicate necroptotic death in the pathology of MDS, which has not previously been explored in 
this disease. These studies provide the foundation for the use of TKO mice as a mouse model of 
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MDS to better understand it’s pathology, potentially identify novel markers of certain MDS 
subtypes, and also new potential therapeutic targets of MDS in the targeting of necroptotic death.  
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Figure 5.1 Loss of Bax, Bak, and Bid promotes bone marrow failure in mice as a result of 
increased TNFα expression that promotes necrosis of the bone marrow 
Studies of VavBaxBakBid TKO mice reveal bone marrow failure as result of increased necrosis 
of the bone marrow. Increased TNFα expression perturbs normal hematopoiesis causing necrotic 
death of myeloid progenitor populations and dysplasia, leading to low peripheral counts. 
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Bid modulates Caspase-8 activity towards Rip1 
 In finding a role for Bid at the physiological level in restraint of necrosis my next set of 
studies sought to understand the role of Bid in necroptosis at the molecular level. To understand 
this, I developed myeloid progenitor cell lines from the bone marrow of our mice. These myeloid 
progenitor cells (MPCs) served as a medium to understand necroptotic signaling following death 
receptor and Toll-like receptor signaling. From these studies, we find a role for Bid in the 
restraint of necroptotic signaling through modulation of an IETD-inhibitable activity towards 
Rip1. While we favor this activity to be mediated by Caspase-8, we also have data to suggest that 
Granzyme B is involved in this process. Our mechanistic studies, informed by mathematical 
modeling studies (data not shown) suggests that Bid performs this function in an intermediate 
complex between complex I and II. Our studies shed light on where in the necroptotic pathway 
Bid functions, however, more questions remain, including which proteins Bid directly interacts 
with? How does Bid’s presence modulate Caspase-8 and/or Granzyme B activity? Is there a 
modification of Bid (e.g. phosphorylation) that inhibits its cleavage by Caspase-8 to inhibit 
apoptosis? 
 Critical to the completion of these studies, I generated MxBaxBak DKO and 
MxBaxBakBid TKO MPCs from DKO and TKO bone marrow. Along with Bid +/+, Bid-/- 
MPCs, I demonstrated that deficiency for proapoptotic proteins in these Type II cells yields in 
the expected pattern of death through examination of their ability to die in response to TNFα to 
stimulate the TNFR plus Actinomycin D to block survival signaling (TNF/ActD). (Loss of Bid 
or Bax and Bak yields protection from death, whereas cells wildtype for Bid or deficient for Bax, 
Bak, and Bid have increased death) These studies solidified that these cells could serve as a tool 
to understand primarily apoptotic (Bid +/+), inhibition of apoptotic (DKO), and necroptotic 
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(TKO) signaling. We next evaluated necroptotic signaling in each of these cells lines, and found 
that signaling through the necroptotic pathway was increased with or without stimulation, 
suggesting loss of Bid and its apoptotic arm of function removes restraint on necroptotic 
signaling. Throughout these studies, we noticed that the levels of Rip1 varied dramatically 
between genotypes, with DKO MPCs having significantly less full length Rip1 as compared to 
TKO MPCs, which had more than Bid +/+ MPCs. We hypothesized that this might be due to 
degradation of Rip1 mediated by Caspases (or other proteases such as Granzyme B or 
Cathepsins) and/or the ubiquitin/proteasome system. We ruled out the role of Cathepsins, the 
ubiquitin/proteasome pathway, and other Caspases (through treatment with a pan Caspase 
inhibitor) in the degradation of Rip1. Our studies instead revealed a role for Caspase-8 and/ or 
Granzyme B in this process, suggesting that the presence or absence of Bid potentiates the 
degradation of Rip1.  
 These studies were followed up with investigation into the location of Bid’s function 
within the necroptotic pathway. To examine this, we performed an immunoprecipitation (IP) for 
FADD, as this is demonstrated to allow for exclusive examination of Complex II downstream of 
death receptor/TLR signaling. Our studies revealed that in the absence of Bid and its apoptotic 
arm of function, Rip1 presence was increased within Complex II, suggesting increased necrotic 
signaling was occurring. This was strikingly different from the result in DKO MPCs, which 
demonstrated little to no presence of Rip1 in this complex. While other expected members were 
also present within this complex, including Caspase-8 and c-Flip, Bid was not. This suggested 
that Bid may instead function more upstream in the necroptotic pathway before Complex II, as 
Rip1 levels were greatly increased within Complex II in TKO MPCs. We next performed an IP 
for Bid, and found that Bid formed a complex containing Bid, Caspase-8, c-FlipL, and Rip1. 
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Collaboration with the Dr. Carlos Lopez (VUMC) aided in modeling this process, and suggested 
that this complex was intermediate between Complex I and Complex II.  
 My studies provide a solid foundation for Bid’s function in the necroptotic arm of 
signaling downstream of death and TLR receptors, however several questions remain. For 
instance, how is it that Bid modulates the activity of Caspase-8 such that it is more specific 
toward Rip1? Previous studies from the lab of Guy Salvesen suggest that Caspase-8 can form 
homodimers with itself or heterodimers with cFlipL. Additionally, these studies suggest that the 
substrate specificity differs between homodimers and heterodimers, with heterodimers having 
decreased specificity toward the canonical apoptotic substrate Bid (80). Further understanding of 
the interaction between these proteins, in particular between Bid, Rip1, and Caspase-8 will likely 
provide some insight into how Caspase-8’s substrate specificity is affected within a heterodimer 
with cFlipL. Another question of interest is if there is a post-translational modification of Bid that 
potentially inhibits its processing by Caspase-8, such as a phosphorylation event (172). Previous 
studies also suggest that Bid is phosphorylated by ATM in the DNA damage response, and that 
this phosphorylation event is required for its role in this process (7, 9, 150, 173). While my initial 
studies did not reveal phosphorylated Bid following IP, there are further methods that can be 
utilized to interrogate a modification of Bid in necroptotic signaling.  
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Figure 5.2 Proposed role of Bid in necroptotic signaling downstream of death receptors 
Death receptor signaling can result in two types of programmed cell death, apoptosis and 
necroptosis. The role of the BCL-2 family member Bid, in the promotion of apoptosis is well-
established, however my studies suggest a novel role for Bid in the inhibition of necroptosis as 
well. My studies suggest this inhibition of necroptosis is mediated through cleavage of Rip1 in 
an intermediate complex with Caspase-8, cFlipL, and Bid. While further study is needed to 
understand how this complex forms, I hypothesize that key interactions, as well as an alternative 
state of Bid (e.g. phosphorylation) are important in the formation and catalytic activity of this 
complex. 
 
 
 
 
 173 
Potential role for Bid in intestinal inflammation 
 In my initial studies with MxBaxBakBid TKO mice, I found that loss of these three 
proteins promotes necrosis of the liver, often leading to lethality. With this finding, I 
hypothesized that loss of these three proapoptotic proteins may play a role in necrotic death 
which frequently causes inflammation. However, while necrotic death is known to promote 
inflammation regardless of cell type, increased or excessive apoptotic death is also purported to 
promote increased inflammation in the setting of the intestine (580). In order to explore how 
apoptotic or necroptotic death might promote inflammation of the intestine, I wanted to subject 
these mice to an inflammatory stimulus within the intestine to better understand how loss of 
these proteins potentiates necrotic signaling. To do this, I utilized the acute DSS colitis model to 
explore how loss Bid and its apoptotic arm of function might promote necrosis and inflammation 
in the intestine. 
 My studies primarily revealed increased inflammation in both DKO and TKO colons 
following DSS, suggesting that loss of these proapoptotic proteins promotes increased 
inflammation in response to DSS. While pathological scores were not different amongst all 
genotypes of mice tested (Bid +/+, Bid -/-, DKO, and TKO), endoscopy reveals increased 
inflammation in DKO and TKO colons. However, the inflammation occurring in DKO and TKO 
colons appeared to be visually different, in a manner that was not captured by the pathological 
scoring method. To attempt to further understand the role of inflammatory signaling, we 
performed a Luminex ELISA on protein extracts from colon sections to examine the levels of 
several cytokines. This assay revealed similar levels of increase in inflammatory cytokines, with 
the TKO having slightly higher levels of cytokine expression as compared to DKO. This finding 
may be due to sampling error as section of colon were taken randomly at sacrifice, and 
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inflammation within the colon after DSS is patchy. However, examination of proteins involved 
in different death signaling pathways revealed increases in Rip1 in TKO but not DKO colons. 
This suggests that epithelial cells in DKO and TKO colons are executing different pathways to 
death.  
My studies provide evidence that loss of Bax and Bak, or Bax, Bak, and Bid promote 
increased inflammation in response to intestinal epithelial cell cytotoxicity. While these studies 
provide initial evidence that loss of apoptosis or loss of necroptotic restraint can promote 
increased inflammation, there are limitations to my studies: 1) A small limitation is that we are 
interested in understanding inflammation in intestinal epithelial cells, but have utilized mice that 
have a germline deletion of Bak and Bid, but not Bax. We have utilized MxCre to promote 
deletion of Bax deletion in any hematopoietic cells present in the colon, and should also promote 
deletion of intestinal epithelial cells. However, this Cre can be inefficient, although we 
anticipated that the primary inflammatory effect would be mediated by hematopoietic cells. 2) 
Additionally, while we hypothesize the death in the epithelial cells of the colons of DKO and 
TKO mice die differently, we have not specifically identified how these cells die. Staining for 
markers of apoptosis (cleaved Caspase-3) and necroptosis (Phosphorylated Rip1) along with a 
nuclear stain and/or electron microscopy studies are needed to definitively classify death in the 
colons of these mice. While these studies hint at a role for the BCL-2 family in intestinal 
inflammation and a role for necroptosis in IBDs, further studies are needed to understand the full 
extent of involvement.  
In summary, my studies demonstrate a novel role for Bid in the inhibition of necroptosis 
in hematopoiesis. I established this role for loss of Bid and its apoptotic arm of function in the 
perturbation of hematopoietic homeostasis through characterization of a mouse deficient for Bax, 
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Bak, and Bid developed within our laboratory. From my studies, I determined that increased 
TNFα signaling promotes inflammatory signaling that specifically affects the HSPC 
compartment and eventually leads to bone marrow failure due to overwhelming necrosis of the 
bone marrow, with a particular effect on the myeloid progenitor and HSC populations. These 
perturbations of homeostasis within the bone marrow manifest in the animal through decreased 
peripheral RBC and platelet counts, as well as dysplasia in multiple myeloid lineages. 
Additionally, studies of TKO mice reveal that their phenotype of bone marrow failure is very 
similar to the human disease MDS. My findings suggest that TKO mice could be utilized as a 
mouse model of MDS in order to provide insights into this disease including methods of 
diagnosis, through examination for positivity of Rip1 and/ or phospho-MLKL, and new 
therapeutic targets, such as targeting cell death in the treatment of this disease. Additionally, this 
finding adds another novel, alternative function for Bid, reinforcing the idea that members of the 
BCL-2 family participate in other cellular functions aside from apoptotic programmed cell death. 
Together these insights contribute knowledge to the field of programmed cell death within the 
emerging field of programmed necrosis, with potential implications for human disease.  
 
Future Directions 
 
Exploring the role of Bid and programmed necrosis in hematopoiesis 
 My studies provide a solid role for Bid in the inhibition of necroptosis and explores how 
increased necrosis in the hematopoietic system perturbs hematopoietic homeostasis. However, 
several questions remain in understanding the mechanism of how increased necrosis actually 
affects hematopoiesis. I preliminarily explore this through examination of TNFα expression in 
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the bone marrow of TKO and TKO transplanted mice and through treatment of mice with an 
inhibitor for TNF signaling, Enbrel. Although I have not included these studies within this 
dissertation, I have also examined lysate from whole bone marrow treated with LPS by Luminex 
ELISA, as well as LSK and myeloid progenitor populations for cytokine expression by flow 
cytometry (Data not shown). These studies reveal increases in TNFα, IL-6, and IL-1β. 
Utilization of pharmacologic inhibitors for other inflammatory cytokines (Such as IL-6 and IL-
1β) or inhibitors of necroptosis (Necrostatin-1 or 7N-1) would provide further insight into the 
role of the role of inflammatory signaling and necroptotic signaling in the bone marrow failure of 
TKO mice. This in turn could provide insight into potential therapeutics for MDS, as initial 
studies with an inhibitor of TNF did not reveal promising responses (568).  
Another method to explore the role of necroptosis in the TKO phenotype is to inhibit 
necroptotic signaling through crossing VavBaxBakBid mice to mice with knockins of the kinase 
dead (KD) version of Rip1 or Rip3 to evaluate the role of Rip kinase mediated necrotic 
signaling. Our hypothesis would be that a Rip1-KD knock-in mouse would be optimal to block 
the bone marrow failure phenotype, as our mechanistic studies suggest that the phenotype is 
mediated through Rip1. However, because Rip1 is also implicated in inflammatory signaling, 
and Rip3 in apoptotic signaling, this cross may produce alternative results. 
 
Necroptotic signaling in MDS 
 The bone marrow death in MDS is purported to be apoptotic in nature. However, the data 
presented in the literature examines samples in less than optimal conditions or utilized methods 
of death detection which do not distinguish between apoptosis or necroptosis (491, 493, 496, 
497). Conversely, my initial studies with samples of MDS suggest that this death is instead 
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occurring through necroptosis. One limitation of this conclusion is that we have examined these 
samples for expression of all Rip1 species, but not for phospho-Rip1 specifically. In order to 
firmly establish a role for necroptosis in MDS it would be necessary to firmly establish increased 
necroptotic signaling (increased Rip1 phosphorylation) as well as to examine the morphology of 
MDS cells through transmission electron microscopy. Although this was previously explored, I 
think it would be useful to continue to evaluate the status of cleaved Caspase-3 in MDS patients 
to establish that apoptosis, while potentially present in MDS samples, is not the primary method 
of programmed cell death in the pathology of this disease. Another limitation is that we 
examined a small cohort of 26 samples, with only a single sample of two of the subtypes. In 
order to establish that necroptosis is the means by which death occurs in MDS overall, it will be 
important to examine a much larger cohort of MDS samples with representation of all subtypes 
to evaluate the role of necroptosis in pathology of certain subtypes.  
Understanding if necroptosis plays a key role in the pathology of the MDS provides great 
potential to target this programmed cell death pathway in treatment of this disease. About one-
third of patients with MDS will transform to an acute myeloid leukemia, and will typically be 
less responsive to treatment. I hypothesize that blocking necroptotic death could potentially stop 
the cycle of death in the bone marrow, in turn blocking the self-renewal and proliferation of 
HSPC populations, and preventing the production of new mutations. Additionally, because there 
is only one curative therapy for MDS that is often difficult to receive (Allogeneic bone marrow 
transplantation), there is a great need for new therapeutics for the treatment of this disease. Thus, 
targeting programmed cell death could be of great therapeutic value in MDS treatment.   
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How do Bid, Rip1, and Caspase-8 interact to inhibit necroptotic signaling? 
 Utilizing cell lines developed from the bone marrow of Bid +/+, Bid -/-, DKO, and TKO 
mice, we found that 1) loss of Bid, Bax, and Bak in MPCs leads to increased presence of Rip1 
overall and within the pronecrotic complex IIB, 2) that TKO MPCs additionally have increased 
downstream necrotic signaling, 3) that loss of Bax and Bak alone leads to decreased Rip1 
expression and increased Bid expression, and 4) that Bid forms a complex with Rip1, Caspase-8, 
and cFlipL that promotes the cleavage and degradation of Rip1, inhibiting necroptosis. Each of 
these proteins have existing interactions with each other, however it not clear how Bid and Rip1, 
Rip1 and Caspase-8, and Caspase-8 and Bid (in the setting of necroptosis inhibition) interact, and 
in what state these proteins are in, to promote an outcome of Rip1 degradation, and maintenance 
of Bid in the setting of Caspase-8 activity. While the Caspase-8:cFlipL is already established, the 
interactions between the remaining members of this complex is not known, although one could 
speculate that a novel interaction between Bid and Rip1 is a key factor in the organization of this 
complex. Another factor that should also be explored is the presence of other proteins within this 
complex. I hypothesize that this complex is intermediate between complex I present at the 
membrane, and complex II within the cytosol. There are many proteins present in complex I that 
may also be present in this intermediate complex with Bid which we did not explore, such as 
cIAPs and TRAFs that could potentiate the outcome of Rip1 stability. Thus this possibility 
should be explored to ensure a clear picture of the mechanism and the proteins involved in this 
process. 
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Understanding how Bid potentiates Caspase-8 activity toward Rip1 
My studies suggest that Bid may modulate the catalytic activity of Caspase-8 and/ or 
Granzyme B in a manner that increases protease activity towards Rip1. One way to understand 
this is to understand how these proteins interact, and what other proteins might be involved. 
Additionally, examination of the catalytic activity of this complex in the presence of known 
involved proteins in vitro would be critical to evaluate the catalytic activity of Caspase-8. A 
common method utilized to understand the proteolytic activity of Caspases is to perform an assay 
utilizing purified proteins included activated versions of the Caspases of interest (591). Utilizing 
this method, and armed with the understanding of the state of each member of the complex (e.g. 
post-translational modification or activation) would aid in understanding how protease activity is 
modulated toward Rip1. Based upon data from our studies, as well as through collaboration with 
our mathematical modeling colleagues, we found that Bid is likely in an alternative state within 
this complex. Previous studies would suggest that this could be a phosphorylation event, 
however further study of Bid within this complex is needed to understand what, if any 
modifications occur and if this modification of Bid is required in the activation of this complex. 
Another state that is likely required in this complex is the formation of a Caspase-8:cFlipL 
heterodimer, a catalytic complex demonstrated to have altered substrate specificity (80). In the 
setting of these modifications, the catalytic activity of this complex can be evaluated through an 
in vitro assay utilizing purified proteins (592). However, examination in this manner has 
limitations as Caspases molecules would be activated in an artificial manner, and the use of 
purified proteins, versus examination within cell lysate (which is possible, but more difficult) 
may not provide the full story regarding how activity is altered within this complex. However, 
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despite these limitations, this type of experiment could provide great insights so that we can 
begin to better understand the novel role of Bid in this pathway.  
 
Exploring the role of Bid and the BCL-2 family in intestinal homeostasis and IBDs 
 My studies with MxBaxBakBid mice with the acute DSS injury model were less clear in 
understanding what role loss of Bid and its apoptotic arm of function might play in intestinal 
homeostasis and injury. While these studies were inconclusive in demonstrating that loss of Bid, 
Bax, or Bak potentiates the response to colonic injury, they did provide some clues as to how 
loss of apoptosis (DKO mice) versus loss of restraint of necroptosis (TKO mice) may affect the 
consequences of colonic injury. For instance, DKO and TKO mice, while exhibiting a similar 
cytokine profile, displays differences in the pattern of expression of markers for apoptosis and 
necroptosis. These differences suggest altered consequences of colonic injury in these different 
genotypes of mice. However, in order to parse these differences out several limitations of my 
initial studies must be addressed.  
 My studies utilize MxCre to promote the deletion of Bax in DKO and TKO mice. MxCre 
promotes the deletion of Bax in hematopoietic cells, including the in the spleen and the bone 
marrow, as well as the liver, kidney, and expression in the epithelium of the intestines (593, 
594). However, it is possible that Cre recombination is incomplete in all tissues, as efficiency is 
not always 100%. It would be useful to explore the degree and location of Bax deletion in the 
intestinal epithelium to ensure that Bax is deleted. Alternatively, future experiments could utilize 
VillinCre or VillinCreERT2 ,expressed within the intestinal epithelium within the small intestine 
and colon, to promote the deletion of Bax embryonically, or conditionally in mature animals with 
tamoxifen treatment, respectively (595, 596). However, because it is unclear whether increased 
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inflammation in this model is caused by intestinal epithelial cell death or hematopoietic 
inflammatory cells, it is unclear how significant use of an alternative Cre recombinase would be.  
 Another key limitation of these studies, is that it is difficult to make a true conclusion 
regarding cell death in the setting of DSS injury and IBDs. While I have performed 
immunohistochemistry to examine if death in these samples was occurring through apoptosis or 
necroptosis, it is difficult to determine how these cells are dying due to our examination of all 
species of Rip1. To truly understand the role of necroptosis in this process it is imperative to 
evaluate if inhibition of necroptosis can block the inflammatory phenotype in TKO mice. 
Understanding the status of necroptotic signaling in IBDs could provide insight into the 
pathology of these diseases, and potentially provide a therapeutic target in the blockage of cell 
death occurring as a result of inflammation.  
 In my dissertation, I have completed studies to understand a novel role for Bid in the 
inhibition of programmed necrosis in the setting of hematopoiesis and intestinal homeostasis and 
inflammation. My studies in hematopoiesis reveal that increased necroptosis perturbs 
hematopoietic homeostasis leading to bone marrow failure in mice that is similar to a human 
disease, MDS. While my studies in the intestine were less conclusive, they do suggest that the 
BCL-2 family and/or programmed cell death may affect intestinal response to insult and 
maintenance of homeostasis. Further studies are needed to better understand these possibilities. 
While my studies have focused on the hematopoietic and gastrointestinal systems and how 
necroptosis dysregulation might be involved in related human diseases, there are a number of 
other settings in which necroptotic death and inflammation lead to human pathologies. My 
studies demonstrate how alterations in necroptotic regulation can contribute to the 
pathophysiology of disease and provide insight into how these diseases can be therapeutically 
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targeted. Additionally, these studies also provide novel insight into the role of the BCL-2 family 
in necroptotic regulation, a previously unrecognized role.  
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APPENDIX  
 
 
 
 
 
Appendix A. Examination of erythroid cell development in Bid+/+, Bid-/-, DKO, and TKO 
mice 
Because TKO mice have drastic decreases in RBCs, we hypothesized that erythroid development 
would be greatly affected. However, in addition to loss of myeloid progenitor cell populations, 
both DKO and TKO mice demonstrate decreases in the erythroblast A population (basophilic 
erythroblast) before phenotype manifestation, and also at time of sacrifice after phenotype 
manifestation. Interestingly, Pro-erythrocyte populations differ between DKO and TKO before 
phenotype manifestation, but are no longer significant at the time of phenotype manifestation.  
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Appendix B. TKO transplanted mice display similar dysplasia to VavBaxBakBid mice and 
VavBaxBakBid bone marrow does not display significant differences in TNFα positivity 
A) Blood and bone marrow smears from Bid +/+, DKO, and TKO mice. B) Blood and bone 
marrow smears from Bid +/+, DKO, and TKO transplant mice. Scale bar indicates 50 microns. 
C) Examination of TNFα in the middle side scatter population in bone marrow from Bid +/+, 
DKO, and TKO mice. Bid +/+ n=4, DKO n= 4, TKO n=4.  
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Materials and Methods 
 
Mice 
VavCre BaxBakBid and MxCre BaxBakBid null mice were developed in our laboratory by 
crossing VavCre+ or MxCre+ mice with Bax F/F Bak -/- mice then subsequently crossing these 
Cre+ Bax F/F Bak -/- Bid mice to Bid -/- mice. VavCre and MxCre BaxBak null mice were 
generated through crosses of Bax F/F Bak -/- mice with VavCre+ mice. Mice were backcrossed 
8 generations with C57/BL6 mice from Jackson Laboratories. MxCre BaxBakBid mice were 
induced to delete Bax with three injections with Poly I;C (GE Healthcare; 27-4732-01) at a 
dosage of 200 mg/kg. Blood was collected in microcontainers with EDTA (365973; BD 
Pharmingen). Complete blood counts completed using a Hemavet 950. Cytospins were 
completed using a Shandon Cytospin 4 and stained using a Protocol HEMA 3 Stat pack (Thermo 
Fisher Scientific; 123-869). For Enbrel experiments: Mice were treated with two doses of Enbrel 
(eternacept) one week apart at a dose of 50mg/kg. Complete blood counts and analysis were 
performed one week after last dose of Enbrel was given. The Vanderbilt University Institutional 
Animal Care and Use Committee approved all experiments.  
 
Myeloid progenitor cell lines  
Myeloid progenitor cells (MPCs) were generated as previously described (Zinkel, et al., 2003). 
Briefly, whole bone marrow was removed from sex-matched 6 to 8 week old mice and depleted 
of mature populations utilizing biotinylated antibodies from BD Pharmingen for B220 (553086), 
Ly6G and C (553125), CD127 (555288), Ter119 (553672), and CD3 (553060). The cells were 
then Hox11-immortalized by growing on irradiated MEFs expressing Hox11. Cells were grown 
in IMDM (Iscove’s modified Dulbecco Medium) supplemented with 20% Calf-serum, WEHI-
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conditioned medium as a source of IL-3, 100U/mL penicillin/streptomycin, 2mM Glutamine, and 
0.1mM β-mercaptoethanol (IMDM 20 WEHI). Media was further supplemented with G-CSF, 
GM-CSF, SCF, and IL-3. Cells were cultured at 37°C in 5% CO2. After immortalization cells 
were grown in IMDM 20 WEHI. 
 
Cell Death Analysis 
For Annexin V/ PI staining, MPCs were collected at designated time points after treatment with 
25 ng/ mL TNFα (T7539; Sigma) and 50 ng/mL Actinomycin D (A9415; Sigma). Cell viability 
was determined using Annexin V (1001; Biovision) and Propidium Iodide (Sigma) staining by 
flow cytometry. Briefly cells were stained in Annexin V staining buffer (10x Staining Buffer: 
0.1M HEPES, pH 7.4; 1.4M NaCl; 25mM CaCl2, Diluted to 1x before use) + Annexin V (500x, 
Diluted to 1x in Staining Buffer) and PI was added at 50 μg/mL just before analysis. Samples 
were run on a BD FACScalibur with CellQuest software and analyzed using FlowJo software 
(TreeStar). For cleaved Caspase-3 staining, MPCs were treated as in death assays, collected at 
designated time points and fixed, permeabilized, and stained per manufacturer’s instructions (BD 
Biosciences). Cells were then stained with rabbit polyclonal Cleaved Caspase-3 antibody 
(Asp175) (9661; Cell Signaling), followed by anti-Rabbit Alexa Fluor 488 (A11008; Invitrogen) 
Samples were run and analyzed as above. 
For electron microscopy, whole bone marrow or MPC samples were washed in a 0.1M 
cacodylate buffer (pH 7.4) then fixed with 2.5% glutaraldehyde + 0.1M cacodylate Buffer (pH 
7.4) solution for 1 hour then overnight at 4° C. Samples were post-fixed in 1% osmium 
tetraoxide and washed 3 times with 0.1 M cacodylate buffer. The samples were dehydrated 
through a graded ethanol series followed by incubation in 100% ethanol and propylene oxide 
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(PO) with 2 exchanges of pure PO. Samples were embedded in epoxy resin and polymerized at 
60C for 48 hours. For each sample 70-80nm ultra-thin sections were cut and mounted on 300-
mesh copper grids. Sections were stained at room temperature with 2% uranyl acetate and lead 
citrate. Samples were imaged on a Phillips T-12 TEM utilizing Tecnai interface software and an 
AMT 2k X 2k CCD camera to capture images. 50-100 cells were scored as being as alive, 
apoptotic or necroptotic based upon presence of morphological features representative of each 
condition. Cells were only scored if the nucleus could be visualized in the image.  
 
Hematopoietic Characterization 
For examination of hematopoietic stem and progenitor cell populations, analysis was performed 
on whole bone marrow. A power analysis was utilized to calculate the number of animals needed 
to analyze from each genotype. Cell suspensions were obtained by flushing the femurs and tibia 
with media. Erythrocytes were lysed using erythrocyte lysis buffer (100μM Tris pH 8, 157mM 
NH4CL, + H2O) and then samples stained with biotinylated antibodies obtained from BD 
Pharmingen (as above in generation of MPC lines) and fluorescent-conjugated antibodies from 
eBioscience CD117 (17-1171), Sca-1 (25-5981), Flt3 (15-1351), CD48 (11-0481), Streptavidin 
eFluor 450 (48-4317), and CD150 (12-1501) to analyze HSC populations. Samples were run on a 
BD LSRII flow cytometer with FACSDiva software and analyzed using FlowJo software (Tree 
Star). For examination of mature populations, single-cell suspensions were obtained from bone 
marrow as above and from spleen through dissociation through a filter. Cells were stained with 
antibodies from BD Pharmingen for CD3 (553062), B220 (553090), CD11b (553311), and Gr-1 
(553127). Samples were run on a BD FACScalibur and analyzed using FlowJo software (Tree 
Star). For intracellular analysis of TNFα, single-cell suspensions of bone marrow were obtained 
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as above. Cells were cultured overnight in IMDM 20 WEHI. Cells were replated the next day 
with fresh media and treated with 200ng/ mL lipopolysaccharide (L4391; Sigma) and Golgi Plug 
per manufacturer’s instructions (BD Biosciences) or Golgi plug alone for five hours. Cells were 
then fixed, permeabilized, and stained with TNFα according to the manufacturer’s instructions 
(554419; BD Pharmingen). Samples were then run and analyzed as above. Numbers of cells 
were calculated through back-calculation of percentages from FlowJo analysis to the total 
number of cells counted when isolated.  
 
Competitive Reconstitution Assay 
Whole bone marrow (femur and tibia) from CD45.2 Bid +/+ and BaxBakBid TKO, and CD45.1 
Bid +/+ mice was isolated and erythrocytes were lysed as above. Bone marrow was mixed in a 
1:1 ratio with Bid +/+ CD45.1 bone marrow: CD45.2 experimental bone marrow then injected 
retro-orbitally into lethally irradiated CD45.1 Bid +/+ mice. Irradiation was performed in two 
doses five hours apart for a lethal 9 gy dose. Approximately 1 million cells were injected. 
Reconstitution was examined every 4 weeks beginning at 8 weeks post-transplantation. This was 
examined through retro-orbital bleeding of mice and separation of nucleated cells from red blood 
cells using lymphocyte separation medium. Nucleated cells were stained with antibodies for 
CD45.1 (553776) and CD45.2 (553772) from BD Pharmingen and analyzed as above. Upon 
sacrifice organs were placed in 10% formalin and were embedded in paraffin wax. Sections of 
lung tissue were utilized for TNFα staining.  
Secondary transplantation was performed through collection of bone marrow from primary 
transplanted animals as above. Percent 45.2 positivity was determined and then number of cells 
needed to have 1:1 ratio with Bid +/+ 45.1 positive cells was calculated. 
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For secondary transplantation of leukemicVavBaxBak DKO bone marrow, bone marrow was 
collected from VavBaxBak DKO mice displaying the leukemia phenotype. Bid +/+ mice were 
sublethally irradiated at a dose of 5gy. Mice were retro-orbitally injected with 5 million bone 
marrow cells.  
 
In Vivo BrdU Assay 
A power analysis was utilized to determine the number of animals needed to analyze from each 
genotype. Mice were injected three times with BrdU over the course of 36 hours (once every 12 
hours) with a total of 4mg of BrdU (550891; BD Pharmingen) injected. Whole bone marrow was 
isolated from mice four hours after the last injection and then lineage-depleted using antibodies 
for CD3, B220, Ly-6G, CD127, and Ter119 from BD Pharmingen (as mentioned above) with 
DynaBeads (11035; Life Technologies). All remaining cells were stained for stem and progenitor 
surface stains from eBioscience (CD117, Sca-1, Flt3, and CD150 as described above) and from 
BioLegend (CD48; 103432). Cells were lastly treated with DNase type I (Sigma; Cat: D5025) 
for 1 hour at 37°C and then stained for BrdU from BD Pharmingen (Cat: 556028). All remaining 
cells were run on a LSRII flow cytometer and analyzed using FlowJo software (Tree Star). 
 
Fluorescent Immunohistochemistry  
For mouse bone marrow analysis paraffin-embedded samples of whole tibia were fixed in 
formalin solution (10% formaldehyde) and then decalcified before embedding. Embedded 
sections were stained with either Rip1 (H-207)(sc-7886; Santa Cruz Biotechnologies, no antigen 
retrieval required) or Cleaved Caspase-3 (9661; Cell signaling). Signal was amplified utilizing 
Fluorescein-conjugated Tyramide Sample amplification kit (SAT701001EA; Perkin Elmer), an 
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Avidin/Biotin blocking kit (SP-2001; Vector laboratories), and a biotinylated anti-Rabbit 
antibody (BA-1000; Vector Laboratories). Samples were mounted with DAPI containing 
mounting buffer (P36941; Life Technologies) or stained with Hoescht (H21492; Life 
technologies) and mounted (P10144, life technologies). For TNF staining in lungs from 
transplant mice, samples were fixed (as above) and embedded, then stained as above with TNF 
(ab9739; Abcam). For human bone marrow aspirate, paraffin-embedded samples of human bone 
marrow aspirate were stained as above as well as with phospho MLKL (S358) 
(Ab187091;Abcam). Samples were imaged on a Nikon AZ100 microscope and images were 
captured using a Nikon DS-Ri1 color camera or on a Zeiss Axioplan microscope using a 
Hamamatsu ORCA-ER monochrome digital camera.  
 
Immunoblot and Immunoprecipitations  
For analysis of whole cell lysate, cells were lysed utilizing Lysis Buffer (25mM HEPES pH 7.5, 
250mM Sodium Chloride, 2mM EDTA, 0.5% NP-40, 10% Glycerol, 1X Complete Mini 
Protease Inhibitor, EDTA free (Roche), 10mM β Glycerophosphate, 0.1 mM Sodium 
Orthovanidate, 10mM Sodium Fluoride, 1mM Sodium Pyrophosphate). Samples were denatured 
by boiling in Laemmli Buffer (containing β-mercaptoethanol), and then run utilizing SDS-
PAGE. For MLKL trimerization, cells were lysed as above and lysates were prepared under non-
denaturing conditions. Stimulation was completed with LPS (L4391; Sigma) and treatment with 
Z-IETD-FMK (550380; BD Pharmingen), Z-VAD-FMK (sc-311561; Santa Cruz 
Biotechnology), and MG132 (BML-PI102; Enzo Biologicals). Samples were immunoblotted 
with antibodies listed below.  
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For immunoprecipitation, cells were lysed utilizing lysis buffer (as above) and then IP was 
performed utilizing sepharose beads (17-0618-02; GE Healthcare) with α-FADD (M-19) (sc-
6036; Santa Cruz Biotechnology) or Biotinylated α-Bid (AF860; R&D systems) with 
Streptavidin agarose beads were used (6923; Novagen) and then lysates were run by SDS-PAGE, 
transferred and immunobloted with antibodies specified below. 
Immunoblotting was performed for Bid (developed by S. Korsmeyer laboratory), Caspase-8 
(4927; Cell Signaling), c-FLIPL (H-150) (sc-8346; Santa Cruz Biotechnology), CYLD 
(GTX100228; GeneTex), FADD (S-18) (sc-6035; Santa Cruz Biotechnology), Rip1 (610459; 
BD Pharmingen), MLKL (LS-C323026; LifeSpan Biosciences), c-Flip (ADI-AAP-440-E; Enzo 
life sciences), and -Actin (A5441; Sigma) 
 
Retroviral Transduction 
Retroviral supernatants were generated through transient transfection of 293T cells using Fugene 
(11814443001; Roche) to introduce a FLAG-HA-tagged Bid +/+ expression vector with a 
retroviral packaging vector. Bid was introduced into BaxBakBid KO MPCs by infection and was 
over-expressed. 
 
Reverse- Transcription PCR to examine Bax deletion 
RNA isolation was completed utilizing Trizol reagent (15596; Invitrogen) from single-cell 
suspensions of bone marrow and spleen prepared as above. Isolation was completed according to 
manufacturer’s instructions. cDNA was prepared using GoScript Reverse Transcription System 
(A5000; Promega). PCR was performed utilizing primers Bax Forward 
(ACAGATCATGAAGACAGGGG) and Bax Reverse (CAAAGTAGAAGAGGGCAACC). 
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Treatment with Granzyme B Inhibitor 
Cells were plated with fresh media on the previous day. The first day, cells were permeabilized 
with 7.5μg/μL Digitonin (dissolved in DMSO) for five minutes. Cells were then treated with 2μg 
of the Granzyme B inhibitor for 90 minutes in the culture medium. The cells were then placed in 
fresh media, and allowed to recover overnight (approximately 18 hours). Cells were then treated 
with LPS for 30 minutes. Afterward lysate was collected as above.  
 
Treatment with DSS and pathological scoring 
MxBaxBakBid and MxBaxBak mice were treated with three doses of 200μg/ ml of Poly(I:C) 
every other day for 6 days. Mice were left for two weeks after the last injection to allow for 
activation of Cre recombination and Bax deletion. Mice were then treated with a 4% DSS 
solution (14489;Affymetrix) in water for 6 days. Mice were weighed each day. On day 5, 
endoscopy was performed on a single mouse per genotype. Mice were sacrificed on day 6 and 
colons were collected for fixation. H&E stained sections were utilized for pathological scoring 
and which was performed by Dr. Kay Washington (VUMC).  
 
Statistical Analysis 
All analyses were completed using either GraphPad Prizm (GraphPad Software) or with the help 
of the Vanderbilt University Medical Center (VUMC) Center for Quantitative Sciences (Heidi 
Chen). Analysis of survival curve was determined through Kaplan-Meier log-rank test between 
all genotypes and DKO versus TKO to examine difference between all genotypes and 
specifically DKO and TKO. Analysis of cell numbers from mouse experiments (Lymphocyte, 
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progenitor, and stem cell populations) was analyzed by one-way analysis of variance to examine 
differences between genotypes. Examination of percent 45.2 reconstitution in competitive 
reconstitution assay (Primary and Secondary) was determined by two-way analysis of variance to 
examine differences in 45.2 reconstitution between genotypes at different timepoints after 
transplantation. Comparison of necrotic death by transmission electronic microscopy in bone 
marrow and MPCs was determined utilizing a chi-squared test on the proportions of the type of 
cell death. Analysis of intracellular cleaved Caspase-3 was completed utilizing a two-way 
analysis of variance to compare differences between genotypes at different timepoints post-
stimulation. Analysis of Enbrel in vivo BrdU assay and complete blood counts completed 
through one-way ANOVA.  
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